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ABSTRACT
The incidence o f  breast cancer has progressively increased, while survival rates have 
sim ultaneously improved. Young women with breast cancer are likely to suffer ovarian 
damage from chem otherapy, w hich can have a profound effect on their quality o f  life. 
At present, it is im possible to predict the functional lifespan o f  the chem otherapeutically 
damaged ovary as there is insufficient data. Ovarian reserve tests (ORT) have the 
potential to estim ate the reproductive age o f the ovaries, which w ould allow  an accurate 
estimation o f fertility status and the risk o f  premature ovarian failure.
This project investigates the use o f ORT in young w om en with breast cancer. To 
achieve this, biochem ical and biophysical ORT were perform ed in a m ixed longitudinal 
and cross-sectional study group comprising young women treated with chemotherapy 
for breast cancer and age-m atched, regularly menstruating controls w ith proven fertility. 
Overall the results indicate potential for the use o f inhibin B, anti-miillerian hormone, 
oestradiol and antral follicle count in the evaluation o f  these patients. An in vitro study 
was perform ed to supplem ent the clinical study, in which the effects o f  cytotoxic agents 
commonly used to treat breast cancer were exam ined by sim ultaneously applying 
equivalent doses o f each to a breast cancer cell line and prim ary granulosa-luteal cell 
cultures respectively. The effects o f these agents were m easured in term s o f cellular 
integrity (apoptosis) and functionality (hormones). Overall the results suggest variations 
in cytotoxicity (LD5 0) between breast and granulosa cells w hich have potential 
therapeutic implications.
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1. BACKGROUND
1.1 BREAST CANCER IN YOUNG WOMEN
1.1.1 INCIDENCE AND SURVIVAL
Breast cancer is the m ost com m on cancer in females in England and W ales, with 41,720 
new cases diagnosed in 2002 (Office for National Statistics 2005; W elsh Cancer 
Intelligence and Surveillance Unit. 2005).
Incidence rates have continued their upward trend, increasing by 80 per cent 
since 1971, and by 16 per cent in the ten years to 2003 (Office for N ational Statistics
2005). Survival trends have also steadily improved, w ith the decline in age-adjusted 
breast cancer m ortality rates almost certainly due to im provem ents in the earlier 
detection o f smaller, palpable tumours and in adjuvant chem otherapy (Jatoi & Miller 
2003; M ettlin 1999). This trend in the United Kingdom is also apparent in many other 
countries in Europe (Botha et al. 2003).
A lthough very few  cases o f breast cancer occur in w om en in their teens or early 
20s, breast cancer is the m ost com m only diagnosed cancer in w om en under 35 in the 
UK. By age 35-39 over 1,400 women are diagnosed each year (Cancer Research UK
2006). In the United States, o f  more than 200,000 new diagnoses o f  breast cancer made 
each year, 15% occur in the reproductive years (< 45 years) (Jemal et al. 2004). 
Furthermore, wom en are delaying childbearing for dom estic, professional and 
educational reasons (Friedlander & Thewes 2003). In England and W ales the average 
age o f mothers at childbirth has increased by three years since 1971, rising from 26.2 
years to 29.1 years in 2000 (Office for National Statistics 2005).
15
Rate per 100,000
140 i Screening introduced
120  -
Incidence
100  -
Mortality40  -
20  -
1971  1975  1979  1983 1987 1991 1995 1999  2003
FIGURE 1. 1. 1 Age-standardised incidence o f  and mortality from fem ale breast cancer, England and 
Wales, Rate per 100,000
Source: National Statistics website: w ww.statistics.gov.uk
Crown copyright material is reproduced with the permission o f  the Controller o f  HM SO .
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1.1.2 TREATMENT AND PROGNOSIS
Y ounger age at diagnosis is considered a poor prognostic feature in breast cancer 
(Goldhirsch et al. 2001). These w om en have a greater chance o f  having an endocrine -  
unresponsive tumour, and are more likely to present w ith a higher grade tum our than 
their postmenopausal counterparts (Colleoni et al. 2002). Com pared with older 
premenopausal women, invasive breast cancer occurring before the age o f  35 years has 
a more aggressive biological behaviour and is associated w ith a worse prognosis 
(Shannon & Smith 2003). Those with oestrogen receptor positive tum ours are 
commonly advised to receive ovarian suppression in addition to chem otherapy, as 
prognosis may be im proved (Aebi et al. 2000; Collichio & Pandya 1994; Early Breast 
Cancer Trialists' Collaborative Group 2000).
A lthough adjuvant chem otherapy is effective in all age groups, the magnitude o f 
benefit is greatest in younger premenopausal patients (Early Breast Cancer Trialists' 
Collaborative Group 2002; Gradishar 2003). This has led to the evaluation o f more 
aggressive therapies such as high-dose chem otherapy with haem atopoietic stem cell 
rescue or autologous stem cell transplantation in women with m etastatic and early poor 
prognosis breast cancer (Farquhar et al. 2003b; Farquhar et al. 2003a). This therapy, 
which one would expect to have significant gonadotoxic effects, does not yet show 
improved outcome com pared to conventional chem otherapy (Tallm an et al. 2003).
F irst-line chem otherapy regimes for breast cancer com m only contain 
cyclophosphamide (C), either as part o f the CMF regim en (M = m ethotrexate, F = 5- 
fluorouracil) or are anthracycline based, containing either epirubicin or doxorubicin. 
Therapy is usually given during 3 - 6  cycles and is individualised. Subtle differences 
only exist between the 2 regimens (Early Breast Cancer Trialists' Collaborative Group 
2002) in term s o f survival advantage. Newer drugs are always being added, which is
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leading to an increased em phasis on targeted therapy (Smith 2002). Taxanes (Docetaxel 
and Paclitaxel) are com m only used in metastatic disease, usually in association with an 
anti-metabolite (e.g. Gemcitabine), and are the subject o f ongoing research in treating 
primary disease (Nabholtz & Gligorov 2005). The newest agents, referred to as targeted 
biologies (trastuzumab) are currently receiving intense interest (O 'Shaughnessy 2005).
W omen with breast cancer who are contem plating having a family have 
additional concerns, given the fact that they are usually advised to delay childbearing 
for 2 - 5 years following diagnosis owing to the increased likelihood o f  recurrence 
within the first few years following treatm ent (Danforth, Jr. 1991; Velentgas et al. 
1999). Furtherm ore, patients w ith oestrogen-receptor positive disease are usually treated 
with adjuvant horm onal therapy such as tamoxifen (Early Breast Cancer Trialists' 
Collaborative Group 2001), in which case pregnancy is not advised for at least 5 years.
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1.2 CHEMOTHERAPY-MEDIATED GONADAL DAMAGE
1.2.1 INTRODUCTION
The gonadotoxic effect o f  chem otherapeutic agents is well docum ented, although the 
prevailing mechanisms are not fully understood.
In general, alkylating agents such as cyclophosphamide (C) w hich are non-cell 
cycle specific, are more cytotoxic to the ovaries than cell cycle specific agents such as 
methotrexate (M) and fluorouracil (F), whose major effect is on ovarian follicle growth 
and maturation (Hensley & Reichm an 1998). This may affect sex steroid production, 
leading to disturbance o f  the hypothalam ic-pituitary-ovarian (HPO) axis (Dnistrian et al. 
1985; Dowsett & R ichner 1991; M ehta, Beattie, & Das Gupta 1992). Ovarian biopsies 
in patients undergoing cyclophospham ide-based treatment reveal com plete absence o f 
ova or small num bers o f inactive ova with fibrosis and no evidence o f  follicular 
m aturation (K oyam a et al. 1977; Warne et al. 1973). In an animal study, M eirow and 
colleagues found a significant inverse relationship betw een the dose o f 
cyclophosphamide and the total num ber o f  follicles counted in the ovaries (M eirow et 
al. 1999).
1.2.2 AM ENORRHOEA AND PREMATURE OVARIAN FAILURE
Chem otherapy-related-am enorrhoea (CRA) is a term used to describe the occurrence o f 
amenorrhoea following chem otherapy, the rate o f which varies according to the 
diagnostic criteria used and length o f follow-up (Bines, Oleske, & Cobleigh 1996). Its 
onset is mediated through ovarian failure, and is based on the observation that the 
horm one profile observed in premenopausal wom en treated w ith adjuvant 
chem otherapy for breast cancer who develop CRA is consistent w ith prim ary ovarian 
failure (Dnistrian et al. 1983; Dowsett & Richner 1991; Rose & D avis 1977). The risk
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of POF with m ultiple agent adjuvant chemotherapy has been reported to range from 
53% to 89% (Del M astro et al. 1997). The rapid evolution o f  chem otherapeutic 
regim ens for breast cancer how ever (Awada et al. 2003), limits the usefulness o f this 
information in modern practice.
Generally, the risk o f  POF is related to the patient’s age, treatm ent protocol and 
type o f  malignancy (M eirow  & N ugent 2001). Age and time to CRA are inversely 
related, as well as cum ulative dose required to produce CRA. The average incidence o f  
CRA for CMF - based regim ens is 40% for women less than 40 years o f  age and 76% 
for those older than 40 (Bines, Oleske, & Cobleigh 1996). This m ay be explained by the 
reduction o f prim ordial follicles with age (Faddy & Gosden 1996), thus making these 
w om en more susceptible to the effects o f chemotherapy. A cohort o f  premenopausal 
women receiving either adjuvant CMF, CEF (E- Epirubicin), tam oxifen, or no treatment 
was followed up prospectively for one year (Goodwin et al. 1999). Age and the use o f 
systemic chem otherapy were found to be independent predictors o f  premature 
menopause. The use o f  CM F or CEF, whether in com bination or not w ith tamoxifen, 
increased the risk o f  m enopause in 40-year-old women from less than 5% to more than 
40% (Goodwin et al. 1999). It would appear that anthracycline-containing regimens 
such as FEC or AC (A =doxorubicin) carry a lower risk o f  inducing POF com pared to 
classic CMF regim ens (Levine et al. 1998; M inton & M unster 2002). D ata regarding the 
effect o f taxanes is limited. A recent retrospective study reported that the incidence o f 
CRA (defined here as am enorrhoea persisting for > 12 m onths after treatment) in a 
group of women < 40 years o f  age treated with adjuvant anthracycline and taxane-based 
chemotherapy was 15% (Form er et al. 2005). One o f the reasons these studies might 
report lower CRA rates is the fact that the cumulative dose o f  cyclophospham ide is 
lower in such regimens. For example AC usually consists o f  4 cycles, whereas standard 
CMF consists o f  6 cycles (see figure 2.2.1). It would seem therefore, that the m ajor
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gonadotoxic effect from adjuvant chemotherapy regimes for breast cancer stems from 
the alkylating agent cyclophosphamide.
There is some data to suggest that commencing chem otherapy during the 
follicular phase o f  the m enstrual cycle is associated with a higher incidence o f  CRA (Di 
Cosimo et al. 2004), a finding not detected previously (M ehta, Beattie, & Das Gupta 
1992). The form er study was limited by the fact that CRA was defined as cessation o f 
menses for at least 3 m onths during or after chemotherapy, highlighting the importance 
o f  a lack o f  a unified definition for CRA. The m edian age was also higher in 
comparison to other studies (42 years).
W hereas the induction o f  ovarian failure may be advantageous w ith respect to 
breast cancer outcom e (Pagani et al. 1998), it is not clear that there is any advantage to 
permanent m enopause over reversible hormonal manipulations (Moore 2000). 
Restoration o f  m enstruation after CRA is possible. Again this is influenced by age and 
duration o f  follow-up, and has been estimated at 22% to 56% in younger women and 
0% to 11% in older patients (Bines, Oleske, & Cobleigh 1996). However, women who 
maintain norm al m enses throughout chem otherapy rem ain at risk for developing POF. 
This is evident from the high rates o f  POF seen in adolescents receiving alkylating 
agents for cancer (Byrne et al. 1992).
Ovarian dam age following chem otherapy can present w ith a variety o f 
symptoms which reflect varying degrees o f damage, culm inating in prem ature ovarian 
failure (POF) (M oore 2000). POF is associated with a wide array o f  effects including 
vasomotor symptoms (hot flashes and night sweats), genitourinary sym ptom s (vaginitis, 
dyspareunia, dysuria) and may contribute to sexual dysfunction (Bakewell & Volker 
2005; Broeckel et al. 2002). Ovarian failure after adjuvant chem otherapy has been 
shown to be associated with rapid bone loss in women with early—stage breast cancer 
(Shapiro, M anola, & L eboff 2001) and osteoporosis that can lead to skeletal fractures
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(Ganz & Greendale 2001). The m anagem ent o f  these sym ptom s is particularly difficult 
in patients w ith breast cancer owing to concerns about horm one replacem ent therapy 
(HRT; Beral 2003; Biglia et al. 2003; Rostom 2001).
3 weeks 1 week 3 weeks
M----------► ++<----------►
M
1 2 3 4 5 5  6 6  7 7  8 8
Cycle number
E-CMF /
3 weeks 
<4----------►
D
1 2  3 4
Cycl e
AC x 4
FIGURE 1.2. 1 Standard chemotherapy schedules for breast cancer
E = Epirubicin, C = Cyclophosphamide, M = Methotrexate, F = 5-Fluorouracil 
A = Anthracycline (doxorubicin)
(Kindly provided by Dr Rob Stein).
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1.2.3 EFFECT ON FERTILITY
Young breast cancer survivors are very concerned about their reproductive capability 
(both before and after treatment), which can have a profound im pact on their self­
esteem (Ganz 2000). Those patients who are not immediately rendered infertile are still 
likely to suffer problem s with infertility and ultimately, a prem ature menopause 
(Meirow 2000). These concerns are important enough to influence treatm ent decisions 
for a significant num ber o f patients (Partridge et al. 2004; Thewes et al. 2005). In 
addition, there is evidence to suggest that discussions about reproductive health are 
overlooked in the counselling process prior to chem otherapy (Duffy, Allen, & Clark 
2005), and that the inform ation needs o f these patients with regard to these issues are 
not being m et (Thewes et al. 2005).
Approxim ately 50% o f  patients younger than 35 resume norm al menses after 
com pletion o f  cytotoxic chem otherapy (regardless o f cancer type; Forbes 1992), and are 
therefore potentially capable o f  becoming pregnant. H owever, although a regular 
menstrual cycle m ay serve as a convenient marker for ovarian function, a normal 
menstrual cycle is not synonymous with fertility. Similarly, irregular menses or 
am enorrhoea does not always imply infertility. This was shown in a retrospective series 
o f  women who received chem otherapy with FAC (A- anthracycline) who were 35 years 
or younger at the tim e o f  treatment. In this series, 33 pregnancies occurred in 25 patients 
(21%), o f  w hich only 64% continued to menstruate regularly during and after 
chemotherapy (Sutton, Buzdar, & Hortobagyi 1990).
Because o f the possibility o f  spontaneous recovery, ovarian function should be 
reassessed periodically in patients with chem otherapy-induced gonadal damage. 
Conversely, i f  fertility is not desired, contraception should be used, and the com bined
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oral contraceptive pill (COCP) has been used for hormone replacem ent therapy (Nasir et 
al. 1997).
The potential effect o f  treatm ent on fertility in other cancers was illustrated by a 
large retrospective survey o f pregnancy outcomes after peripheral blood or bone 
marrow transplantation which revealed that only 0.6% o f  patients conceived after 
autologous or allogenic stem cell transplantation (SCT), but the pregnancies were likely 
to have a successful outcome (Salooja et al. 2001).
Overall the data available relating to pregnancy rates and outcom es following or 
during breast cancer is lim ited and relates only to small, defined cohorts w hich may not 
be representative o f  the entire population. Furthermore, follow up is alm ost always 
limited in duration.
1.3 BREAST CANCER AND PREGNANCY
1.3.1 INTRODUCTION
W omen who contem plate childbearing after a diagnosis o f  breast cancer have to 
consider (Collichio, Agnello, & Staltzer 1998) the effect pregnancy will have on their 
cancer, and vice versa. It is im portant to consider these very difficult issues, which are
made even more com plex by the fact that their ability to conceive m ay already be
limited.
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1.3.2 EFFECT OF PREGNANCY ON DISEASE RECURRENCE 
Patients who wish to have children after treatment for prim ary breast cancer may seek 
advice as to whether or not pregnancy would increase their chance o f  disease 
recurrence. Although it is clear that a wom an’s risk o f developing breast cancer is 
closely related to reproductive factors, the exact relationship, especially w ith regards to 
prognostic influence, is not clearly defined (Daling et al. 2002). It has been estimated 
that 3-7% o f  women becom e pregnant following a diagnosis o f  breast cancer (Kroman 
et al. 1997b; Saunders & Baum 1993). Reviews on the topic agree that there is no 
evidence that pregnancy after breast cancer treatment has a negative influence on 
prognosis (Kasum 2006; K rom an & M ouridsen 2003; Upponi et al. 2003). The evidence 
for this is based m ainly on retrospective, case-control studies w ith lim ited numbers 
(Dow, Harris, & Roy 1994; K rom an et al. 1997; M ueller et al. 2003; Sankila et al. 1998; 
Velentgas et al. 1999; von Schoultz et al. 1995). Gelber and colleagues performed a 
retrospective review  where an attempt was made to form a non-pregnant comparison 
group, matched according to age, nodal status, tum our size and year o f  diagnosis. 
Patients in the non-pregnant group were free o f  relapse for at least as long as the time 
between breast cancer diagnosis and completion o f  pregnancy for patients in the 
pregnant group (G elber et al. 2001). Overall survival in the pregnant group, as assessed 
by 5- and 10- year survival percentages was actually superior to the non-pregnant group 
(Gelber et al 2001). A lthough this may be explained by a proposed anti-tum our effect o f 
pregnancy, it may also be explained by a previously reported “healthy m other effect” 
(i.e., that only women who “feel healthy” get pregnant and those who are affected by 
the disease do not); (Sankila, Heinavaara, & Hakulinen 1994).
Therefore, despite encouraging reports to date, there is a need for prospective 
data to clarify the issue convincingly (Surbone & Petrek 1997), especially in younger
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premenopausal patients who are at a higher risk o f  relapse (Krom an et al. 2000). The 
best evidence to address this question is never likely to be forthcom ing, as it would be 
im possible to perform a random ised controlled trail in this context.
1.3.3 TERATOGENICITY
It is known from animal studies that various cytotoxic agents are m utagenic to female 
germ cells at various stages o f  maturation (M eirow et al. 2001). Studies in humans have 
not reported the expected translation o f these effects into increased m iscarriage rates or 
congenital abnorm alities com pared to the general population, but these studies were 
confined to patients w ith haem atological malignancy (Green 1997; Holmes & Holmes 
1978; Sanders et al. 1996). These findings provide reassurance but m ust be cautiously 
interpreted due to the lack o f data in humans (M eirow & Schiff 2005).
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1.4 OPTIONS FOR PRESERVING FERTILITY
1.4.1 INTRODUCTION
Advances in reproductive technology have made fertility preservation techniques a real 
possibility for these patients. Decision-m aking in this area is particularly difficult 
because o f the experim ental nature o f many techniques.
1.4.2 EM BRYO CRYOPRESERVATION
This is the only established method available in clinical practice to preserve fertility in 
women being treated for cancer prior to chemotherapy (Revel & Schenker 2004). 
Pregnancy rates are reported to be 20-30 % per transfer o f two to three embryos (Lobo 
2005). Drawbacks to its use include the need for a partner (or donor sperm), the fact that 
a harvest o f viable em bryos cannot be guaranteed, and any com plications or delay in the 
IVF cycle m ay delay the com m encem ent o f  chemotherapy (Thom son et al. 2002).
Perhaps the m ain obstacle to its use in patients with breast cancer involves the 
need for a stim ulated cycle and IVF, which is theoretically harm ful to patients with 
hormone-sensitive breast cancer. This risk has been circum vented in the past by 
employing natural-cycle IVF (Brown et al. 1996), but pregnancy rates are low  with this 
method (Pelinck et al. 2002). Tam oxifen has been shown to increase ovulation rates in 
premenopausal w om en (Sunderland & Osborne 1991). IVF and embryo 
cryopreservation after ovarian stimulation with tam oxifen has been em ployed with some 
success whilst possibly providing a safer alternative to ovarian stim ulation in these 
patients (Oktay et al. 2003). In that study, tam oxifen stim ulation resulted in 2.5-fold 
increase in embryo yield com pared to patients undergoing natural-cycle IVF without 
cancer recurrence in short-term follow-up. Tamoxifen is known to increase oestradiol 
levels in prem enopausal wom en (Jordan et al. 1991). Based on this know ledge, the same
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investigators studied the use o f a 3rd generation aromatase inhibitor (Letrozole), which 
would be expected to induce ovulation without raising oestrogen levels. Combination o f 
Letrozole with FSH stim ulation in a prospective cohort o f patients w ith breast cancer 
yielded a higher num ber o f  embryos than tamoxifen stim ulation alone, w ithout the 
associated rise in oestradiol nor an increased recurrence rate (Oktay et al. 2005). These 
results have been interpreted with caution however, as the study design (small sample, 
non-randomised short follow-up) precludes any definitive conclusions about the safety 
o f IVF in patients w ith breast cancer (Partridge & W iner 2005). Finally, the fate o f  the 
embryos should be considered at the outset, given the possibility that potential offspring 
may lose their mothers to the disease (Posada, Kolp, & Garcia 2001).
1.4.3 OOCYTE CRYOPRESERVATION
This is an attractive option for women without a partner. Drawbacks are analogous to 
embryo cryopreservation as a stimulated cycle is required.
Since the first report o f  a birth from a frozen oocyte (Chen 1986), the results o f 
this procedure worldw ide have been variable w ith a reported success rate o f  < 2% 
despite the improved success rate when combined with ICSI (Porcu et al. 2000). The 
poor success rates are due to the fragility o f  the meiotic spindle upon thawing, with an 
estimated 37% surviving the thawing process (Fabbri et al. 2001). O ktay and colleagues 
confirmed in a recent meta-analysis that live-birth rates per oocyte thawed were 
significantly lower (1.9%  with a slow-freeze protocol) when com pared w ith the case o f 
IVF with unfrozen oocytes (Oktay et al 2006). Despite this, the technique is still 
considered to have an im portant place in reproductive medicine, especially in this group 
o f patients who require fertility preservation (Van der Elst 2003).
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FIGURE 1.4. 1 Options for IVF in patients with breast cancer.
A suggested approach for oestrogen-receptor negative (ER -VE) patients might be to undergo natural- 
cycle or conventional IVF. Since the possibility exists that ER-VE patients can still have a small fraction 
of cells staining for the ER, one might consider Tamoxifen or Letrozole stimulated protocols for all 
patients. If high ER positivity is a concern, one might exclude the Tamoxifen/FSH protocol as this can 
cause high circulating oestradiol levels (Oktay et al. 2005).
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1.4.4 OVARIAN TISSUE CRYOPRESERVATION
This has been a topic o f renewed and intense interest as a viable alternative to restore 
both fertility and ovarian function to women with cancer (Falcone et al. 2004). Earlier 
studies provided a basis for the technique by showing that pregnancies and livebirths 
could be achieved in anim als by reimplanting cryopreserved-thawed ovarian cortical 
strips in sheep (Baird et al. 1999; Gosden et al. 1994).
There are im portant concerns regarding this technique. First, the tissue is 
obtained from cortical slices o f  the ovary obtained at laparoscopy, w hich exposes the 
patient to a surgical procedure requiring anaesthesia. Following storage, the options are 
regrafting the frozen-thaw ed ovarian cortex as an orthotopic (Radford et al. 2001) or 
heterotopic auto graft (Oktay & Karlikaya 2000).
A significant step was achieved when the first livebirth after transplantation of 
ovarian tissue in non-hum an primates was reported (Lee et al. 2004). Progress in 
humans has also finally becom e possible after several years o f  effort. Oktay recently 
described fertilisation and form ation o f  a four-cell embryo using eggs retrieved from re­
implanted ovarian tissue from a 30 year old wom an with breast cancer (Oktay et al. 
2004). In another m ajor breakthrough, Donnez and colleagues recently announced 
resumption o f  ovarian function followed by a livebirth in a w om an with H odgkin’s 
lymphoma, who underw ent orthotopic autotransplantation o f  cryopreserved ovarian 
tissue almost six years after removal (Donnez et al. 2004).
One o f the problem s encountered with this technique is the short-term viability 
o f the graft, regardless o f w hether it is an orthotopic or heterotopic allograft, resulting in 
a limited window of opportunity. This necessitates an intention to conceive w ithin a 
short space o f  time, and may preclude patients o f an older age group from offering such 
treatment, as the num ber o f  follicles obtained is likely to be lower (O ktay et al. 2001;
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Oktay & K arlikaya 2000). W hole ovary transplantation has been attempted with 
successful pregnancy following transplantation o f frozen-thawed rat ovaries (W ang et al. 
2002). An attempt to do the same in humans has recently been reported with limited 
success (Bedaiwy & Falcone 2004). M ore recently, using a m icrosurgical technique, 
large pieces o f  ovarian cortex from a monozygotic twin was transferred to the atrophic 
ovary o f a recipient tw in who had undergone POF, with viability o f  the transplant being 
documented (Silber et al. 2005).
Concern about the possibility o f  grafting tissue which can potentially harbour 
malignant cells has been raised using a mouse lymphoma model (Shaw et al. 1996). 
Recom mendations put forw ard to reduce this risk include the identification o f  patients 
with low risk o f m alignant potential, careful histological evaluation o f  retrieved tissue 
and the use o f  m olecular biologic techniques to detect occult cancer cells (Sonmezer, 
Shamonki, & Oktay 2005). An attractive solution to these concerns would be in vitro 
maturation o f  prim ordial follicles (discussed below) or xenotransplantation. The latter 
carries the risk o f  transm ission o f  prions or animal viruses accom panying the retrieved 
oocytes.
Advances in this field, w hich have only recently been announced, have created a 
new sense o f  enthusiasm and optimism for a technique that up to now  has been 
completely experimental.
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FIGURE 1.4. 2 Options for the use o f cryopreserved ovarian cortical tissue.
Ovarian grafts can be re-implanted into the donor (allograft) either at the same site (orthotopic) or 
elsewhere (heterotopic). Follicles can be cultured from the same tissue to undergo in-vitro maturation 
(IVM). Here the mature follicles can be cryopreserved for future use. The final option is to xenograft the 
tissue into an animal host.
1.4.5 IN VITRO M ATURATION OF OOCYTES
This is considered an attractive goal as it w ould elim inate any risk o f  re-im planting 
residual cancer cells and could in theory produce m ore m ature oocytes by avoiding 
follicle wastage created by ischem ia or normal atresia. Follow ing retrieval from fresh 
cortical tissue or follicular aspirate, the oocytes are m atured in-vitro following which 
they m ay be vitrified or fertilised by  ICSI and cryopreserved (Cha & Chian 1998). 
A lthough not w idely practised, pregnancy rates after IVM (using im m ature antral 
follicles) has exceeded 30% in some centres, with an estim ated 300 healthy infants bom
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worldwide (Chian, Lim, & Tan 2004). Primordial follicle culture how ever has proven to 
be particularly more challenging and is the subject o f intense research interest (Gosden 
et al. 2002).
Although the advantages o f  this procedure in patients w ith cancer are readily 
apparent, there are im mense ethical, moral and sometimes legal dilem m as associated 
with these procedures and as such should not be ignored (Robertson 2000). W ith this in 
mind, continuing research in the field has created optimism for clinical use in the future 
(Chian, Lim, & Tan 2004). Until then, it should not be considered a viable alternative 
for patients who want fertility preservation if  more established alternatives are an option 
(Revel & Schenker 2004).
1.4.6 OVARIAN PROTECTION
The potential protective role o f  luteinizing-releasing-hormone agonists on the 
primordial follicle pool was first established in rodents (Ataya et al. 1985), then rhesus 
monkeys (Ataya et al. 1995). A ttem pts have been made in humans by the administration 
o f prior and concom itant treatm ent with gonadotrophin releasing horm one analogues 
(GnRHa) (Blum enfeld et al. 1996; Blumenfeld et al. 1999). These studies were 
relatively small and the duration o f follow up was short, thus preventing a true 
estimation o f  the protective effect o f  GnRH agonists.
Zoladex™  has been com pared with CMF where it was found that Goserelin 
offers an effective, w ell-tolerated alternative to CMF in prem enopausal patients with 
ER-positive and node-positive early breast cancer (Jonat et al. 2002). Concerns exist 
regarding the side effects o f  Goserelin, but these are considered to be reversible 
(Nystedt et al. 2003).
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Despite encouraging results in animal models, few clinical studies have 
evaluated the effect o f  GnRHa co-treatment in preventing chem otherapy induced POF 
in cancer patients (Blumenfeld 2003). The questionable presence o f  GnRH receptors in 
human gonadal tissue also challenges the presumed m echanism  o f  action (Clayton & 
Huhtaniemi 1982). Prim ordial follicles are believed to initiate grow th via an FSH 
independent receptor m echanism  (Gougeon 1998). I f  this is the case, it implies that 
GnRH agonists could not mediate their protective effect via FSH receptors. Furthermore, 
the safety o f  their use is yet to be established. These questions can only be answered by 
sufficiently large, random ised prospective studies. One such study is currently 
underway in the UK attem pting to address this issue (O varian Protection Trial In 
Oestrogen N on-responsive Premenopausal Breast Cancer Patients Receiving Adjuvant 
or N eo-adjuvant Chem otherapy “ O P T IO N ” ; Scottish Cancer Network).
1.4.7 OOCYTE DONATION
It should not go unm entioned that the only option available to w om en who have 
undergone POF (other than adoption/surrogacy) remains oocyte donation. In this 
technique, the donor undergoes IVF while the recipient needs horm one replacement 
therapy for uterine support. Success rates are very good, in the range o f  40 to 50 %  per 
cycle (Lobo 2005). A nother advantage is that the age o f  the recipient is not a factor. One 
major practical drawback is that donors are very difficult to find.
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1.4.8 SUM M ARY OF FERTILTY PRESERVATION TECHNIQUES
Fertility preservation techniques have evolved to the extent that there are now several 
options available to the patient with breast cancer. It is im portant to rem em ber that 
despite several encouraging advances m ade in this area, the best option for patients who 
are suitable rem ains embryo cryopreservation. W ith the continual developm ent o f  these 
techniques however, the ideal scenario m ay develop where it m ight be possible to offer 
an individualised approach to m anagem ent (Del Mastro & Venturini 2006; Sonm ezer & 
Oktay 2006). This process m ight be facilitated by accurate estim ation o f  a patient’s 
ovarian reserve prior to undergoing fertility preservation, as will be discussed in the 
following section. Safety rem ains a m ajor concern how ever (Gerber et al. 2007; Jones 
2006; W ildiers et al. 2006). The Am erican Society o f  Clinical Oncology (ASCO) has 
responded to these concerns by publishing guidelines on fertility preservation during 
cancer therapy (Lee et al. 2006). It is essential therefore that further research is 
perform ed to validate the clinical safety o f  these procedures before m aking them part o f 
routine clinical practice.
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FIGURE 1.4. 3 Success rates for various methods of fertility preservation.
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1.5 OVARIAN RESERVE
1.5.1 DEFINITION A N D  INTRODUCTION
Fertility potential in the female patient is related to the total num ber and quality o f the 
primordial follicles rem aining in the ovaries and is referred to as ovarian reserve. The
function o f these follicles is twofold: gametogenesis (which governs fertility potential),
and steroidogenesis (which governs the onset o f  a premature menopause).
Ovarian reserve tests (ORT) have become established in the fertility setting 
where the association o f  poor ovarian response due to dim inished reserve leads to cycle 
cancellation and reduced success rates in in-vitro fertilisation (IVF) (Pellicer et al. 
1987). A lthough natural fecundity and pregnancy rates decrease with increasing age (te 
Velde & Pearson 2002), the need for ORT was clearly apparent when it was established 
that chronological age and menstrual characteristics were unreliable in predicting 
reproductive age (Scott et al. 1995). Several models have now  been described which 
accurately depict the progressive decline o f  primordial follicles in the ovary with a 
w om an’s age (Faddy et al. 1992; Faddy & Gosden 1996; Gougeon, Ecochard, & 
Thalabard 1994; Richardson, Senikas, & Nelson 1987).
The m ost im portant aspect o f  dim inished ovarian reserve and the associated 
decline in reproductive potential is that its onset is highly variable (Scott, Jr. & 
Hofmann 1995). Furtherm ore, the presence o f regular menses does not establish the 
presence o f adequate ovarian reserve, as the ovary has the ability to m aintain a high 
frequency and number o f  ovulations despite continuously declining follicle number 
(Gosden 1987). Hence the continual decline in follicle num ber and quality can best be 
described as a dynamic process, the mechanisms o f which are not yet fully understood 
(te Velde 1993).
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1.5.2 REPRODUCTIVE AGEING AND OVARIAN RESERVE
Reproductive ageing is a concept intimately related to ovarian reserve, as it could 
potentially predict age at menopause, a measure which is known to be highly variable 
(Treloar 1981). Biochemical markers also show a marked variability, w ith FSH levels 
not increasing perm anently until 1-5 years after the onset o f  the perim enopause (Burger 
et al. 1999). Inhibins and activins have also been explored (Santoro, Adel, & Skumick
1999), and it has been suggested that there is a subtle decrease in inhibin B prior to the 
rise o f  FSH (Soules, Battaglia, & Klein 1998). U ltrasound determ ination o f  ovarian 
volume and AFC have also been utilised with some success (Flaws et al. 2001).
Several hypotheses have been forwarded in an attempt to describe the process o f 
reproductive ageing (Lobo 2003; N ikolaou & Templeton 2003). The basic doctrine 
which has prevailed to explain the concept o f ovarian reserve and reproductive ageing 
assumes that the age-dependent loss o f fertility in females is dictated by a continual 
process o f  follicle depletion (from a pool that is fixed from fetal life), leading to a 
reduction in both oocyte quantity and quality. This has recently been challenged by the 
reported finding o f  the existence o f  proliferative germ cells that sustain oocyte and 
follicle production using a mouse model (Johnson et al. 2004b) -  a finding that has yet 
to be replicated or confirmed. The prevailing concept rem ains therefore that 
reproductive ageing itse lf is highly variable (te Velde & Pearson 2002).
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1.5.3 OVARIAN RESERVE AND CANCER
The concept o f ORT in patients with cancer is a relatively new  one, and as such data 
pertaining to ovarian reserve tests in cancer are limited.
Initial studies in breast cancer documented the effect o f  cyclophospham ide on 
cyclical ovarian function (Koyam a et al. 1977; Rose & Davis 1977; W am e et al. 1973). 
Studies at that time were more focused on the therapeutic significance o f ovarian 
suppression in the treatm ent o f  breast cancer, and it is fair to say that m any clinical trials 
on breast cancer treatm ent failed to report this effect on ovarian function. Later studies 
focused on the relationship between patient age, type and dose o f  chem otherapy with 
the onset o f am enorrhoea and premature ovarian failure (POF) using clinical and 
biochemical param eters. Biochem ical parameters used were alm ost exclusively 
gonadotrophin estim ation (FSH and LH) and oestradiol. These studies revealed an 
endocrine profile in am enorrhoeic patients resembling premature ovarian failure (POF) 
and an inverse relationship with age (Bonadonna, Rossi, & V alagussa 1985; Dnistrian et 
al. 1983; Jordan, Fritz, & Torm ey 1987; Padmanabhan et al. 1987; Rose & Davis 1977; 
Samaan et al. 1978; Sherman, W allace, & Bean 1982). Reduced m enstrual activity (not 
amenorrhoea) was also shown to be associated with a highly variable endocrine profile 
(Dowsett & Richner 1991). These studies were mostly retrospective and heterogeneous 
in terms o f definitions used for am enorrhoea and POF respectively. They did however 
establish that ovarian dysfunction was related to patient age, dose and duration o f 
treatment (Reichman & Green 1994; Shapiro & Recht 1994). Ovarian volum e has been 
estimated in patients w ith breast cancer but the objective here was to establish a 
reference range for ovarian volume in postmenopausal patients on tam oxifen (Cohen et 
al. 1997). Overall, there is a lack o f pertinent data relating to ovarian reserve testing in 
patients with breast cancer.
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M ore progress has been achieved with regards to estim ating ovarian reserve in 
patients w ith haem atological malignancy. For example, it has been shown in a 
prospective study that ovarian volume in patients with lymphoma and leukaem ia treated 
by high-dose chem otherapy and radiotherapy was reduced by 50% within 72 hours o f 
cessation o f  high dose therapy (Chatterjee et al. 1994). In another study using the HMG 
test there was dim inished ovarian reserve in patients with lym phom a treated by BEAM 
(carmustine, etoposide, cytarabine and melphalan) chem otherapy, and many patients 
had dim inished ovarian reserve even prior to chem otherapy due to antecedent 
chemotherapy or disease (Chatterjee & Goldstone 1996). This led to the description o f 
the Gonadal Insufficiency -  Prem ature Gonadal Failure syndrome (Chatterjee & 
Kottaridis 2002). As the nam e implies, the syndrome describes a heterogeneous picture 
whereby the gonadotoxic effect o f  these agents is not “all or nothing” but can be both 
acute and cum ulative, w ith the ovaries possessing a limited capacity for recovery. These 
authors m ade an attem pt to grade the extent o f damage using clinical, biochemical and 
biophysical param eters, how ever it was noted that the clinical picture was variable and 
as such did not always com ply with these parameters. As such the potential for ovarian 
recovery, as well as the response to therapy, was unpredictable. W hile this model may 
not be directly applicable to breast cancer, it remains an attractive one w hich highlights 
the importance o f  developing tests which can accurately estimate ovarian damage and 
correlate it w ith clinical features.
More recently, inhibin A and inhibin B (in addition to FSH, LH and oestradiol), 
have been assessed prospectively as prognostic factors for resum ption o f  ovarian 
function in patients with lym phoma who received GnRH analogue co-treatm ent, with 
encouraging results (Blumenfeld 2002).
Recognition o f the fact that successful treatment o f  childhood cancer can be 
associated with im paired gonadal function in adulthood (Thom son et al. 2002) has led to
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increased efforts to estimate ovarian reserve in long-term survivors o f  childhood cancer. 
Basal gonadotrophins are unreliable in prepubertal children due to the relative 
quiescence o f  the HPO axis. Some investigators have proposed the use o f  inhibin B 
levels where suppression may have been indicative o f  arrested follicle development 
(Crofton et al. 2003). A nother study revealed that despite regular m enstrual cycles, 
survivors o f childhood cancer had smaller OV, reduced AFC and inhibin B compared 
with controls (Larsen et al. 2003b). The same authors showed that in a cancer survivor 
cohort with FSH levels < 10 IU/1, ovarian reserve was still reduced as evidenced by 
smaller ovarian volum es and lower AFC compared with age-m atched controls (Larsen 
et al. 2003a). A sim ilar cohort o f cancer survivors, that included some w om en on the 
com bined oral contraceptive pill (COCP), had tests o f ovarian reserve performed 
following an FSH stim ulation test. Here the investigators found differences in AMH, 
FSH and OV com pared with controls (Bath et al. 2003).
Despite these findings, the data cannot necessarily be extrapolated to patients 
with different types o f  cancer due to differences in disease, type o f  chem otherapy and 
the demographics o f  the population studied.
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FIGURE 1.5.1 Pathophysiology o f chemotherapy-induced gonadal damage.
Current evidence suggests chemotherapy type and dose in combination with patient age are major 
determinants of reduced ovarian reserve. Less evidence exists to support the notion that the cancer disease 
process itself may be implicated, as well as the patient’s ovarian reserve prior to treatment. The major 
sequelae are reduced fertility and premature ovarian failure.
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1.5.4 CLASSIFICATION OF OVARIAN RESERVE TESTS (ORT)
There are various ways o f  classifying ORT. In terms o f  m echanism  o f  action they can 
be classified as being static or dynamic in nature or alternatively, as being direct or 
indirect. The most specific classification would divide ORT into clinical, biochemical 
and biophysical param eters. This classification will be em ployed throughout the thesis.
1.5.4.1 CLINICAL PARAM ETERS
These would usually include chronological age in years, body mass index (BMI) and 
menstrual characteristics.
1.5.4.2 BIO CHEM ICA L PARAM ETERS
These would include basal (early follicular phase) levels o f follicle stim ulating hormone 
(FSH), Luteinising horm one (LH), Oestradiol (E2), inhibin A and B, activin A, 
follistatin and anti-mullerian hormone (AMH). Ovarian stim ulation tests include the G- 
test, the HM G stim ulation test, the exogenous FSH stim ulation test, and the clomiphene 
citrate challenge test.
1.5.4.3 BIOPHYSICAL PARAM ETERS
These include ultrasound determ ination o f ovarian volume, antral follicle count, doppler 
indices o f ovarian stromal blood flow and uterine dimensions. A lso included in this 
category is histological determ ination o f  follicle density in ovarian cortical specimens.
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1.5.4.4 RESPONSE TO CONTROLLED OVARIAN HYPERSTIM ULATIO N 
This is the response, measured in biochemical, biophysical or other param eters (oocyte 
or embryo retrieval, pregnancy etc.) to controlled ovarian hyperstim ulation (COH) 
during IVF.
BIOPHYSICAL BIOCHEMICAL
ULTRASOUND:
• 2D OR 3D
• OVARIAN VOLUM E
• ANTRAL FOLLICLE COUNT
• OVARIAN STROM AL BLOOD 
FLOW
BASAL (EARLY FOLLICULAR) 
LEVELS:
• FSH, (LH)
• E2
• INHIBIN B, (INHIBIN A)
• ANTI M ULLERIAN HORMONE
• (ACTIVIN A, FOLLISTATIN)
• (PRO aC)
(FOLLICLE D ENSITY) OVARIAN STIM ULATION  TESTS:
• G-TEST
• HM G TEST
• CLOM IPHENE CITRATE 
CHALLENGE TEST (CCCT)
• FSH (EFORT)
TA B L E  1.5. 1 Established b iochem ical and biophysical ovarian reserve tests in reproductive m edicine. 
Markers in parentheses have as yet a very limited research base to support their use as markers o f  ovarian
reserve.
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1.5.5 CLINICAL PARAMETERS
1.5.5.1 CHRONOLOGICAL AGE
W hile it is important to make the distinction between chronological age as opposed to 
reproductive age, there is no doubt that the former is inherently linked to ovarian 
reserve. The evidence pertaining to the continual decline o f  prim ordial follicles with 
increasing age has already been mentioned. Similarly, the effect o f  age on female 
fecundity has been well docum ented (Noord-Zaadstra et al. 1991; Schw artz & M ayaux 
1982), while the effect on oocyte quality is depicted in rising aneuploidy rates and 
implantation failure (O 'Connor, Holman, & W ood 1998).Ovarian reserve is not solely 
dependent on age however. W hile it is clear that assisted conception outcomes are 
com prom ised by advanced maternal age (Klipstein et al. 2005; Swanton & Child 2005), 
it is certainly not the only factor as outcomes have been shown to be compromised 
independent o f  age (Scott et al. 1995). The limitations o f chronological age as a marker 
o f  ovarian reserve m ake the investigation o f other markers compulsory.
1.5.5.2 BODY M ASS INDEX (BMI)
This is an internationally agreed objective assessm ent o f  obesity. The exact relationship 
however between BM I and pregnancy outcome remains unclear. W hilst it seems BM I is 
related to m enstrual irregularity and anovulation, published studies conflict as to 
whether or not BMI may predict pregnancy outcome (Frankel & Staeheli 1992; 
Frattarelli & Kodama 2004; Lashen et al. 1999; Lashen, Fear, & Sturdee 2004; Lewis et 
al. 1990; Loveland et al. 2001; Tinkanen et al. 1999; W ang, Davies, & N orm an 2000; 
W ittem er et al. 2000). It is considered a poor estimate o f ovarian reserve.
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1.5.6 BASAL BIOCHEMICAL PARAMETERS
1.5.6.1 FOLLICLE STIM ULATING HORM ONE (FSH)
Basal serum follicle stim ulating hormone (bFSH) is considered an indirect estimate o f 
ovarian reserve and depends on the presence o f  an intact hypothalam ic-pituitary-ovarian 
(HPO) axis. It is one o f the longest established param eters for estimating ovarian 
reserve. The first reports on the usefulness o f bFSH measurements showed FSH to be 
predictive o f ovarian response and pregnancy outcome in IVF cycles (M uasher et al. 
1988; Scott et al. 1989), and to be more predictive than the patient’s age (Toner et al. 
1991). Subsequent studies have supported this, including a large retrospective analysis 
o f IVF patients where elevated FSH was associated with high pregnancy loss and poor 
live birth rates, regardless o f age (Levi et al. 2001).
However there are now several studies that challenge the predictive capabilities 
o f  bFSH, especially when a patient’s age is considered. For example, in patients 
undergoing their first IVF cycle, bFSH concentration was a better predictor o f 
cancellation rate than age, yet age was a stronger predictor o f  pregnancy rate (Creus et 
al. 2000; Sharif et al. 1998). Some studies suggest that young age exerts a protective 
effect over the deleterious effects o f  reduced ovarian reserve (Hanoch et al. 1998), while 
others reveal no difference in outcome between younger and older w om en with elevated 
bFSH (El Toukhy et al. 2002). A retrospective cohort study o f  IVF patients revealed 
that increasing age, but not bFSH, was associated significantly w ith reduced 
implantation and pregnancy rates (Chuang et al. 2003). A recent prospective study in 
which regularly cycling women above and below  the age o f 40, w ith elevated bFSH 
levels undergoing their first IVF cycle were compared for ovarian response, ongoing 
pregnancy rates and implantation rates. A lthough younger women with elevated bFSH 
levels had higher cycle cancellation rates, im plantation and ongoing pregnancy was
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superior to their older counterparts (van Rooij et al. 2003). This has prompted the 
distinction that when a comparison is made, age better reflects egg quality whilst FSH 
reflects egg quantity (Toner 2003). This study has been criticised how ever for a lack o f 
adequate controlling and statistical power (M cDonough 2003).
Cut-off levels for bFSH are also an issue. In one study, w hich is unique for its 
duration o f follow-up, ongoing pregnancy was seen in as many as 28% o f regularly 
cycling women with FSH levels between 15-20 IU/1. Only when the FSH level 
exceeded 20IU/1 was there a clear fall in ongoing pregnancy rate regardless o f age (van 
Rooij et al. 2004). A high cut-off level o f FSH to achieve acceptable prediction o f 
treatment failure has been reported elsewhere (Bancsi et al. 2000). It seems therefore 
that younger w om en w ith moderate elevations o f FSH should not be ignored (Toner 
2004). Younger wom en (age < 41  years) with elevated bFSH levels who have a poor 1st 
response to IVF how ever may represent a specific group which should be counselled 
against further attem pts as was shown in a recent retrospective study (Klinkert et al. 
2004). W hich threshold level o f  bFSH to use is the question, as some investigators have 
shown that moderately elevated levels o f FSH (defined as 10-11.4 IU/L) are difficult to 
interpret as these may be confounded by a poor response to gonadotrophin stimulation 
(Esposito, Coutifaris, & Barnhart 2002).
As m ost o f the data regarding the performance o f  bFSH in predicting ovarian 
reserve comes from studies in an IVF population, it is significant that a recent m eta­
analysis concluded that the performance o f basal FSH for predicting poor ovarian 
response in this group was moderate, while prediction o f  non-pregnancy was poor 
(Bancsi et al. 2003). Information pertaining to the general subfertile population is 
lacking, but a nested case-control study revealed no statistically significant difference in 
cumulative pregnancy rates between patients with elevated bFSH levels and controls 
(Van Montfrans et al. 2000). Others have shown elevated bFSH to be o f  limited value in
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patients w ith regular cycles, in that it should not lead to exclusion o f  treatment (van 
Rooij et al. 2004).
Questions remain regarding the reproducibility o f  bFSH m easurem ents (Sharara, 
Scott, Jr., & Seifer 1998). One o f  its main limitations is the significant intercycle 
variability o f FSH, hence limiting the usefulness o f a normal value (Scott, Jr. et al. 
1990). A recent random ised prospective study revealed that wom en w ith limited ovarian 
reserve exhibited strong intercycle variability o f bFSH and FSH response to clomiphene 
citrate (Kwee et al. 2004). A study performed on normally ovulating wom en under the 
age o f 35 revealed a large inter-individual variation in bFSH (Schipper, de Jong, & 
Fauser 1998). Intracycle variability seems to be less o f an issue, w ith some flexibility 
being apparent in sam pling from days 2-5 o f a regular menstrual cycle (Hansen et al. 
1996; K lein et al. 1996). Repeat basal FSH measurements have also been shown to be 
futile both in a retrospective (Abdalla & Thum 2006) as well as in a prospective 
analysis (Bancsi et al. 2004), in that reproductive outcome is not altered.
A nother concern is the establishment o f  normative data w ithin individual 
laboratories owing to the likelihood o f interassay variability (Hershlag et al. 1992). The 
establishment o f threshold values within individual assay systems is also important to 
prevent errors in interpretation o f results especially when clinical outcom es are being 
correlated. This is more likely to happen in institutions where the clinical volume o f 
patients is insufficient to allow these threshold values to be established (Scott, Jr. 2004).
Other reasons for an elevated bFSH should be considered (Lam balk 2003). 
Laboratory errors can occur in the presence o f  heterophilic antibodies, which can 
interfere with the FSH im munoassay (Cahill, Fox, & Thomas 1992; de Koning et al. 
2000). Increased levels and pulsatility o f FSH in the follicular phase is seen in mothers 
o f hereditary dizygotic twins (Lambalk et al. 1998). FSH receptor variants have now 
been identified (Perez et al. 2000; Sudo et al. 2002). There are two known
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polym orphisms o f clinical relevance in the follicle-stimulating hormone (FSH) receptor 
exon 10 alanine or threonine at position 307, and asparagine or serine at position 680, 
giving rise to two discrete allelic variants: Thr307/Asn680 and Ala307/Ser680. It has 
been hypothesized that FSH receptor genotyping could potentially be used as an adjunct 
indicator o f ovarian reserve as the presence o f  such variants m ay cause slightly 
diminished receptor function, resulting in higher levels o f  FSH to achieve adequate 
receptor response whilst not necessarily affecting ovarian reserve (Falconer et al. 2005).
The sensitivity o f  bFSH in identifying women who will not becom e pregnant 
with IVF has been calculated to be only 8%, whereas it is considered to be a specific 
test, in that 98% o f w om en who achieved pregnancy had normal findings (Barnhart & 
O sheroff 1998). The positive predictive value (possibility o f not becom ing pregnant 
given a positive test result) o f the test is difficult to interpret, especially in younger 
patients or the general subfertile population where the prevalence o f  nonpregnancy is 
lower. As such there is a danger o f  overinterpreting its predictive value (Barnhart & 
O sheroff 1999). The reasons for these conflicting reports are not entirely clear, but are 
certainly related to the varying methodologies employed by different investigators, 
especially with regard to different cut-off values for FSH, study groups, outcome 
measures and their definitions, duration o f  follow up and data analysis.
Efforts to increase the sensitivity o f prediction have been attempted by 
combining FSH with Luteinising hormone (LH) as a ratio o f  FSH: LH with limited 
success (Kim et al. 1997; M ukherjee et al. 1996).
Despite these limitations, more studies have been performed, and hence much 
more is known, about the predictive value o f FSH than any other m arker o f  ovarian 
reserve. This, combined with the relative practicality, patient tolerability and low cost o f 
performing the test, is likely to result in basal FSH rem aining one o f  the most 
commonly performed tests o f  ovarian reserve for some time to come.
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1.5.6.2 OESTRADIOL
The condensed follicular phase length in older women may be as a result o f a more 
advanced follicular recruitm ent by cycle day 3. This early dominant follicle selection is 
expressed by high serum oestradiol (E2) concentrations (Licciardi, Liu, & Rosenwaks 
1995).
It has been shown in an ART population (where G nR H a’s were not 
administered) that increasing day 3 oestradiol concentrations are associated with 
decreasing oocyte numbers and pregnancy rates (Licciardi, Liu, & Rosenwaks 1995), a 
correlation which has been repeated elsewhere (Smotrich et al. 1995). In patients with 
normal FSH levels, bE 2 has been shown to predict high cancellation rates and low 
oocyte yield in IVF (Evers et al. 1998). In another study, cancellation rates did correlate 
with bE2 levels but did not correlate with pregnancy outcome in those patients who were 
not cancelled (Frattarelli et al. 2000). Pregnancy rates have also been shown to be 
higher in a group o f  w om en undergoing in-vitro maturation due to male/tubal factor 
(Mikkelsen et al. 2001). The predictive ability o f  bE2 is im proved in patients o f 
advanced reproductive age, especially when combined with basal FSH (Buyalos, 
Daneshmand, & Brzechffa 1997). However, these observations have not been 
confirmed by others (Lee et al. 1988; Scott et al. 1989). Com bination with serum 
progesterone as a ratio did not improve predictive capacity (Hofmann, Khoury, & 
Michener 2002; Younis et al. 2001).
No data are currently available regarding basal oestradiol levels in the general 
subfertile population (Bukman & Heineman 2001). Furthermore there appears to be 
significant intra-cycle variability (Hansen et al. 1996). Further studies including data on 
day 3 oestradiol values and fecundity in spontaneous cycles are required before 
evaluating this param eter further. For the moment it appears not to provide any more 
information than bFSH alone.
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outcom e better 
than age and 
bFSH
bE2 can 
predict 
response to 
IVF in 
presence o f  
normal bFSH
bE2 predicts CR  
but not 
pregnancy  
outcom e if  
on going  
pregnancy
TABLE 1 .5 .3  Basal oestradiol as a predictor o f  fertility.
PR = pregnancy rate, CR = cancellation  rate, CPR = clinical pregnancy rate, FR = fertilisation rate, 
LBR = live birth rate, RO = retrieved oocytes, A R T = A ssisted reproduction
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1.5.6.3 INH IBINS, ACTIVINS A N D  FOLLISTATINS
Inhibins and activins are glycoproteins that belong to the transforming growth factor - p 
(TGF-P) family (see figure 2.5.3). Activins are dimers o f  P subunits and act as 
functional antagonists o f  inhibin to stimulate pituitary FSH synthesis and secretion 
(Muttukrishna & Knight 1991). Pro aC  consists o f  higher m olecular weight inhibins 
containing the pro region o f the a  subunit and the biologically inert monomeric pro 
alpha subunits. Follistatin is a cysteine rich monomeric peptide structurally unrelated to 
inhibin or activin. Its m ain function is to bind irreversibly to and neutralize activin 
(Nakamura et al. 1990). Activins and inhibins and their receptors are known to 
modulate a variety o f  physiologic processes in various tissues including the human 
breast, where they potentially play a role as inhibitors o f  cell proliferation and breast 
tum our suppression respectively (Reis et al. 2004).
The role o f  activin and follistatin as markers o f  ovarian reserve is not clear. 
There is little doubt that these hormones have autocrine/paracrine actions on the HPO 
axis, as shown in patients w ith PCOS with follicular arrest (Eldar-Geva et al. 2001). 
More recently, inhibin concentrations from follicular fluid were also shown to be 
reduced in patients w ith PCOS (W elt et al. 2005). Overall, it seems from studies on 
different species that in normal circumstances activin secretion is decreased whilst 
inhibin and follistatin production is increased as a follicle matures (Schneyer et al. 
2000). There is how ever evidence relating to the role o f activin A and follistatin in 
abnormal pregnancies, an active area o f research (M uttukrishna et al. 2004). M ost o f the 
following discussion will focus on the role o f inhibins as ovarian reserve markers.
Inhibins are heterodimers consisting o f two dissimilar subunits ( a  and p) linked 
by disulphide bridges, and are secreted by the ovarian granulosa and luteal cells during 
the menstrual cycle (Lockwood, Muttukrishna, & Ledger 1998). They are a part o f  the
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HPO axis, specifically having an inhibitory effect on pituitary FSH synthesis and 
secretion (M uttukrishna & Knight 1990) (See figure 2.5.5). Serum dim eric inhibin B is 
regarded as a direct m easure o f  ovarian reserve as it is m ainly secreted by pre-antral 
follicles (Klein et al. 1996), whereas inhibin A is produced prim arily during the late 
follicular phase by the m ature follicle and by the corpus luteum (Roberts et al. 1993).
INHIBIN B
INHIBIN A
©  CD
PRIMARY P R E -A N T R A L  a m t b a i  r n i i i n t :  P R E -O V U L A T O R Y  (MATURE)
FOLLICLE FOLLICLE ANTRAL FOLLICLE FOLLICLE
FIGURE 2.5. 2 Differential secretion o f inhibin A and inhibin B by granulosa cells at different stages of 
follicle maturation.
Inhibin B rises from early in the follicular phase to reach a peak coincident w ith the 
onset o f  the m id-follicular phase decline in FSH concentrations, and then declines 
during the luteal phase apart from a peri-ovular peak, which m ay represent release o f  
follicular inhibin B from the rupturing follicle into the circulation (G room e et al. 1996; 
M uttukrishna et al. 1994). Inhibin B has also been shown to respond to exogenous FSH 
adm inistration in the follicular phase (Burger, Groome, & Robertson 1998). The close 
tem poral relationship between changes in levels o f  inhibin B and FSH in the m id- 
follicular phase suggest that the release o f  inhibin B by  the preovulatory follicle
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critically regulates pituitary FSH secretion, with inhibin B exhibiting a distinct 
periodicity in normal women (Lockwood et al. 1998). Studies in older women reveal 
significantly lower levels o f  inhibin B in women o f 40-50 years o f  age with raised FSH 
compared to women with normal FSH (Klein et al. 1996b; M uttukrishna et al. 2000). 
Additionally, concentrations o f inhibin A and B have been shown to be lower in women 
with elevated FSH and regular menstrual cycles (de Koning et al. 2000).
Studies in an ART population demonstrated that w om en with low cycle day 3 
inhibin B concentrations (<45 pg/ml) had a poorer response to ovulation induction and 
decreased likelihood o f achieving pregnancy compared with w om en who had higher 
day 3 inhibin B levels (Seifer et al. 1997). Decreased inhibin B was also found in 
w om en w ith norm al FSH levels implying that decreased inhibin B precedes a rise in 
FSH (Seifer et al. 1999). D oubt has been expressed however regarding the quality o f the 
inhibin B assays used in these earlier studies (Bancsi, Broekmans, & te Velde 1997).
Correlation with other markers o f  ovarian reserve has been shown (Tinkanen et 
al. 2001). There is evidence that early follicular inhibin B levels correlate with follicle 
cohort size (Elting et al. 2001) and oocytes retrieved following controlled ovarian 
stimulation with FSH (Eldar-Geva et al. 2000; Eldar-Geva et al. 2002), and with an 
improved sensitivity and specificity compared to other basal markers o f  ovarian reserve 
(Ficicioglu et al. 2003). A nother study which also showed good correlation with oocytes 
retrieved did not show  a correlation with pregnancy (Fried et al. 2003). Inhibin B levels 
on cycle day-5 have been shown to be predictive as an early indicator o f  response 
during ovarian stimulation as well as outcome (Fawzy et al. 2002; Penarrubia et al.
2000). The predictive ability o f  basal inhibin B with regards to pregnancy has not been 
confirmed by several authors, leading to doubt regarding the clinical usefulness o f day 3 
inhibin levels in clinical practice (Corson et al. 1999; Creus et al. 2000; Dumesic et al. 
2001; Hall, Welt, & Cram er 1999).
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Studies regarding basal inhibin A have also shown a link with ovarian function 
and follicular development, but limited value in predicting IVF outcome (Casper et al. 
2001; Hall, Welt, & Cramer 1999). Inhibin A may be o f more value in older women 
where it has been shown that the follicular phase peak o f  inhibin A was significantly 
lower in women with raised FSH (M uttukrishna et al. 2000).
W ith regards to dynamic testing, inhibin B has been evaluated in predicting 
response to ovarian stim ulation (Ficicioglu et al. 2003). These include the clomiphene 
citrate challenge test (CCCT) (Hofmann, Danforth, & Seifer 1998), gonadotrophin- 
releasing hormone agonist test (G- test) (Ravhon et al. 2000) and the FSH stimulation 
test (EFORT) (Dzik et al. 2000; Eldar-Geva et al. 2002). These studies are all limited by 
the fact that although they show correlation with ovarian response, predictive value was 
not evaluated (W elt 2002). M ore recently however, studies suggest that the incremental 
increase in inhibin B following ovarian stimulation may be more predictive o f ART 
outcome than basal levels o f  inhibin B. In a prospective study, the inhibin B response to 
exogenous FSH correlated well with the antral follicle count (AFC) and the number o f 
oocytes received (Yong et al. 2003). Kwee and colleagues undertook a prospective 
randomised study, w hich compared endocrine markers o f  ovarian reserve using the 
CCCT and EFORT to predict ovarian response, and revealed a high correlation with 
inhibin B in EFORT for num ber o f follicles after ovarian stim ulation, w ith increments 
in oestradiol and inhibin B providing prediction o f ovarian capacity (Kwee et al. 2003).
The reasons for these conflicting reports are not clear and m ay reflect inter-assay 
variability and differing reference points and standards am ongst different institutions, 
resulting in reduced specificity o f  the inhibin assay. Given the expense o f  performing 
the test, further prospective evaluation and confirmation o f  its predictive capacity is 
required before inhibin B can assume a routine place in the clinical assessm ent o f 
women with reduced ovarian reserve (Tong, Wallace, & Burger 2003).
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S S S
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FIGURE 1.5. 3 Structure of inhibin A, inhibin B, activin and follistatin. 
Follistatin structure represents a polypeptide.
S = disulphide bridge
58
1.5.6.4 ANTI-M ULLERIAN HORMONE (AM H)
Also known as mullerian inhibiting substance (MIS), this is the m ost recent o f the 
biochemical ovarian reserve markers to be investigated. In females, the granulosa cells 
o f the ovary produce AM H, which is a member o f  the transform ing growth factor -p 
(TGF-P) family. Levels can be almost undetectable at birth (Rajpert-De M eyts et al. 
1999), with a subtle increase noted after puberty (Hudson et al. 1990). Serum levels on 
day 3 o f the menstrual cycle show a progressive decrease with age, w hich correlates 
with antral follicle counts (de Vet et al. 2002).
The exact physiological basis o f AMH is poorly understood in humans. The 
main physiologic effect is the regression o f M ullerian ducts in male fetuses (Josso et al. 
1998). In females, based mainly on in vitro work and experiments performed in rats, 
AMH seems to play a pivotal role with regard to follicle selection and recruitment. 
There is evidence that AM H is mainly expressed in pre-antral and early antral follicles 
and not by prim ordial follicles (Baarends et al. 1995). Using a bone morphogenetic 
protein (BMP) -  like pathway, A M H signalling inhibits the recruitm ent o f  primordial 
follicles into the pool o f  growing follicles and also decreases the responsiveness o f 
growing follicles to FSH, thus regulating dominant follicle selection (Durlinger, Visser, 
& Themmen 2002; Visser & Themmen 2005). Recent progress has been made with 
regards to elucidating the role o f AMH during folliculogenesis in humans. Using 
immunohistochemistry on ovarian sections obtained from healthy, regularly cycling 
women, the authors were able to show that AMH expression was sim ilar to the patterns 
seen in mice (W eenen et al. 2004). AMH also appears to encourage growth o f 
primordial follicles in vitro (Schmidt et al. 2005).
In vivo studies during controlled ovarian hyperstim ulation (COH) have shown 
AMH levels declining gradually, presumably due to the increased num ber o f  mature
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follicles expressing less AMH (Fanchin et al. 2003), then increase during the mid-luteal 
phase, reflecting luteal follicle development (Fanchin et al. 2005). These findings 
suggest that AMH is solely produced by antral follicles capable o f  growing, and as such 
serum levels o f AMH may represent both the quantity and quality o f  the ovarian follicle 
pool (te Velde & Pearson 2002). The potential exists therefore for AM H to provide an 
accurate estimate o f  the size o f the growing follicular pool -  a direct m arker o f ovarian 
reserve. Studies have shown an association between reduced baseline serum AM H and 
poor response to IVF (Seifer et al. 2002; van Rooij et al. 2002). The potential to assess 
oocyte quality is reflected in studies which show that AMH best predicts clinical 
pregnancy rate com pared to other markers (Hazout et al. 2004) as well as embryo 
morphology (Silberstein et al. 2006). The relationship between AM H and other markers 
o f ovarian reserve has been assessed, where AMH was found to correlate more strongly 
with the antral follicle count (AFC) than basal inhibin B, E2, FSH and LH in an infertile 
population (Fanchin et al. 2003). Correlation with AFC was also confirmed in patients 
with PCOS, even into late reproductive age (Piltonen et al. 2005). W hen compared to 
these markers in term s o f  predicting IVF outcome, AM H appeared to be superior 
(Eldar-Geva et al. 2005; M uttukrishna et al. 2004).
Serum AM H levels have been measured at different tim es during the menstrual 
cycle, suggesting minimal fluctuation. (Cook et al. 2000) This im plies that AM H levels 
are relatively convenient to determine, making it an attractive determ inant o f ovarian 
reserve (Gruijters et al. 2003). One study in an IVF setting showed im proved predictive 
capacity o f day 5 AM H over basal levels (Penarrubia et al. 2005). More recently 
however, a study has shown that AMH measurement on any day o f  the menstrual cycle 
could predict ovarian response in women undergoing IVF (La M arca et al. 2007). 
Normative data have been published (Cook et al. 2000), and it w ould appear that AMH 
expression is relatively stable throughout the menstrual cycle (La M arca et al. 2006). A
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recent study has suggested that inter-cycle variability is m inimal (Fanchin et al. 2005). 
The assays are expensive, though sensitive and specific (Long et al. 2000). New er 
assays are being developed, which should help address the issues o f  expense, inter-assay 
variability and the setting up o f  standardised reference values (Al Qahtani et al. 2005).
The potential o f AM H as a direct m arker o f  ovarian reserve, and its relatively 
stable expression during the m enstrual cycle, would appear to justify  further validation. 
More research is required into the relationship between AMH and ovarian follicle 
dynamics, and as a m arker o f  ovarian reserve in the general population before allowing 
its entry into clinical practice.
FSH
AMH
+VE
- VE
PRIMARY
FOLLICLE
PRE-ANTRAL
FOLLICLE
ANTRAL
FOLLICLE
PRE-OVULATORY
FOLLICLE
RECRUITMENT SELECTION
FIGURE 1.5. 4 Role of AMH in folliculogenesis.
Granulosa cells from the developing antral follicles produce AMH, which has an inhibitory effect on 
follicle recruitment and inhibits the stimulatory effect o f FSH on pre-antral and antral follicles, thus 
influencing dominant follicle selection.
-VE = negative feedback, +VE = positive feedback
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TABLE 1 .5 .5  A M H  as a marker o f  ovarian reserve.
RO = retrieved oocytes, a  = proportional, A FC  = antral fo llic le  count, A R T  = assisted reproduction
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1.5.7 DYNAM IC OVARIAN RESERVE TESTS
1.5.7.1 INTRODUCTION
The recognised limitations o f  basal biochemical markers o f  ovarian reserve has led to 
the development o f a num ber o f dynamic ovarian tests in an attem pt to “unmask” 
patients whose dim inished ovarian reserve may have been missed using basal markers 
(Scott, Jr. & Hofmann 1995).
1.5.7.2 GnRH AGONIST STIM ULATION TEST (G-test)
This test evaluates the oestradiol serum concentration change from cycle day 2 to day 3 
after adm inistration o f  a GnRH agonist. This is administered at a supraphysiologic dose, 
causing a tem porary increase in pituitary secretion o f FSH and LH, to w hich the ovaries 
respond by releasing oestradiol (Sharara, Scott, Jr., & Seifer 1998).
Early studies were able to show a limited ability for the early rise in oestradiol 
concentration to predict ovarian response during IVF, albeit with different cut-off values 
(Avrech et al. 1996; Padilla 1995; W inslow et al. 1991). Others have looked at the sum 
o f stimulated and basal FSH concentrations with some success, but was not superior to 
bFSH (Galtier-Dereure et al. 1996). In a significant study, the actual increase in 
oestradiol concentration from day 2 to day 3 (AE2) following GnRH agonist 
administration on day 2 was a better predictor o f  ovarian reserve than age, basal FSH 
and FSH: LH ratio (Ranieri et al. 1998). The same authors were also able to 
demonstrate that such an assessm ent would also allow effective drug regim en selection 
for IVF (Ranieri et al. 2001).
As inhibin B is considered a direct marker o f  ovarian reserve, com bining it with 
the G-test might improve the predictive value o f the test for IVF outcome. In fact,
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changes in the concentrations o f inhibin B and oestradiol have both been shown to 
correlate highly with the ovarian response to stimulation for IVF treatm ent (Ravhon et 
al. 2000). A recent study used single or repeated G-test and com pared it with other 
markers o f ovarian reserve. W hilst the G-test was able to predict poor response in IVF, 
it was poor at predicting ongoing pregnancy, especially com pared to AFC and inhibin B. 
Furthermore, there seemed to be no advantage in using repeated tests (Hendriks et al. 
2005b).
The G-test appears to have much promise as a dynamic test o f  ovarian reserve 
but has not yet been validated outside an assisted reproductive setting. Furthermore the 
cost o f perform ing the test has limited its acceptability in the general infertility 
population.
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TABLE 1.5. 6 G -test as a marker o f  ovarian reserve.
PR = O ngoing pregnancy rate, RO = retrieved oocytes, ART = assisted reproduction 
AE2 = difference betw een stim ulated and baseline oestradiol levels
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1.5.7.3 CLOM IPHENE CITRATE CHALLENGE TEST (CCCT)
First described by N avot in 1987, this test involves the adm inistration o f lOOmg 
clomiphene citrate on cycle days 5-9, and the determination o f  FSH (or inhibin) 
concentrations on days 3 and 10 (Navot, Rosenwaks, & M argalioth 1987). In women 
with normal ovarian reserve, the overall increase in oestradiol and inhibin production by 
the developing follicles should be able to overcome the oestrogen antagonist effect o f 
clomiphene on the H -P -0  axis, and suppress FSH levels back into the normal range by 
day 10.
Evidence for the physiologic suppressive effect o f inhibin was supported by a 
study, which showed reduced inhibin B levels following the CCCT in women with 
reduced ovarian reserve (Hofmann, Danforth, & Seifer 1998). In this way, the CCCT 
may be more indicative o f oocyte quality than quantity. Nevertheless, a quantitative 
relationship between the CCCT and follicle density has been shown (Gulekli et al. 
1999).
Several studies have now  been published which show that w om en with a normal 
test respond better to ovarian stimulation, while an excessive response predicted a poor 
outcome to controlled ovarian hyperstimulation for IVF (Csemiczky, Harlin, & Fried 
2002; Hofmann et al. 1996; Loumaye et al. 1990; Ng et al. 2005; Tanbo et al. 1992). 
Correlation with biophysical markers o f ovarian reserve (ovarian volum e, AFC) has 
been shown in an infertile population (Erdem et al. 2004). The CCCT also predicts for 
improved pregnancy rates compared with age alone in an IVF (Scott, Jr. & Hofmann 
1995) or general subfertile population (Scott, Jr. et al. 1993).
A retrospective study o f  women under 40 years o f age revealed an inverse 
relationship between the likelihood o f successful pregnancy and CCCT findings, with 
no definite threshold being identified for FSH beyond w hich no pregnancy could be 
achieved (Yanushpolsky et al. 2003). The patient’s age should not be ignored however,
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as pregnancy rates still dim inish in patients with advancing age despite a normal CCCT 
(Scott et al. 1995). This limitation renders the test, although highly specific, o f low 
sensitivity (26%), albeit higher than that o f bFSH (Barnhart & O sheroff 1998).
There has been renewed interest in the evaluation o f the CCCT. In a recent 
meta-analysis, there appeared to be no advantage o f the CCCT over bFSH in predicting 
clinical pregnancy (Jain, Soules, & Collins 2004). Reproducibility has been addressed, 
as repeating the CCCT predicts poor outcome just as well as a single test, but neither 
single or repeat CCCT performed better than a combination o f other markers (Hendriks 
et al. 2005a). A nother investigator however detected significant intercycle variability 
with the CCCT, which correlated with reduced ovarian reserve (Kwee et al. 2004).
These results are possibly related to the fact that the exact relationship between 
elevated day 3 FSH levels and day 10 levels following the CCCT remains to be 
elucidated (Scott et al. 1995).Until this question is answered from further prospective 
study, the value o f  perform ing the test in the presence o f a raised bFSH m ust remain in 
doubt.
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TA BLE 1.5. 7 CCCT as a marker o f  ovarian reserve.
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1.5.7.4 EXOGENOUS FSH OVARIAN RESERVE TEST (EFORT)
This test combines bFSH with the rise in oestradiol (AE2) over a 24-hour period after 
administration o f a standardised dose (300IU) o f purified FSH on day 3. More recently, 
other markers have been incorporated as part o f the test (inhibin B, AM H, AFC), which 
adds to the evaluation o f  these markers as it applies to follicle dynamics (Hohmann et al. 
2005).
Using this test, one group was able to improve the predictive value o f bFSH 
alone for IVF outcome in stim ulated cycles (Fanchin et al. 1994). A randomised, 
prospective study in w hich basal and dynamic tests o f ovarian reserve were compared 
revealed that EFORT was the best predictor o f ovarian reserve (Kwee et al. 2003). More 
recently, various biochem ical and biophysical markers o f ovarian reserve were assessed 
as part o f the EFORT. This study revealed that AFC, basal AMH and stimulated inhibin 
B provided good predictive capacity for oocytes retrieved (Eldar-Geva et al. 2005). In 
another study, stim ulated levels o f inhibin B correlated better with age than basal 
markers (Pastor et al. 2005). Further prospective evaluation is required to validate this 
test properly.
1.5.7.5 HMG STIM ULATION TEST
In comparison to other stim ulation tests, the HMG test provides perhaps the greatest 
ovarian stimulation. In the most recent study using this test, basal values o f  FSH, E2 and 
inhibin were compared with hormonal and ultrasound param eters perform ed after 5 
days stimulation with HM G (Fabregues et al. 2000). Although the predictive value o f 
the rise in E2 for response to IVF was better than bFSH alone, it was not very specific. 
Furthermore, the ability to predict pregnancy was less than that provided by the 
wom an’s age (Fabregues et al. 2000). These results, and the expense o f  performing it
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may explain the relative lack o f  popularity in performing this dynamic test in routine 
practice (Sharif et al. 1998).
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K w ee 
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POPULATION A R T A RT A R T A R T
A ge < 38
ST U D Y  DESIG N Prospective Prospective Prospective RCT Prospective
PT/CY C LES 52 80 110 56
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Inhibin B 
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TABLE 1.5. 8 EFORT and HM G as markers o f  ovarian reserve.
A RT = assisted reproduction, PR= pregnancy rate, CR = cancellation rate, RO = retrieved oocytes, 
N S = not specified , N /A  = not applicable
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1.5.7.6 RESPONSE TO CONTROLLED OVARIAN HYPERSTIM ULATION 
Regardless o f  which method is used to predict ovarian response in IVF, one could argue 
that the final assessment lies in the patient’s response to controlled ovarian 
hyperstimulation (COH). The concept o f differentiating a patient’s response to 
gonadotrophin stim ulation into high, intermediate or low developed many years ago is 
still applicable today (Jones, Garcia, & Rosenwaks 1984). A lthough this group o f 
patients are distinct from the general subfertile population, studies in this area have 
provided useful insight into the concept o f ovarian reserve. One m ight consider it to be 
an extended form o f dynam ic testing.
O f particular interest, distinct cohorts o f infertile women, w ith regular cycles (de 
Boer et al. 2003) and in addition normal basal FSH levels who do not respond to COH 
(poor responders), have been shown to develop premature ovarian failure (Farhi et al. 
1997; Lawson et al. 2003; N ikolaou et al. 2002). This potential relationship has been 
challenged by others (De Sutter & Dhont 2003), especially if  the poor response is 
detected at a young age (Hanoch et al. 1998). Poor responders also seem to exhibit 
characteristics o f  reduced ovarian reserve when they are tested following a poor 
response to COH (Beckers et al. 2002). Despite these findings, w om en with a poor 
response to COH in the 1st IVF cycle can still have a normal response in subsequent 
cycles (Klinkert et al. 2004). W hat adds to the difficulty o f interpreting these events is 
the lack o f a uniform definition for poor response among different institutions. It would 
seem that the most widely used definition pertains to the num ber o f  oocytes retrieved in 
a first or subsequent cycle (Hellberg, Waldenstrom, & Nilsson 2004).
Accurately identifying poor responders to IVF remains the focus o f  extensive 
and ongoing research, but effective treatment has proven to be extrem ely difficult 
(Lashen et al. 1999; Tarlatzis et al. 2003). Whilst it does seem that repeated stimulation 
cycles are not detrimental to ovarian reserve (Serna & Garcia-Velasco 2005), there is
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recent evidence to support the notion that natural or semi-natural cycle IVF may be just 
as effective as COH, especially in younger patients (Castelo et al. 2005; M orgia et al. 
2004).
Poor response to COH has been attracting considerable interest recently as a 
marker o f  ovarian ageing. This is likely to have a considerable im pact on the long-term 
quality o f life o f  patients. Although the m odel it provides is attractive, in that it involves 
a dynamic test w ith strictly controlled conditions and outcomes, it is lim ited by the fact
that application to the general population is not appropriate.
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T A B L E  1.5. 9 Poor response to Controlled Ovarian H yperstim ulation as a predictor o f  POF. 
POF = Premature ovarian failure, A R T  = assisted reproduction, A E2 = delta oestradiol
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FIGURE 1.5.5 The Hypothalamic -  Pituitary-Ovarian (HPO) axis and the physiologic basis for 
biochemical tests o f ovarian reserve.
The ovary is shown during different phases o f follicular maturation. Components of dynamic ovarian 
reserve testing are shown at the points on the HPO axis where they act.
+VE = positive feedback, -VE = negative feedback
? = Not yet fully elucidated, GnRH = Gonadotrophin releasing hormone, G-test — GnRH analogue 
stimulation test, EFORT = Exogenous FSH ovarian reserve test, HMG = human menopausal 
gonadotrophin, AMH = anti-mullerian hormone
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1.5.8 BIOPHYSICAL PARAMETERS
1.5.8.1 INTRODUCTION
These tests offer an opportunity to assess follicle dynamics directly by examining 
ovarian morphology, and thus are considered direct measures o f  ovarian reserve. One 
may deduce that the num ber o f remaining follicles in the ovary is related to fertility or 
the likelihood o f entering menopause (Faddy et al. 1992). The routine presence o f 
transvaginal ultrasound in general fertility and gynaecology clinics m ay also contribute 
to the increased popularity o f these methods.
1.5.8.2 ANTRAL FOLLICLE COUNT (AFC)
Since the relationship between declining AFC and increasing age was first described 
(Ruess et al. 1996), many attempts have been made to establish a relationship between 
AFC and ovarian reserve. The assumption is that the number o f antral follicles
originating from the cohort o f  growing follicles also correlates w ith the number o f
primordial follicles, or ovarian reserve (Scheffer et al. 1999). AFC is usually defined as 
the number o f  follicles less than 1 Omm in diameter detected by ultrasound in the early 
follicular phase.
Studies in women with proven fertility reveal a continual decline o f AFC with 
age, which correlates better w ith chronological age than other horm onal and ultrasound 
markers (Ng et al. 2003; Scheffer et al. 2003). In this population, it appears that AFC 
correlates best with other markers o f ovarian reserve especially in older age groups 
(Erdem et al. 2003; Kline et al. 2005).
AFC has been shown to be predictive o f ovarian response (Chang et al. 1998a; 
Chang et al. 1998b; Frattarelli et al. 2003; Hsieh, Chang, & Tsai 2001; M uttukrishna et 
al. 2005; Nahum et al. 2001; Ng, Tang, & Ho 2000; Pohl et al. 2000; Tom as, Nuojua-
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Huttunen, & M artikainen 1997), and can predict pregnancy loss in patients undergoing 
IVF (Elter et al. 2005). This predictive capacity seems to improve with advancing age 
(Klinkert et al. 2005). Compared with other markers o f  ovarian reserve, the AFC may 
be the best predictor o f  response to exogenous gonadotrophins (Bancsi et al. 2002) and 
correlates independently w ith the number o f  oocytes retrieved during IVF (Yong et al
2003). A recent m eta-analysis was conducted which com pared the perform ance o f AFC 
with bFSH to predict poor ovarian response in IVF. The results showed that AFC was 
superior at predicting poor ovarian response, but was not very good at predicting non­
pregnant outcome (Hendriks et al. 2005c). These poor responders, as predicted by AFC, 
do not benefit from increasing the starting gonadotrophin dose (Klinkert et al. 2005). 
Kwee and colleagues conducted a randomised, prospective study that compared antral 
follicle count (AFC), basal ovarian volume (BOV), the exogenous FSH ovarian reserve 
test (EFORT) and the clomiphene citrate challenge test (CCCT), with respect to their 
ability to predict poor and hyper responders. They concluded that AFC performed well 
as a test for ovarian response, being superior or at least similar to what they described as 
complex expensive and time consuming endocrine tests, thus supporting the use o f AFC 
in general fertility practice (Kwee et al. 2007).
Reproducibility has been addressed and described as being moderate, with 
decreasing agreement at higher AFC (Scheffer et al. 2002). However this study was 
limited to two observers. Intercycle variability has also been described as moderate in a 
fertile population (Scheffer et al. 1999). Others have shown that intercycle variability 
was greater than interobserver variations, suggesting a biological variation o f AFC from 
cycle to cycle (Hansen et al. 2003). The only prospective assessm ent o f  intercycle 
variability in a general subfertile population revealed that it increased w ith younger age 
(Elter, Sismanoglu, & Durmusoglu 2005). As has been reported by other investigators, 
identification o f  an optimal cycle for stimulation did not predict significantly better
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outcomes, and as such a single measurement o f AFC is recom m ended (Bancsi et al. 
2004; Hansen et al. 2003). There has been recent debate however regarding the optimal 
time in the cycle to perform AFC. Some argue that in order to detect developing 
follicles optimally, AFC should be assessed from day 5-7 as opposed to the early 
follicular phase (Durmusoglu et al. 2004; Kline et al. 2005). As w ould be expected, 
there also appears to be a link between AFC and the age o f onset o f  menopause, yet the 
exact relationship remains to be defined (Broekmans et al. 2004).
Overall the results o f these studies show considerable promise for the use of 
AFC in the estimation o f ovarian reserve. The procedure is relatively inexpensive and 
easy to perform, and can provide information immediately - before biochemical results 
are obtainable. M ore data is required in different cohorts and a more rigorous 
assessment o f interobserver variability is required before it becomes part o f  routine 
clinical practice.
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TABLE 1.5. 10 Antral fo llic le  count as a predictor o f  ovarian reserve.
CR = cancellation rate, RO = retrieved oocytes, OR = ovarian response, PR = pregnancy rate, O V  = 
ovarian volum e, EFO RT = exogenous FSH ovarian reserve test, CCCT = clom iphene citrate challenge  
test.
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1.5.8.3 O VARIAN VOLUM E (OV)
The hum an ovary is a dynamic organ, which changes in size and activity throughout its 
lifetime. M ean OV increases from 0.7cm3 at age 10 years to 5.8cm3 at age 17 years 
(Ivarsson, Nilsson, & Persson 1983). Although there is limited data on OV in normal 
fertile women (Lass & Brinsden 1999), studies suggest that there are no m ajor changes 
in OV during the reproductive period in individual women until the premenopausal 
period (Christensen, Boldsen, & W estergaard 1997; Ng et al. 2003). Ovarian size has 
been shown to decrease in wom en > 40 years old, a trend which is apparently unaffected 
by parity (A ndolf et al. 1987; Oppermann, Fuchs, & Spritzer 2003). The largest study to 
address the relationship between age and ovarian volume showed a progressive decline 
in OV from age 30 to 70, w ith a dramatic drop in OV occurring after the menopause 
(Pavlik et al. 2000) . These findings have led to the evaluation o f  OV as a useful marker 
o f  menopausal status (Flaws et al. 2000; Flaws et al. 2001), with good correlation being 
shown between OV, m enopausal status and age (Giacobbe et al. 2004).
W ith regards to assessm ent o f  ovarian reserve, an early study found a correlation 
between OV and reproductive outcome in IVF cycles, but no correlation was found with 
chronological age (Syrop, W illhoite, & Van Voorhis 1995). Stronger correlations have 
since been shown between OV and controlled ovarian hyperstim ulation (COH) (Lass et 
al. 1997; Sharara & M cClam rock 1999). Small OV (<3cm 3) is associated with a poor 
response to HMG and a very high cancellation rate during IVF (Syrop et al. 1999). One 
study was able to show a relationship between OV and the num ber o f  follicles before 
stimulation, but not the num ber o f  oocytes retrieved (Tomas, N uojua-Huttunen, & 
M artikainen 1997), a finding that has been confirmed elsewhere (Dum esic et al. 2001; 
Tinkanen et al. 1999). W hen likelihood ratios are calculated from some o f  these studies, 
the overall conclusion is that OV is not a good predictor o f  pregnancy (Bukman &
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Heineman 2001), but when a cut-off value o f 3cm3 is used, OV can be predictive o f 
failure o f  follicular stimulation (Lass & Brinsden 1999).
More recently, studies in an IVF setting have shown that a m ean ovarian volume 
(MOV) o f < 2cm3 (Frattarelli et al. 2004) and mean ovarian diam eter < 20.6 mm 
(Vladimirov, Tacheva, & Kalinov 2004) correlates with higher cancellation rates. W hen 
compared with other markers o f ovarian reserve as part o f a CCCT, OV performed well 
in predicting ovarian response (Erdem et al. 2004).
Wallace and colleagues have recently proposed a model using ovarian volume to 
predict reproductive age. By estimating the mean primordial follicle population in 
women aged 25 to 51 years using the Faddy-Gosden equation (Faddy & Gosden 1996), 
and correlating it w ith m ean ovarian volume at each chronological age as described by 
Pavlik (Pavlik et al. 2000), reproductive age (age at menopause in this model) can be 
estimated (W allace & K elsey 2004). Others have produced a quadratic model which 
shows that ovarian volum e follows a continuously increasing rate o f decline after age 30 
(Tufan, Elter, & D urm usoglu 2004). These models make a critical assumption that 
primordial follicle populations are fixed at birth, a notion that has recently been 
challenged (Johnson et al. 2004). Correlation has been shown between decreasing MOV 
and age with inhibin B and FSH in women aged 35-50 (Vural, Vural, & Yucesoy 2005). 
Whether or not ovarian volume can accurately reflect prim ordial follicle numbers or 
indeed follicle quality is questionable. The latter may be more im portant if  reproductive 
age is to be correlated w ith fertility outcome.
Intra and inter-observer variations in measurement o f  OV have been reported by 
some as being small, ensuring reproducibility (Higgins et al. 1990; Lass et al. 1997). 
Intercycle variability has recently been reported as being significant in a general 
infertile population, which appeared to be independent o f age (Elter, Sismanoglu, & 
Durmusoglu 2005).
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OV estimation using conventional ultrasound is inexpensive and relatively easy 
to perform. A recent meta-analysis compared the predictive capacity o f  OV towards 
poor response with AFC in an IVF setting. In this study, both param eters were found to 
have a poor overall accuracy for predicting non-pregnant outcome. However, OV was 
found to be inferior to AFC, thus leading to the recom mendation that AFC and not OV 
be the first choice in evaluating patients prior to IVF (Hendriks et al. 2007).
Perhaps the main limitation regarding the use o f ovarian volum e measurements 
at present in clinical practice is the lack o f data regarding OV measurements in the 
general population, both fertile and infertile, across different age cohorts. W hen this is 
achieved, ovarian volum e measurements are likely to play a more im portant role in the 
clinical estim ation o f  ovarian reserve.
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TABLE 1.5. 11 Ovarian volum e as a predictor o f  ovarian reserve.
M O V  = Mean ovarian volum e, PR = pregnancy rate, CR = cancellation rate,
RO =  retrieved oocytes
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1.5.8.4 OVARIAN STROMAL BLOOD FLOW (OSBF)
The rationale for this test lies in the supposition that the primordial follicles in the ovary 
have no independent capillary network, and therefore depend on their proxim ity to the 
stromal vessels for their supply o f  nutrients and hormones (Findlay 1986). Studies have 
shown a relationship between peri-follicular blood flow doppler indices and oocyte 
developmental competence/im plantation potential (Chui et al. 1997; Huey et al. 1999; 
Nargund et al. 1996).
A relationship has been established between ovarian stromal blood flow velocity 
and ovarian follicular response (Zaidi et al. 1996). This was confirmed in a cohort o f 
patients with normal basal FSH undergoing IVF treatment following pituitary 
suppression, in w hich mean ovarian stromal peak systolic velocity (PSV) was a better 
predictor o f ovarian responsiveness than age (Engmann et al. 1999), while resistance 
index (RI) was more predictive in a similar study (Bassil et al. 1997). By assigning a 
quantitative “total doppler score” based on the number and area o f  doppler signals in the 
ovary, some investigators have been able to predict ovarian response in IVF (Popovic- 
Todorovic et al. 2003) In another study based on a fertile population however, age was 
not related to mean PSV, although power doppler was not used (Ng et al. 2003). When 
3D power doppler was employed, the results implied that OSBF indices declined slowly 
with age, becoming significantly reduced only in women > 41 years (Ng et al. 2004). 
The same authors have studied 2D power doppler in an IVF setting and were unable to 
determine any predictive capacity for OSBF indices with regard to ovarian response (Ng 
et al. 2005).
A limitation o f this technique is that it is very operator dependent. It requires an 
ultrasonographer o f  considerable experience to obtain accurately the angle between the 
ultrasound beam and the intra-ovarian vessels in order to measure peak systolic velocity. 
This may result in a prolonged scanning time for acquisition o f data. It has been
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suggested that 3D USS can circumvent this difficulty (Kupesic & Kurjak 2002). Using 
vascularisation-flow indices, 3D power Doppler USS has been used to show that flow 
intensity in the ovarian stroma decreases with age in general (Pan et al. 2002) and is less 
in infertile patients (Kupesic et al. 2003). Another study was unable to show a 
correlation between these indices and ovarian response during IVF, with inter and intra­
observer variability being described as acceptable (Jarvela et al. 2003). M ore recent 
applications using 3D power-doppler are now being reported, including measurement o f 
endometrial and subendometrial blood flow, the results o f which are very preliminary 
(Ng et al. 2006).
Further study is required to assess the predictive value and reproducibility o f 
ovarian stromal blood flow measurements compared to other biophysical markers o f 
ovarian reserve before entering routine clinical practice.
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TABLE 1.5. 12 Ovarian stromal blood flow  parameters.
RO = retrieved oocytes, PR = pregnancy rate, OR = ovarian response P SV  = peak systo lic  velocity , RI =  
resistance index, PI = pulsatility index
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1.5.8.5 THREE DIM ENSIONAL ULTRASO UND (3D USS)
It has been suggested that 3D USS can improve the prediction o f  ovarian response to 
gonadotrophin stimulation, compared to conventional transvaginal ultrasound with 
power Doppler imaging. 3D imaging yields a more accurate estimate o f OV, 
endometrial volume, AFC and assessment o f ovarian stromal perfusion by 3D power 
doppler (Kupesic 2001). Initial attempts to evaluate the use o f 3D USS in studying low 
responders to stim ulation for IVF proved that the technique was useful in differentiating 
poor responders who had normal baseline FSH levels (Pellicer et al. 1998). This study 
did not attempt to com pare 3D USS with conventional transvaginal (TV) ultrasound 
imaging. The role o f  3D USS in assessing OSBF has already been addressed in the 
previous section. To add to this, one study evaluated the use o f AFC, OV, stromal area 
and OSBF as assessed by 3D USS in predicting ovarian response and IVF outcome. In 
this study, OSBF and AFC seemed to be better predictors o f ovarian response than 
ovarian volume and total stromal area (Kupesic & Kurjak 2002). Reproducibility has 
been assessed with regard to AFC in a comparison between 2D and 3D USS, and has 
been described as being adequate (Scheffer et al. 2002).
One significant advantage o f 3DUSS over conventional TV USS that has 
emerged from these studies is the reduction in exam ination time required for these 
patients. Imaging data can be stored allowing further assessment to be performed 
without the presence o f  the patient. A significant disadvantage is the high cost o f  3D 
USS over conventional USS. M ore studies are required to compare the predictive ability 
o f both modalities prospectively. Until this data becomes available, 3D USS would not 
be expected to replace conventional USS for some time to come.
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REFERENCE Pellicer  
et al. 
1998
Kupesic 
et al. 
2002
K upesic  
et al. 
2003
POPULATION A RT ART A R T
ST U D Y  DESIGN Prospective
C ase-control
Prospective Prospective
PARAM ETERS
M EA SU R ED
A FC  and OV AFC, OV, total 
stromal area, O SBF
FLOW  IN D E X
A FC
OV
PT/CYCLE N U M B E R 18 56 56
O UTCO M E
M EA SU R E
Com parison between  
normal and low  
responders
RO, PR RO, FR, PR
C O N C L U SIO N A FC  but not OV  
discrim inates normal 
from low  responders
AFC and O SBF  
predicts outcom e
G ood correlation with  
age and ovarian 
response
TABLE 1.5. 13 3 D U S S a s a  predictor o f  ovarian reserve.
RO = retrieved oocytes, PR = pregnancy rate, FR = fertilisation rate,
A RT = assisted reproduction
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1.5.8.6 O VARIAN FOLLICLE DENSITY (OFD)
The histopathological exam ination o f ovarian biopsy specimens has been advocated as a 
direct marker o f ovarian reserve. Assessment o f follicular density from ovarian biopsies 
taken from 60 subfertile women with normal basal FSH levels showed a decline with 
increasing age, but the study did not follow up for pregnancy outcome (Lass et al. 
1997). A study performed on a cohort o f patients with Turner’s Syndrome who were 
undergoing ovarian tissue cryopreservation showed that OFD correlated with levels o f 
FSH (Hreinsson et al. 2002). In a unique study, women over 35 years o f age undergoing 
oophorectomy for uterine pathology had indirect markers o f ovarian reserve assessed in 
a previous cycle (G ulekli et al. 1999). Although a positive correlation was identified 
between basal serum oestradiol concentrations and follicle density in ovarian tissue, no 
significant correlation was seen between basal and clomiphene-stimulated FSH levels 
and OFD (Gulekli et al. 1999). Recent studies have suggested that while OFD may not 
add additional inform ation in patients with diminished ovarian reserve, the potential 
exists for it to be m ore informative in patients with POF (M assin et al. 2004; Vital- 
Reyes et al. 2006).
A major problem with this technique lies in the possibility that the follicle 
density measured in a particular specimen (biopsy site or histological section) may not 
reflect the picture in the rest o f  the ovary (Lass 2001). This was shown recently, where 
the follicle density o f  ovarian biopsy specimens obtained at the time o f  ovarian tissue 
cryopreservation varied by more than two orders o f magnitude, although there was a 
significant inverse linear correlation with age (Schmidt et al. 2003). Lam balk and 
colleagues attempted to investigate this further by performing multiple biopsies o f  2 and 
5mm and whole ovaries from 5 patients o f reproductive age, during operations not 
involving ovarian pathology (Lambalk et al. 2004). The authors attem pted to estimate 
total ovary follicle num ber by transforming biopsy counts based on surface area.
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Despite this, predictive values based on the biopsies were widely varied (Lam balk et al.
2004). At present, there are no standardised measures for OFD am ongst histopathology 
laboratories. This “correction factor” is necessary to account for that proportion o f the 
ovary not included in the sampling analysis, and may account for the large discrepancy 
in follicle numbers reported by various laboratories (Tilly 2003).
Another m ajor pertains to acquisition o f an adequate specimen, which includes 
the invasiveness o f  performing a biopsy and the risk o f  adhesion formation (Sharara & 
Scott 2004). One cannot put a patient through a surgical procedure to obtain a biopsy o f 
ovarian tissue o f  unproven value.
In the specific situation o f cancer patients undergoing ovarian tissue freezing for 
fertility preservation, OFD may be a useful research tool (Poirot et al. 2002). This 
possibility, as well as progress in estimating the distribution o f follicles in the ovarian 
cortex, still provides some hope for the clinical application o f this test in the future 
(Lass 2004; Sharara & Scott 2004).
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1.5.9 SUMM ARY OF OVARIAN RESERVE TESTS 
ORT has been developed originally in an assisted reproduction setting in the search for 
more reliable predictors o f IVF outcome. FSH is the longest established ORT, and 
appears to be superior to clinical predictors. The recognised limitations o f  basal markers 
such as FSH have led to the evaluation o f several other tests o f  ovarian reserve. 
Dynamic testing has the potential to unmask poor responders, in that it may reveal 
patients who would not have a good response to IVF stim ulation despite a normal 
baseline profile. New er biochemical parameters such as AMH and inhibin B have a 
sound physiologic basis as direct markers, but are expensive to perform. Biophysical 
markers such as AFC and ovarian volume are relatively convenient and easy to perform 
and provide “real tim e” inform ation on ovarian reserve. However, they require skilled 
personnel to perform transvaginal ultrasound especially if  OSBF is being measured. The 
expense is increased when 3D USS is considered.
Despite all the options available however, the ideal ovarian reserve test has yet 
to be identified. A recent systematic review showed that the O RT’s known to date have 
only modest to poor predictive properties with regards to IVF outcome, and as such 
should not be considered suitable for relevant clinical use (Broekmans et al. 2006). The 
poor predictive capacity o f ORT in the assisted reproduction setting has led to some 
considerable debate as to the value o f routine ovarian reserve testing (Balmaceda & 
Schwarze 2007; M aheshwari, Fowler, & Bhattacharya 2006). It would be fair to say that 
the tests perform fairly well as far as predicting response to ovarian stimulation, but 
can’t predict non-pregnant outcome because there are too many variables.
More information is required, using adequately controlled and prospective study 
designs o f  sufficient statistical power, outside a fertility setting.
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2. AIMS, HYPOTHESES AND STUDY DESIGN
2.1 IN VIVO STUDY
2.1.1 INTRODUCTION
In the previous chapter, several important points were established. These may be
summarised as follows:
• There is a rising incidence o f breast cancer and a significant proportion o f
women being treated for breast cancer are o f reproductive age at the time o f
diagnosis.
• These patients represent a distinct cohort with specific concerns regarding their 
fertility and the possibility o f having premature ovarian failure (POF).
• Ovarian reserve testing has become established in the fertility setting, where it is 
used as a counselling tool and a guide to treatment.
• The ideal ovarian reserve test (ORT) has yet to be identified.
• Very little is know n about chemotherapy-induced alterations in ovarian reserve.
• There is a lack o f  pertinent data relating to ovarian reserve testing in cancer, and 
information pertaining to ORT in a subfertile population cannot be extrapolated 
to include patients with cancer, as the pathophysiology is distinct.
• At the m om ent it is impossible to predict the exact life span o f  the
chemotherapeutically damaged ovary and the reproductive potential o f these 
patients.
• Patients with cancer would benefit from knowledge o f  their functional ovarian 
reserve. W ith this information, ovarian reserve testing could be applied clinically 
in patients with cancer as a guide to counselling and treatm ent w ith regards to 
reproductive health and fertility preservation.
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2.1.2 STUDY AIM AND HYPOTHESIS
The aim o f this study was to evaluate ovarian reserve in young women treated by m ulti­
agent cytotoxic chemotherapy for breast cancer by using clinical, biochemical and 
biophysical parameters. This was based on the hypothesis that cytotoxic drugs used to 
treat premenopausal patients with breast cancer can cause ovarian dam age resulting in 
diminished ovarian reserve.
2.1.3 STUDY DESIGN
2.1.3.1 INTRODUCTION
Information from previous studies on ovarian reserve in cancer are limited by a 
heterogeneous case m ix (including cancer diagnosis, chemotherapy regimens and age), 
as well as a lack o f prospective, controlled data. For this study, a breast cancer cohort 
was chosen for several reasons. First, it is the most common cancer in women o f 
reproductive age in the United Kingdom (and therefore relevant) and allows the study to 
be disease standardised. Second, the chemotherapy regimens used are similar (mainly 
E-CMF or FEC) and are cyclophosphamide based (thus reducing confounding due to 
type o f chemotherapy used). A control group was chosen that was not only age-matched, 
but had proven fertility, thus increasing the likelihood that the data obtained on ovarian 
reserve accurately reflected the normal range in a general fertile population. Finally the 
methodology employed for ovarian reserve testing was particularly robust in order to 
ensure reproducibility. A mixed longitudinal and cross sectional prospective case 
controlled study was designed, which for statistical purposes would need to comprise at 
least 20 patients and a similar number o f controls. Ethical approval was approved for 
the study to be undertaken comprising 80-100 chemotherapy treated cancer patients and 
60-80 age-matched, healthy control subjects.
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2.1.3.2 SAMPLE SIZE
Statistical advice was obtained from Dr Rumana Omar (M edical Statistics Department 
o f the Research and Developm ent Directorate, University College London). Based on 
her recommendations, it was estimated that a sample size o f  18 in each group (patients 
and controls) would have provided a 90% power o f detecting a statistically significant 
difference between the two groups. However to allow for dropouts or missing values the 
aim was to recruit at least 2 0  patients and 2 0  controls.
This recom mendation was based on published data regarding ovarian reserve in 
a general population, as well as in a fertility setting [FSH/LH (Van M ontfrans et al. 
2000), Oestradiol (Ranieri et al. 1998), Inhibin B (Seifer et al. 1997), M OV and AFC 
(Chang et al. 1998; Lass et al. 1997)]. There were insufficient data on all other indices 
of ovarian reserve used in this study in the general population.
PARAMETER MEAN S.D. ABNORMAL
CUT-OFF
Basal FSH 6.4 mlU/L 1.5 > 10.0
Basal LH 4.8 mlU/L 1.9 > 2 2 .0
Basal E2 180 pmol/L 50.0 < 120.0
a e 2 250.2 pmol/L 13.4 < 180.0
Basal inhibin B 143.73 pg/ml 46.0 < 4 5 .0
Mean Ovarian Volume 6.3 ml 3.1 < 2 .9
AFC 11.6 6.2 < 4 .0
TABLE 2. 1 R eference ranges used to perform the power calculation. 
S.D. = standard deviation.
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2.1.3.3 INCLUSION AND EXCLUSION CRITERIA 
Inclusion criteria for the study were as follows:
• Any patients with primary breast cancer prior to or after com pletion o f 
chemotherapy
• Age range 20 to 45 years
• Controls comprised women o f  the same age group and with at least one 
childbirth in the past
Exclusion criteria for the study were as follows:
• Patients with recurrent breast cancer
•  Patients who had received
o Zoladex ™  within the last 12 weeks 
o Tam oxifen within last 12 weeks
• Controls who had been on the oral contraceptive pill (OCP) within the last 8  
weeks
• Patients or controls with
o Premature ovarian failure 
o Suspected or proven pregnancy 
o Previous hysterectomy 
o Endocrinological illness 
o Poor medical condition
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2.1.3.4 STUDY PROTOCOL
In this study, pre-menopausal rec ip ien ts  o f  chemotherapy for breast cancer were 
analysed in two groups -  a long itud ina l arm (group 1) and a cross-sectional arm (group 
2). As all patients were recruited f ro m  a single centre, the chem otherapy regimens 
employed were standardised. T lre re  were two predom inant regimens, both 
cyclophosphamide-based. The first was E-CM F, which consisted o f  4 cycles o f 
epirubicin (E), followed by 4 cycles o f  cyclophosphamide(C), m ethotrexate(M ) and 5- 
fluorouracil(F). The second was F E C ,  w hich consisted o f 6  cycles o f  5-fluorouracil, 
epirubicin and cyclophospham ide. Some patients received taxanes (docetaxel or 
paclitaxel), usually as part o f a th e ra p eu tic  trial (TANGO).
In group 1, patients were o f fe re d  ovarian reserve testing prior to receiving 
chemotherapy. The same patients w e r e  then followed up longitudinally by performing 
further testing im mediately follow ing chemotherapy. In group 2, patients were tested for 
ovarian reserve prior to ch em o th erap y  (some patients were also part o f  the longitudinal 
study) and after chem otherapy (o n c e  regular menstrual cycles had resumed). Patients 
with oestrogen-sensitive cancer were rec ru ited  provided they had not taken tam oxifen or 
GnRH analogues (goserelin or le u p ro lin )  for at least the preceding 12 weeks.
Controls were age-matched, h a d  no m edical illness, had proven fertility (defined 
by virtue o f having at least one c h ild b ir th  previously) and had a normal menstrual 
history. Those on oral contraception were asked to discontinue it and use alternative 
(barrier) contraception for at least 8 w reeks prior to testing.
Informed consent was obtained f r o m  all participants. This study received ethical 
approval from the Joint UCL/UCLH E th ic s  Committee.
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Patient entry
Response to 
stimulation
Ovarian tissue 
freezing
Clinical data
BIOPHYSICAL
Embryo/ egg 
freezing
Treatment
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At testing
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Measure parameters 
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• FSH, LH, E2
• AMH
• Inhibin A and B
• Activin A, follistatin,
• Pro aC
FIGURE 2.1.1 IN VIVO STUDY DESIGN -  PART 1
This diagram illustrates the three main sources o f recruitment for the in vivo study. Once the inclusion 
criteria were met, appropriate consent was obtained and clinical details were recorded. Patients then 
underwent biochemical and biophysical ovarian reserve tests at various times as shown. Biochemical 
ovarian reserve tests were performed both as a baseline and as a component of the G-test (see chapter 4- 
methods) and included FSH, LH, E2, AMH, Inhibins A and B, Activin A, Pro aC and Follistatin. 
Biophysical ovarian reserve tests included antral follicle count and ovarian volume (total and mean), 
doppler flow indices (MPI and MPS) and uterine dimensions (CSA and ET). Response to ovarian 
stimulation and follicle density were not included in this study, but are areas of potential future interest.
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FIGURE 2.1.2 IN VIVO DESIGN - PART 2
This diagram illustrates where patients were grouped in the study. Patient’s recruited pre-chemotherapy 
also contributed to the cross-sectional analysis as shown. There were also three prospective time points 
studied as shown.
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FIGURE 2.1.3 Schedule for ovarian reserve tests
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2.1.4 ETHICAL APPROVAL AND INFORMED CONSENT
This study received ethical approval from the Joint UCL/UCLH committees on the 
ethics o f human research on 1st September 2003 (Research Ethics Committee (REC) R ef 
No: 03/0156; REC Name: Committee A).
Study title: Estimation of ovarian reserve in patients treated with cytotoxic
drugs for cancer
Informed consent was obtained from all patients and volunteers who agreed to 
participate in the study after being provided with verbal and written explanation. Both 
the information leaflets and consent forms were very comprehensive (appendices 9.3 
and 9.4 respectively).
2.1.5 DEMOGRAPHIC DATA
Clinical details o f  all patients and controls were recorded. This included data such as 
age, parity, m edical and gynaecologic histories, family history o f  breast and other 
cancers, premature m enopause, social and personal history (including smoking), 
medications and clinical characteristics such as height, weight and body mass index 
(BMI).
For patients who had already completed chemotherapy, data included full 
diagnosis (e.g. stage/grade etc), cancer treatment history and planned treatment and 
length o f remission. For patients who opted to have fertility treatment, data included 
number o f embryos (or eggs) stored, pregnancy and implantation rates, etc. For patients 
who opted to have ovarian tissue storage, data from the routinely taken histology 
(biopsy) sample were used, including the number o f eggs contained in, or the follicle 
density o f  the sample.
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2.1.6 DATASTORAG E
The research team was primarily responsible for security and access to data. All data 
was pseudoanonymised or linked in accordance with the data protection act 1998. Data 
safety, confidentiality and security were maintained by irretrievably removing names 
and identifiers. All samples and data were coded with the key available only to the main 
investigators.
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2.2 IN VITRO STUDY
2.2.1 INTRODUCTION
In the previous section, an in vivo study was described which was designed to examine 
the effect o f cytotoxic agents on ovarian reserve in patients receiving chemotherapy for 
breast cancer. As discussed earlier, the mechanism o f chem otherapy-induced ovarian 
failure is poorly understood. One o f the parameters involved in this process is the dose 
of chemotherapeutic agent administered. This is difficult to ascertain accurately in vivo, 
as other variables such as patient age and pre-morbid ovarian reserve m ust be taken into 
account. It seemed logical therefore that after performing the in vivo measurement, one 
should examine the effect o f these agents on specific ovarian cells and to compare the 
potency o f the drugs used between breast and ovarian cells to investigate the difference. 
An attempt was therefore made in vitro to compare the cytotoxicity o f  drugs commonly 
employed in breast cancer on granulosa cells, as the function o f  these cells could be 
considered analogous to markers o f ovarian reserve.
2.2.2 BACKGROUND
Granulosa cells proliferate with follicular development, and their functional capacity 
can be estimated in follicular fluid by measuring inhibin and activin (Lau et al. 1999). 
The secretion o f  inhibin and activin has been shown to controlled differentially by 
gonadotrophins in vitro (Muttukrishna, Groome, & Ledger 1997). Steroidogenesis can 
also be assessed by measurement o f oestradiol and progesterone, which has been shown 
to vary with chronological age from cultured human ovarian granulosa cells (Denkova 
et al. 2 0 0 0 ).
Few studies exist that evaluate the effect o f cytotoxic agents used to treat breast 
cancer on granulosa cell function. One study showed that cyclophosphamide
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metabolites, at concentrations achievable in vivo during cyclophosphamide therapy, 
decrease rat and human granulosa cell function in vitro as assessed by progesterone 
accumulation (Ataya, Pydyn, & Ramahi-Ataya 1990).
Apoptosis, or programmed cell-death, has been shown to occur in granulosa 
cells as part o f  the process o f follicular atresia where it is an important determinant o f 
reproductive ageing (Piquette et al. 1994; Tilly et al. 1991; Tilly 1996; Yuan & Giudice
1997). Studies in a reproductive medicine setting have revealed that an increase in the 
number o f luteinised granulosa cells undergoing apoptosis is associated with increased 
FSH (Seifer et al. 1996) and reduced ongoing pregnancy rates after IVF (Oosterhuis et 
al. 1998).
Experiments using a rat model have shown that apoptosis-associated signalling 
pathways are required for chemotherapy-mediated female germ cell destruction (Perez 
et al. 1997). Furthermore, studies performed on the breast cell line M CF-7 have shown 
that chem otherapy-induced apoptosis plays a critical role in breast cancer therapy 
(Simstein et al. 2003).
The cytotoxic effect o f  chemotherapeutic agents used to treat breast cancer on 
granulosa cells function can therefore be assessed by m easuring hormones and cell 
integrity assessed by apoptosis.
2.2.3 STUDY AIM AM D HYPOTFIESIS
The aim o f this study was to examine the dose-related effect o f cytotoxic agents used to 
treat breast cancer on granulosa cells, by assessment o f granulosa cell function and 
integrity in vitro. This was based on the hypothesis that cytotoxic drugs used to treat 
premenopausal patients with breast cancer can cause granulosa cell injury and death.
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2.2.4 STUDY DESIGN
2.2.4.1 INTRODUCTION
In order to study the effect o f  cytotoxic agents on granulosa cells, a breast cell line 
(MCF-7) was used as a control to establish the dose range under which the LD50 (dose 
required to kill 50% o f the cells) in granulosa cells would lie. Four cytotoxic agents 
were chosen that represent commonly used drugs in patients w ith breast cancer. These 
agents have all been shown to induce apoptosis in the human breast cell line MCF -  7: 
Doxorubicin (D) and M elphalan (M) (Kugawa et al. 2004), Paclitaxel (P) (Saunders et 
al. 1997) and Cisplatin (C) (Blanc et al. 2000).
2.2.4.2 STUDY PROTOCOL
The first part o f this study involved establishing the dose range for each drug using the 
MCF-7 cell line. Once the dose range was established, a prim ary granulosa cell culture 
was established by isolating these cells from human follicular fluid obtained from 
patients undergoing in-vitro fertilisation (IVF). Ethical approval for this aspect o f the 
study was obtained from the jo in t UCL/UCLH ethics committee.
Once both culture conditions were optimised, experiments were performed 
which involved application o f similar dosages o f cytotoxic drugs in parallel. After a 
defined exposure time, the cells were isolated from the culture medium and analysed by 
flow cytometry. In addition, determining the concentrations o f  inhibin A and oestradiol 
released respectively functionally assessed the granulosa cells in culture in the presence 
o f these agents.
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FIGURE 2.2. 1 IN VITRO STUDY DESIGN -  PART 1
Cell culture conditions were optimised for both the breast cell line and the granulosa cells prior to 
simultaneous application of equivalent dosages of cytotoxic agents. Cells were then extracted and 
cytometric data obtained for both cell types. From this data, dose response curves were obtained. Further 
information was obtained from the granulosa cells where hormone assays were performed for inhibin A 
and oestradiol contained in the culture medium.
HUMAN FOLL. FLUID = Human follicular fluid
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FIGURE 2.2.2 IN V ITRO  STUDY DESIGN- PART 2
This diagram displays specifically what parameters were measured from both cell types.
1 0 4
2.2.4.3 CYTOTOXIC AGENTS
DOXORUBICIN
This is an anthracycline antibiotic, also known as adriamycin hydrochloride. The drug 
acts to bind to deoxyribonucleic acid (DNA) and inhibits reverse transcriptase and 
ribonucleic acid (RNA) polymerase. It forms part o f most anthracycline-based regimens 
used to treat breast cancer.
O  O H  O
O H
FIGURE 2.2. 3 Structure o f  doxorubicin.
M olecular W eight (M W ) 579.
MELPHALAN
This is a nitrogen mustard derivative that forms DNA intrastrand crosslinks by 
alkylation o f the 5’-(GGC) sequence. It was chosen as the as an alternative to 
cyclophosphamide in this study. Cyclophosphamide is also a nitrogen mustard 
derivative, which requires activation by the hepatic cytochrome P-450 enzyme system 
to become biologically active. For in vitro study, the activated form o f the drug -  4- 
hydroxycyclophosphamide would have to be used. Administration o f  the activated form 
has been shown to exert a dose-dependent reduction in progesterone levels in rat
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granulosa cells (Ramahi-Ataya et al. 1988). This “activated” form o f  the drug was very 
difficult to obtain commercially. Melphalan is considered to be similar to 
cyclophosphamide in potency and mechanism o f action, and has been shown to have 
activity against breast cancer in vivo (Carpenter, Jr. & Maddox 1983) as well as in vitro 
against an MCF-7 cell line (Hathout et al. 2002). For these reasons, melphalan was used 
instead o f 4-hydroxycyclophosphamide in this study.
C l
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FIGURE 2.2 . 4 Structure o f  melphalan. 
Molecular w eight 305 .20
PACLITAXEL
This is a potent drug that binds to the N-terminal region o f  B- tubulin, promoting the 
formation o f highly stable microtubules that resist depolymerisation, thus preventing 
normal cell division and inducing apoptosis. These agents (part o f the taxane group) are 
considered one o f the major recent advances in the treatment o f  breast cancer (Nabholtz 
& Gligorov 2005).
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FIGURE 2 .2 . 5 Structure o f  paclitaxel 
M olecular w eight 853.91
CISPLATIN
The mechanism o f  action o f this drug is to form cytotoxic adducts with the DNA 
dinucleotide, inducing intrastrand crosslinks and apoptosis. It is given usually in 
combination with other drugs to treat advanced breast cancer refractory to other 
treatments (Heinemann et al. 2005) or as first-line therapy (Vassilomanolakis et al.
2005).
Cls  p i
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\
FIGURE 2.2. 6 Structure o f  cisplatin. 
M olecular w eight 300.05
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2.2.4.4 ASSESSM ENT OF CELL INTEGRITY
In this study, the Annexin V -  affinity assay was chosen to assess cell integrity by 
measuring apoptosis and cell death respectively (van Engeland et al. 1998). Annexin V 
is a calcium-dependent phospholipid-binding protein with high affinity for 
phosphatidylserine residues on the outer cell membrane. An early, irreversible stage o f 
apoptosis (independent o f cell type) involves loss o f membrane permeability, resulting 
in translocation o f phosphatidylserine residues from the inner cell membrane (where 
they are inaccessible to annexin V) to the outer surface. In this way, A nnexin V could 
be used to identify and quantitate the number o f cells undergoing apoptosis. In necrosis 
or cell death, cell membranes are permeable to propidium iodide that stains the whole 
cell. By using a com bination o f annexin/PI staining, cells undergoing early to late 
stage apoptosis and cell death could be quantified.
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3. METHODS
3.1 CLINICAL PARAMETERS
C lin ica l characteristics were obtained from all study subjects, and included:
•  Date o f  birth (age calculated in years)
•  Parity
•  M enstrual cycle length (days)
•  Body mass index (kg/m2)
For patien ts  only, specific data included:
•  Chem otherapy type, schedule, cumulative dosage
•  Chem otherapy start and finish date (including length o f time from completion 
o f  chemotherapy to time o f first testing in the case o f  patients recruited for the 
first time following chemotherapy)
3.2 BIOCHEMICAL OVARIAN RESERVE TESTS
3.2.1 SAMPLE COLLECTION, PREPARATION AND STORAGE
Blood sam ples (15ml) were obtained from all subjects during the early follicular phase 
o f the m enstrual cycle (day 2 -  5). Four timed samples were perform ed, 15 minutes 
apart. T o  minimize discomfort, venesection was performed by inserting an indwelling 
“b u tte rf ly ” needle. This allowed timed samples to be taken over the 45-m inute time 
span w ith o u t the need for repeated needlsticks. Following the last tim ed sample, the G- 
test w a s  commenced. This involved administering a gonadotrophin releasing hormone 
analogue  (GnRHa) -  Buserelin (Sanofi-Aventis, UK) lm g  subcutaneously. This route 
was c h o se n  to ensure compliance as opposed to intranasal adm inistration, which would 
have in v o lv ed  giving 4 separate doses. Administration o f  the G-test would result in a
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transient and reversible ovarian stimulation comparable in m agnitude to a physiologic 
response. This response was quantified after performing a single repeat blood sample 
approximately 24 hours later. Serum was separated and stored at -2 0  °C for hormone 
measurements. Assaying each o f the 4 samples and determining an average value then 
determined mean serum concentrations for FSH, LH and oestradiol. This was designed 
to overcome the effect o f pulsatile gonadotrophin release, the frequency o f which is 
increased in the follicular phase (Filicori et al. 1986; M cCartney et al. 2002). For the 
activins, inhibins and AM H, pooled samples were obtained from the 4-timed samples 
prior to assaying (obtained by mixing equivalent volumes from each timed sample prior 
to freezing).
3.2.2 INHIBIN A, ACTIVIN A, PROaC AND FOLLISTATIN 
These were all in-house, two-site “sandwich” enzyme-linked im m unosorbent assays 
(ELISA ’s), which use monoclonal antibodies for highly specific subunit capture and 
detection. These antibodies have been developed and the ELISA m ethods validated by 
researchers at Oxford Brookes headed by Professor Nigel Groome (Evans LW  & 
Groome 2001). In all these assays, the alkaline phosphatase detection system is used 
(ELISA Amplification System, Invitrogen Life Technologies, Paisley, UK). In this 
system, the bound enzyme acts as a substrate whose product initiates a secondary cyclic 
enzyme reaction, resulting in a coloured product.
110
NAD*
FormazarV 
Diaphorase
I NT-Violet
NADH
Alkaline Phosphatase
NADPH
Colored end product
Ethanol
Alcohol Dehydrogenase
Acetaldehyde
FIGURE 3.2.1 B iochem ical basis for ELISA amplification system .
Substrate: R educed nicotinam ide adenine dinucleotide phosphate (N A D PH ).
The rate o f  reduction o f  the tetrazolium  salt (IN T -V iolet) is directly proportional to the concentration o f  
reduced nicotinam ide adenine dinucleotide (N A D H ) originally formed by the en zym e in the bound 
conjugate.
I l l
3.2.2.1 GENERAL A SSA Y  REQUIREMENTS
These assays require the use o f buffers, which are produced in-house as described below: 
BUFFERS:
• Inhibin A assay diluent
• Normal ELISA wash buffer
• Manual wash buffer
PREPARATION OF BUFFERS 
Inhibin A assay diluent:
Enzyme im munoassay diluent was made using 10% (w/v) bovine serum albumin (BSA), 
5% (v/v) mouse serum), 5% (v/v) Triton® X-100, 0.15 M sodium chloride and 0.1% 
sodium azide made up in 0.1M Tris -  HC1 buffer at pH 7.5. For example, a 200ml stock 
solution o f inhibin A assay diluent would be made up by adding together 20g BSA, 
10ml mouse serum, 10ml Triton® X-100 (Sigma-Aldrich Company Ltd., Gillingham, 
Dorset SP8  4XT, UK.), 1.75g sodium chloride, 0.2g sodium azide and 18ml 1M Tris 
HC1 buffer with 162ml distilled water. The constituents are then m ixed well for at least 
30 to 60 minutes, and then filtered through cotton wool. This was then stored in a 
refrigerator at 4-8 °C.
Normal ELISA wash buffer (X 20 stock):
Stock ELISA wash buffer was made using 0.05M Tris base, 0.15M sodium chloride and 
0.05% sodium azide mixed together using distilled water and pH neutralised to pH7.5 
using concentrated hydrochloric acid (HC1).
Normal wash buffer was then made up by adding stock buffer to distil water, tween 20 
and then stirred well for 30 minutes and stored at room temperature.
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3.2.2.2 GENERAL PRINCIPLES
Laboratory safety procedures and protocols were adhered to at all times. W hite labcoats
were worn at all times inside the lab and protective gloves were used w henever samples
were handled. A lab-book was used to make a detailed account o f  all experim ents 
undertaken.
Samples were allowed to defrost at room tem perature a couple o f  hours prior to 
the assay being performed. Once fully defrosted, samples were properly m ixed (Vortex 
Genie II, Scientific Industries, Inc. Bohemia, NY 11716 USA) prior to use.
3.2.2.3 INHIBIN A
This uses a highly specific m onoclonal antibody (E4) to the pA subunit (Groom e 1991), 
w hich is adsorbed to the microplate for capture, and a monoclonal antibody (R l)  
(Groome et al. 1990) to a  subunit as a Fab alkaline phosphatase conjugate for detection. 
As such, all forms o f  inhibin that contain a PA subunit found in hum an serum  and 
follicular fluid w ould be m easurable by this assay (Groome & Evans 2000).
INHIBIN A
N-TERMINAL a C-TERMINAL
DISULPHIDE
BRIDGE s s
P a
FIGURE 3.2.2 Structure of inhibin A.
113
ASSAY PROCEDURE
PREPARATION OF PLATES:
Anti (3A (E4) coated plates:
Monoclonal antibodies against the Pa subunit o f human inhibin (E4; (Groome & 
Lawrence 1991) were covalently linked to 96-well microtiter plates (Immunoplate, 
Maxisorb, Nunc, Denmark).
To achieve this, E4 was made in bicarbonate buffer (0.2M) to pH 9.4 (Pierce; 
Rockford 111, USA) up to a final concentration o f lOpg/ml. Once this is prepared, 50pl 
was dispensed into each well. The plate was incubated overnight at room temperature in 
a moist chamber/environment. After overnight incubation, excess antibody was 
discarded from the wells and the plate dried by inversion onto paper towelling. A dry 
coating agent ( 1 :2  dilutions with distilled water) was then added in a volume o f 
120jnl/well, and then incubated for 2 hours at room temperature. Following incubation, 
the excess dry-coating agent was discarded and the plate placed under a flow hood to air 
dry for a minimum o f  4 hours. After this was completed, the plates were foil-wrapped 
with a pack o f desiccant or stored dry in sealed bags to prevent moisture in the 
environment (which would have spoiled the plates).
REAGENTS:
• Amplification system (Invitrogen Life Technologies, Paisley, UK.)
• Fetal calf serum (FCS; Sigma-Aldrich Company Ltd.Gillingham , Dorset, UK.)
• Stop solution (0.3M H2SO4 ; Sigma)
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DAY 1: PREPARATION OF STANDARDS AND SAMPLES 
A plate plan was prepared prior to starting the assay.
All samples and standards were made using 2ml flat bottom disposable plastic tubes 
(Hughes & Hughes Ltd. UK). These were all defrosted and vortexed prior to use.
Human recombinant inhibin A (National Institute for Biological Standards 
[NIBSC], Potters Bar, Herts UK.) standard was stored at lng/m l or 50 pg/50pl (lpg/jul, 
200pl aliquots) and used as a reference standard. This was serially diluted in enzyme 
immunoassay diluent alone or in enzyme immunoassay diluent m ixed with an equal 
volume o f pooled hum an post-menopausal serum (PMS). The top standard was prepared 
by adding 200pl o f  FCS (equivalent to lOOOpg/ml). A further 7 doubling dilutions were 
then made by mixing 200pl o f FCS with 200pl o f the higher standard concentration to 
give the following range o f standards:
25pg/well/50pl (top), 12.5pg/well, 6.25pg/well, 3.13pg/well, 1.56pg/well, 
0.78pg/well, 0.39pg/well and 0.195pg/well 
The minimum detection limit for this assay was 2 pg/ml (NIBSC, UK.) and the intra- 
and inter-assay variations were < 6%. Any duplicate showing variability > 10% was 
repeated.
Samples and standards were then added to the tubes as follows:
• Standards: 125pi to labelled tubes
• Blanks: 125pl FCS
• Samples: 125pi to labelled tubes
Quality controls (Q C’s): 125pl/tube QC1 = 1:500 human follicular fluid (hFF), QC2 = 
1:200 hFF, QC3 = l.TOOhFF. Alternatively, quality controls were derived from pooling 
6 patient serum samples and 6 control samples respectively.
All samples, standards and quality controls were diluted (1:1) using 125pl o f inhibin A 
assay diluent.
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The sensitivity o f the assay can be improved by a pre-assay oxidation step 
(Muttukrishna et al. 1994). This was achieved by adding 50pl o f  10% (v/v) hydrogen 
peroxide (H2O2; Sigma) to all tubes (available from stock at 30%, stored at 4° C). The 
tubes were then mixed thoroughly and incubated for 30 minutes at room temperature 
before transferring lOOpl aliquots (blank/standard/sample/QC) to the E4-coated plates. 
Following transfer o f the oxidised standards and samples to E-4 coated plates; the plates 
are then covered with a lid and incubated overnight in a moist box at 4°C.
DAY2:
After overnight incubation, the samples are discarded and the plate washed (10 cycles) 
using an automated microplate washer (Labsystems W ellwash 4 M k 2, Finland). 
Following this, 50pl o f alkaline phosphate-conjugated anti-alpha subunit antibody 
(1:200 dilutions in assay diluent, R l-Alkphos) is added to each well. After incubating 
for 2 hours in a moist box at room temperature on a microplate shaker (Labsystems 
Wellmix, Finland), plates were washed extensively (17 cycles), with the first 15 cycles 
being done using an automatic microplate washer. The final 2 washes are done by using 
the manual wash buffer (250pl/well) and incubating on the plate shaker for 10 minutes 
before repeating.
Quantification o f bound alkaline phosphatase was made using a com mercially 
available enzyme immunoassay amplification kit (Invitrogen Life Technologies, Paisley, 
UK.), which was used according to the supplier’s instructions. To minimise the risk o f 
temperature-dependent variation in signal generation, both incubation steps were 
performed at ambient temperature. After incubation w ith ‘k it substrate solution’ 
(50pl/well) for 1 hour on a microplate shaker, 50pl/well o f ‘kit am plifier solution’ was 
added to each well. The amplification reaction was stopped when before blank wells 
began to show significant colour development by adding 50pl o f  0.3M  sulphuric acid
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(normally stopped after ~  lh). Absorbance at 492nm was read on an enzym e 
im munoassay plate reader (Dynex Technologies Inc., VA, USA) and data processed by 
im m unoassay curve-fitting software (Dynex Technologies Inc., VA, USA).
3.2.2.4 ACTIVIN A
This assay uses a m onoclonal antibody E4 to the PA subunit attached to a m icroplate for 
capture and biotynilated E4 and streptavidin alkaline phosphatase for detection (Knight, 
M uttukrishna, & Groome 1996). The activins are structurally and functionally related to 
the inhibins. W hile inhibin-A and B are heterodimers consisting o f  an alpha subunit and 
a beta A or beta B subunit linked by disulphide bonds, activins are dim ers o f  beta 
subunits. This assay measures total activin A (follistatin bound and unbound activin A). 
The detection lim it o f  this assay for human recombinant activin A was 50 pg/m l. Intra- 
and inter-assay variations were 8.5 and 9.8% respectively (Genentech, San Francisco, 
CA, USA). Duplicates, which varied > 10%, were repeated.
Activin A Activin AB Activin
Pa Pa Pb
S S s
P PB P b
FIGURE 4.2.3 Structural relationship of the activins.
Structural relationship of the activins, which are dimers of the P subunits o f the inhibins linked by 
disulphide bonds (S).
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ASSAY PROCEDURE
REQUIREMENTS:
BUFFERS:
• Sample buffer: PBS (phosphate buffered saline) + 10% BSA (bovine serum 
albumin)
• Inhibin A assay diluent
• Normal ELISA wash buffer >  (Previously described section 4.2.2.1)
• Manual wash buffer
Preparation o f sample buffer (PBS + 10%BSA):
Sample buffer (100ml) was made by dissolving 1PBS tablet in 100ml (25mmol)
distilled water. This was added to lOg BSA and lOOmg sodium azide and the entire
solution mixed properly on the magnetic stirrer (Genesis hotplate stirrer, Jencons 
Scientific Ltd, Bedfordshire, UK).
REAGENTS:
Amplification system (Invitrogen)
Stop solution (0.3 M H 2SO4)
PLATES:
Anti pa (E4) coated plates (previously described in section 3.2.2.1)
DAY 1: PREPARATION OF STANDARDS AND SAMPLES 
A plate plan was prepared prior to starting the assay.
All standards, samples and controls were defrosted and m ixed prior to use. Heat 
resistant eppendorf tubes (Sarstedt, Aktlengesellshaft & Co. Germany) were used for 
preparing all samples and standards. The activin A standard consisted o f  affinity 
purified human follicular fluid which was standardised against human recombinant 
Activin A (Genentech, San Francisco USA). The standard was prepared beforehand by 
adding 250ng activin A to 5ml PBS+1% BSA and 0.1% azide and mixed well. This 
provided a reconstituted concentration o f 50ng/ml (lOOpl aliquots), which is stored at - 
20°C.
To prepare the top standard concentration, 400pl o f PBS + 10%BSA were added 
to the stored standard and mixed well. This provided a top standard concentration o f 
500pg/well/50]ul (lOng/ml). A further 7 doubling dilutions were made by mixing 200pl 
o f PBS+10%BSA with 200 pi o f the higher standard concentration to give the following 
range o f standards:
250pg/well/50pl, 125 pg/well/50pl, 62.5 pg/well/50pl, 31.3 pg/well/50pl, 15.6 
pg/well/50pl, 7.8 pg/well/50pl and 3.9 pg/well/50pl.
Blank samples were made up o f PBS+10%BSA buffer only. Quality controls (QC’s) 
were derived from third trimester pregnancy serum as follows: QC1 = 1:8 dilution, QC2 
= 1:4 dilution and QC3 = 1:2 dilution as well as a representative sample o f  6  patients.
Volumes (175 pi) o f diluted samples and standards were transferred to 1.5ml 
Eppendorf tubes and mixed with an equal volume (175pi) o f  15% (wt/vol) sodium 
dodecyl sulphate (SDS). This was prepared by mixing together (by inversion) 1.5g SDS 
with lOml-distilled water warmed to about 60°C. The tubes were then incubated for 10 
minutes at 85-90°C in a waterbath (Grant Instruments, Cambridge, UK). This step is
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done to overcome interference caused by follistatin seen in previous assays (Wong et al. 
1993) by dissociating follistatin, thus allowing measurement o f  total activin A. After 
cooling for about 5 minutes, 30jul o f hydrogen peroxide solution was added to all tubes 
(30%, vol/vol; Sigma Chemical Co., St. Louis MO, USA). The tubes were mixed well 
on the whorly mixer and incubated for a further 10  minutes at room temperature.
The E4 dry coated plate was prepared by first adding 25pl/well inhibin A assay 
diluent using an electronic multi-channel dispenser (Genex Alpha, Genex Laboratory 
Products, Northampton UK). Duplicate lOOpl aliquots o f  standards/samples were then 
transferred to the plate and then mixed on a microplate shaker for a few minutes. 
Biotynilated E4 (25pl) was then added to each well (dilute 1:100 using inhibin A 
diluent; stock ~ 0.14mg/ml). The plate was then incubated overnight in a humidified 
box at 4 °C.
DAY 2:
The plate was washed 10 times using the automatic plate washer with the ELISA wash 
buffer, and then dried by inversion onto paper towelling. Alkaline phosphatase- 
conjugated extravidin (1:10000, vol/vol; Sigma) was then added (50pl/well) using a 
manual multichannel dispenser (Scientific Laboratory Supplies, Nottingham , UK). The 
plate was then incubated for 2  hours at room temperature in a m oist box on a plate 
shaker, then washed for 15 cycles using the automated plate washer and dried on paper 
towelling. This was followed by 2 manual washes using the manual w ash buffer. The 
latter was achieved by adding 250pl/well manual wash buffer and incubating on the 
plate shaker for 5 minutes before repeating.
Bound alkaline phosphatase was then quantified using a com m ercially available 
amplification kit (Invitrogen Life Sciences). Substrate was added (50pl/well) and the 
plate incubated for 1 hour on a moist box placed on a shaker. Am plifier was then added
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(50jLxl/well) and the reaction stopped using 50pl/well stop solution when the blanks
started to develop colour. Absorbance was then read at 490nm.
3.2.2.5 FOLLISTATIN
Follistatin is a monomeric glycosylated polypeptide chain. There are 2 m ature 
mammalian follistatin (FS) forms: FS 288 and FS 315, although the latter is only 10% 
cross-reactive. This ELISA uses a pair o f mouse monoclonal antibodies to FS 288: 29/9 
as the capture antibody and the Fab’ fragment o f monoclonal antibody 17/2 for 
detection. Use is m ade o f  a dissociating diluent to disrupt activin/follistatin complexes 
so that the assay measures ‘total’ human follistatin (Evans, M uttukrishna, & Groome
1998).
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FIGURE 3.2.4 Structure of follistatin.
ASSAY PROCEDURE
REQUIREMENTS:
BUFFERS:
Follistatin sample buffer (dissociating solution):
1L PBS is used to make 1L buffer, to which the following were added and mixed (in 
this order): 35g sodium deoxycholate (3.5%w/v); 34g Tween 20 (3.4% w/v); lOg BSA 
(l% w /v); 50ml mouse serum (5%w/v); lg  sodium azide (0.1% w/v). After mixing the 
buffer was stored at 4°C.
Follistatin assay buffer (Tris conjugate buffer):
500ml o f 25mM  Tris HC1 (pH 7.5) is used to make 500ml assay buffer, to which the 
following were added and mixed (in order): 5g BSA (l% w /v); 4.4g NaCl (0.15M); 
2.5ml Tween 20 (0.5% v/v); 0.5g sodium azide (0.1%w/v). After mixing the buffer was 
stored at 4°C.
Normal ELISA wash buffer: (previously described in section 3.2.2.1)
PLATES:
29/9-coated 96-well plates (ready to use)
REAGENTS:
Amplification system (Invitrogen Life Sciences)
Stop solution (0.3M H2SO4 ; Sigma)
DAY 1: PREPARATION OF STANDARDS AND SAMPLES 
A plate plan was prepared prior to starting the assay.
All samples and standards were made using 2ml flat bottom disposable plastic tubes, 
after defrosting and mixing. The standard (freeze-dried, im m unopurified human 
follistatin) was reconstituted in 10.3mls dissociating solution giving a top standard o f 
2500pg/ml. Further dilutions were made to provide the following standard dilutions:
2500pg/ml; 1250pg/ml; 625pg/ml; 313pg/ml; 156pg/ml; 78pg/ml; 39pg/ml 
and 19.5pg/ml.
Serum samples and Q C ’s were diluted 1:3 in dissociating solution. The purpose o f  the 
dissociating solution is to disrupt activin-follistatin complexes, thus enabling only total 
follistatin to be measured (Groome et al. 2001b). The sensitivity o f this assay was 
2 0 pg/ml, and the intra- and inter-assay variations were less than 1 0 % respectively. 
Duplicates above 10% were repeated.
Duplicate 50pl amounts o f standards, samples, blanks (sample buffer) and Q C’s 
are added to the wells on the plate, which were then sealed and incubated overnight 
stationary at room temperature in a sealed, moist box.
DAY 2:
The plate was washed 10 times with ELISA wash buffer in the automated plate washer. 
To each well 50pl o f approximately lp l/m l solution o f the Fab fragm ent o f clone 17/2 
(attached to alkaline phosphatase) was added, diluted in Tris conjugate buffer. After 2- 
hour incubation in a moist box at room temperature, the plate was again washed 
thoroughly 10 times and dried by inversion unto paper towelling. A lkaline phosphatase 
substrate (50pl) was added to each well and the plate-incubated (stationary at room 
temperature) for 24 hours. Amplifier solution (50pl) was then added to each well and
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colour allowed to develop. The reaction was stopped using stop solution (50pl) to each
well when the blanks developed colour. The absorbance was read at 490nm.
3.2.2 .6 PROaC
This assay uses a monoclonal antibody to the pro region o f the hum an inhibin a  subunit 
for capture and the same R1 Fab alkaline phosphatase conjugate as in the inhibin B 
ELISA’s for detection (Groome et al. 1995). This assay is expected to measure 
precursor forms o f both inhibin A and inhibin B (shown below) carrying the full-length 
a  subunit as well as free forms o f the a  subunit such as pro aC  and pro ocNocC. Since 
these free forms are present in excess over dimeric inhibins in most body fluids in 
practice, the assay is measuring higher molecular weight dimeric inhibins and non­
bioactive monomeric a  subunits. The detection limit for this assay was approximately 
2 pg/ml, and the intra- and inter-assay variations <15%.
^ -----  (a) Detected in pro-mC assay  —
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FIGURE 3.2.5 Diagramm atic representation o f  inhibin precursor form s m easurable by this assay. 
(Adapted from Oxford Brookes w ebsite http://w w w .brookes.ac.U k/inhibin/l.
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ASSAY PROCEDURE
REQUIREMENTS:
BUFFERS:
• Inhibin A assay diluent
• Normal ELISA wash buffer
• Manual wash buffer 
REAGENTS:
Amplification system (Invitrogen Life Sciences) 
Fetal calf serum (FCS; Sigma)
Stop solution (0.3M  H 2SO4 ; Sigma)
PLATE:
96 well Pro aC  dry -coated  plate (ready to use)
>. (previously described in section 3.2.2.1)
DAY 1: PREPARATION OF STANDARDS AND SAMPLES 
A plate plan was prepared prior to starting the assay.
All samples and standards were made using 2ml flat bottom disposable plastic tubes. 
The standards (Pro aC  peptide kindly provided by Professor N igel Groome, Oxford 
Brookes, UK.), which were stored at 2ng/ml stock, were serially diluted in enzyme 
immunoassay diluent alone ( 1 :1) to obtain the top standard concentration 
(50pg/well/50|nl). A further 7 doubling dilutions were made by m ixing 1 50 j l l 1 (for 1 
plate) of assay diluent with 150pl o f the top standard concentration to give the 
following range o f standards:
200pg/ml (top), lOOpg/ml, 50pg/ml, 25pg/ml, 12.5pg/ml, 6.25 pg/ml, 
3.13pg/ml and 1.56pg/ml.
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All samples were defrosted and mixed prior to assaying. Blank wells comprised lOOpl 
assay diluent only. Quality controls comprised 1 OOju.1 hum an follicular fluid (hFF) 
available in dilutions o f 1:5000, 1:2500 and 1:1250 with assay diluent. Pooling 6  
samples and performing dilutions o f 1:2, 1:4 and 1:8 provided additional controls. To 
each labelled well, 100pl o f  blanks, standards and samples were added in duplicate. The 
plate was then incubated in a moist box on a microplate shaker.
DAY 2:
Following overnight incubation, the plate was washed 10 times using an automated 
plate washer, and then dried by inversion on paper towelling. To each well, 50pl o f 
1:200 alkaline phosphatase conjugated R1 Fab was added. The plate was then incubated 
for 2 hours in a moist box. After this, the plate was washed a further 17 times: the first 
15 washes using the automated plate washer and the final 2  times done manually using 
250pl/well o f manual wash buffer. The plate was then dried by inversion on paper 
towelling.
Substrate was prepared 10 minutes prior to adding to all wells (50p,l/well) in the 
same sequence that the R1 Fab was added. The plate was then incubated in a moist box 
for 1 hour. Amplifier was then added (50 pl/well) to each well in the same sequence as 
the substrate. The plate was then mixed for a few minutes on the automated plate 
shaker and the reactions stopped using 50pl/well stop solution before the blanks 
develop colour (normally 10-20 minutes). The absorbance was read at 492nm.
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3.2.3 INHIBIN B
This assay was first developed in 1996 where it was used to study serum  inhibin B 
concentrations throughout the human menstrual cycle (G room e et al. 1996). It uses a 
monoclonal antibody to the PB subunit adsorbed to a m icroplate for capture and a Fab 
conjugate o f  monoclonal antibody R1 attached to alkaline phosphatase for detection. 
This assay is predicted to m easure a range o f  size isoforms o f  inhibin B found in hum an 
serum and follicular fluids (Groome et al. 2000).
INHIBIN B
N-TERMINAL C-TERMINAL
DISULPHIDE q  q
BRIDGE ^  ^
P b
FIGURE 3.2.6 Structure of inhibin B. S = disulphide bonds 
ASSAY P R IN C IP L E
A commercial kit — the DSL-10-84100 ACTIVE* Inhibin B Enzym e-Linked 
Immunosorbent A ssay (ELISA) Kit (D iagnostic Systems laboratories, Inc. Texas, USA.) 
was used for all inhibin B assays perform ed in this study. In this assay, Standards, 
Controls and unknown serum samples were incubated overnight in m icrotitration wells, 
which had been coated with anti-inhibin Pb subunit antibody. A fter incubation and 
washing, the wells were incubated with biotynilated anti-inhibin a -subun it detection 
antibody and the im m unoreactions monitored by subsequent addition o f  streptavidin 
labelled with enzyme horseradish peroxidase (HRP). A fter a third incubation and 
w ashing step (the w ashing steps were crucial to the perform ance o f  the assay), the wells 
were incubated w ith the substrate tetram ethylbenzidine (TM B).
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An acidic stopping solution was then added and the degree o f  enzymatic 
turnover o f the substrate is determined by dual wavelength absorbance measurement at 
450 and 620nm. The absorbance measured was directly proportional to the 
concentration o f inhibin B present. The sensitivity o f this assay was approximately 10 
pg/ml, and the intra- and inter-assay variations < 1 0 %.
This assay has a small cross-reaction with inhibin A (0.5%). The cross-reaction 
is only an issue when attempting to measure very low concentrations o f  serum inhibin B 
in samples with extremely high inhibin A, which can occur in late pregnancy (Groome 
et al. 2001). It would not therefore, be expected to be an issue in this study.
REQUIREM ENTS:
All products were stored at 2 - 8 ° C until ready for use.
1. Anti-inhibin B- coated microtitration strips (plate)
2. Inhibin B Standard A/Sample diluent (2ml)
3. Inhibin B Standards: Each vial contained 1ml each containing concentrations o f 
approximately 10, 30, 100, 250, 500, and lOOOpg/ml dimeric inhibin B in fetal 
bovine serum (FBS).
4. Inhibin B Controls: Each vial contained 1ml each containing low and high 
concentrations o f dimeric inhibin B in FBS.
5. Inhibin B Sample Buffer A
6 . Inhibin B Sample Buffer B
7. Inhibin B Antibody-Biotin Conjugate
8 . Streptavidin-Enzyme Conjugate
9. TMB Chromogen Solution
10. Wash Concentrate: 100ml bottle containing buffered saline with a non-ionic 
detergent. The wash solution was prepared by adding 900ml o f  distilled water.
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ASSAY PR O C ED U R E 
DAY 1:
A plate plan was prepared prior to starting the assay.
Using a pipettor (Gilson S.A.S. France) 50pl o f standards, controls and samples were 
transferred into the appropriate microtitration wells. This was followed by adding 25pl 
o f Inhibin B sample buffer A and B respectively to each well using a semi-automatic 
dispenser (Gilson, France). The plate was then incubated in a moist box, overnight at 
room temperature on the workbench (static incubation).
DAY2:
Following overnight incubation (14-18 hours), the wells were washed five times with 
distilled water using an automatic microplate washer (Labsystems W ellwash 4 Mk2, 
Finland), and the plate blotted dry by inversion on a paper towel. The next step was to 
add 50pl o f biotinylated anti a  subunit to all wells in the plate, which was then 
incubated for one and a half hours at room temperature in a m oist box. Using a semi­
automatic dispenser, 50pl o f  the streptavidin-enzyme conjugate was added to each well. 
The plate was then covered and incubated for 20 minutes at room tem perature. A further 
2 washing cycles followed using the wash solution. In the first, the plate was washed 6  
times using an automatic microplate washer. After the last washing cycle, the washer 
was stopped and the wells soaked in the wash solution for 15 minutes. The second wash 
cycle was then commenced for a total o f 6  cycles. After the last cycle, the plate was 
then dried by inversion on paper towelling.
To each well, lOOpl o f TMB chromagen solution was added using a semi-automatic 
dispenser. The plate was covered with foil (to avoid direct sunlight) and incubated for 
15-30 minutes at room temperature. Once optimal colour developm ent had been 
achieved, 1 0 0 pi o f stopping solution was added to each well using a semi-automatic
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dispenser. Absorbance at 450nm was read on an enzyme im munoassay plate reader 
(Dynex Technologies Inc., VA, USA) within 30 minutes o f  adding the stopping solution 
and the data processed by immunoassay curve-fitting software (Dynex Technologies 
Inc., VA, USA).
3.2.4 ANTI MULLERIAN HORMONE (AMH)
A commercial kit -  the Immunotech AMH enzyme immunoassay (Imm unotech SA 
Marseille, France) was used for quantification o f AMH in all serum samples used in this 
study.
ASSAY PRINCIPLE
This ELISA was a two-step sandwich type assay. In the first step, a monoclonal 
antibody attached to the microtiterplate was used for capture. In the second step a 
biotynilated monoclonal antibody mixed with streptavidin alkaline phosphatase was 
used for detection. The sensitivity o f this assay was 0.7pM, and the inter- and intra­
assay variations 14.2% and 12.3% respectively. Duplicates, which varied > 10%, were 
repeated.
REAGENTS:
The kit including the reagents was stored at 2-8°C until ready for use, when it is allowed 
to come to room temperature. The expiry date was checked prior to use.
1. Anti-AMH antibody-coated plate (ready to use)
2. Reaction buffer (ready to use)
3. Biotynilated monoclonal antibody (for reconstitution)
4. AMH calibrator (for reconstitution)
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5. Calibrator 0 (human serum)
6 . Wash solution (for dilution)
7. Streptavidin-HRP (ready to use)
8 . Substrate (ready to use)
9. Stop solution (2N H 2SO4)
ASSAY PROCEDURE
PREPARATION OF STANDARDS AND SAMPLES 
A plate plan was prepared prior to starting the assay.
All samples and standards were defrosted and mixed prior to use, and prepared using 
2 ml flat bottom disposable plastic tubes.
The 1500pM (top) and OpM (bottom) calibrators were reconstituted using distilled water 
and used to make a fresh dilution series as follows:
Calibrator concentration (pM) AMH Calibrator 0 
(pL)
150 50pL of 1500 pM calibrator 450
81 200pL o f 150pM calibrator 170
27 lOOpL o f 81pM calibrator 2 0 0
9 lOOpL o f 27pM calibrator 2 0 0
3 100p,L o f 9pM calibrator 2 0 0
0 - 2 0 0
TABLE 3.2.1 Preparation o f  A M H  calibrators.
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PROCEDURE:
2 5 jj.L of samples and standards were added to each well in duplicate according to the 
plate plan. To each well, lOOpL o f reaction buffer was added. The plate was then 
incubated at room temperature (18-25 °C) on the plate shaker for 2 hours. After this, the 
plate was washed manually a total o f 5 times.
In the next step, 50pL o f biotynilated antibody and 50pL o f  streptavidin-HRP 
were added to the wells. The plate was then incubated for 30 minutes at room 
temperature on the plate shaker. Following this incubation, the plate was again washed 
manually 5 times.
In the final step, lOOpL o f substrate was added to each well and the plate 
incubated at room temperature for 30 minutes on the shaker and colour allowed to 
develop. The reaction was stopped using stop solution (50pl) to each well when the 
blanks developed colour. The absorbance was read at 490nm using an enzyme 
immunoassay plate reader (Dynex Technologies Inc.) and data processed by 
immunoassay curve-fitting software (Dynex Technologies Inc).
3.2.5 FOLLICLE STIMULATING HORMONE (FSH)
A commercial kit -  the IBL FSH EIA (IBL Immuno-Biological Laboratories Hamburg, 
Germany) was used for quantification o f FSH in all serum samples used in this study.
ASSAY PRINCIPLE
FSH is a glycoprotein hormone, which is part o f a family o f  cysteine rich proteins 
consisting o f an alpha (a )  and beta (p) subunit. Like other glycoprotein hormones such 
as Luteinising hormone (LH), Thyroid stimulating hormone (TSH) and Human 
chorionic gonadotrophin (HCG), the alpha subunit is com m on to each o f these
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hormones for a given species, while the p subunit is assumed to confer hormone 
specificity.
This was a solid phase ELISA based on the sandwich principle. The microtiter 
wells were coated with a monoclonal antibody directed towards a unique antigenic site 
on a p-FSH molecule. An aliquot o f sample serum containing endogenous FSH was 
incubated in the coated well with enzyme conjugate, which is an anti-a-FSH  antiserum 
conjugated with horseradish peroxidase. The amount o f bound peroxidase was therefore 
proportional to the am ount o f FSH in the sample. The sensitivity o f  this assay was 
2mIU/ml, and the intra- and inter-assay variations were less than 10%. Duplicates which 
varied > 1 0 % were repeated.
REAGENTS:
The kit including the reagents was stored at 2-8°C until ready for use, when it is allowed 
to come to room temperature. The expiry date was checked prior to use.
1. Microtiter plate coated with anti-FSH monoclonal antibody
2. Enzyme conjugate (ready to use)
3. FSH standards: lyophilised, for reconstitution in distilled water
4. Substrate: TMB (ready to use)
5. Stop solution: 0.5M H2SO4
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PREPARATION OF STANDARDS AND SAMPLES 
A plate plan was prepared prior to starting the assay.
All samples and standards were made using 2ml flat bottom disposable plastic tubes 
(Hughes and Hughes Ltd.) after defrosting and mixing. Once the assay had started, it 
was important that all steps should be completed without interruption. Absorbance is a 
function o f the incubation time and temperature, and as such manual pipetting o f all 
standards, samples and controls were completed within 1 0  minutes.
Standards were prepared by reconstituting the lyophilised contents o f the 
standard vials with lm l-distilled water to create the following range o f  dilutions: 
Concentration (mlU/ml): 0 5 10 20 50 100
Quality controls were provided by pooled samples as previously described.
ASSAY PROCEDURE:
To appropriate wells were added 25pL o f standards, controls and samples. Following 
this step, l OOpL o f  enzyme conjugate were added to each well. The plate was then 
mixed thoroughly for 1 0  seconds and then incubated on a m icroplate shaker for 30 
minutes at room temperature (18-24 °C). Following the incubation, the plate was 
manually washed with distilled water and the plate dried by inversion onto paper 
towelling. Substrate was then added at timed intervals to each well in 100pL volumes, 
and the plate covered in foil and incubated for 10  minutes at room tem perature to allow 
colour to develop. The enzymatic reaction was stopped by adding 50pL o f stop solution 
to each well in a similar timed interval as described above. The absorbance was read at 
450nm using an enzyme immunoassay plate reader w ithin 10 minutes o f  adding the stop 
solution (Dynex Technologies Inc), and data processed by im munoassay curve-fitting 
software (Dynex Technologies Inc).
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3.2.6 LUTEINISING HORMONE (LH)
A commercial kit -  the IBL LH EIA (IBL Immuno-Biological Laboratories Hamburg, 
Germany) was used for quantification o f FSH in all serum samples used in this study. 
ASSAY PRINCIPLE
Human luteinizing hormone is a glycoprotein, which consists o f  2 polypeptide chains 
called a  and p. The a  - subunit is identical to the a  - subunits o f  other human 
glycoprotein hormones such as FSH, HCG and TSH. The p - subunit confers specificity 
and the immunological behaviour o f the hormone.
The microtiter wells o f the plate were coated with a m onoclonal antibody 
directed towards a unique antigenic site on a p-LH molecule. An aliquot o f sample 
serum containing endogenous LH was incubated in the coated well w ith enzyme 
conjugate, which is an anti-a-LH  antiserum conjugated with horseradish peroxidase. 
The amount o f bound peroxidase was therefore proportional to the am ount o f  LH in the 
sample. After addition o f  substrate, the intensity o f colour developed was proportional 
to the concentration o f  LH in the serum. The sensitivity o f this assay was 2mIU/ml, and 
the intra- and inter-assay variations less than 7%. Duplicates >10% were repeated.
REAGENTS:
The kit including the reagents was stored at 2-8°C until ready for use, and then allowed 
to come to room temperature when ready for use after the expiry date was checked.
1. Microtiter plate coated with anti-LH monoclonal antibody
2. Enzyme conjugate (ready to use)
3. LH standards: lyophilised, for reconstitution in distilled water
4. Substrate: contains tetramethylbenzidine (TMB; ready to use)
5. Stop solution: 0.5M  H 2SO4
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ASSAY PROCEDURE
PREPARATION OF STANDARDS AND SAMPLES 
A plate plan was prepared prior to starting the assay.
All samples and standards were made using 2ml flat bottom disposable plastic tubes 
after the samples were defrosted and mixed. Once the assay had started, all steps had to 
be completed without interruption within 1 0  minutes for the same reasons described 
earlier for FSH. Standards were prepared by reconstituting the lyophilised contents o f 
the standard vials with lm l-distilled water to create the following range o f  dilutions:
Concentration (mlU/ml): 0 10 20 40 100 200
PROCEDURE:
To appropriate wells were added 25pL of standards, controls and samples. Following 
this step, lOOpL o f  enzyme conjugate was added to each well. The plate w as then mixed 
thoroughly for 10  seconds and then incubated on a microplate shaker for 30 minutes at 
room temperature (18-24 °C). The plate was then manually washed with distilled water 
and the plate dried by inversion onto paper towelling. Substrate was added at timed 
intervals to each well in lOOpL volumes, and the plate covered in foil and incubated for 
10 minutes at room temperature to allow colour to develop. The enzym atic reaction was 
then stopped by adding 50pL o f stop solution to each well in a sim ilar tim ed interval as 
described above. The absorbance was then read at 450nm using an enzyme 
immunoassay plate reader within 10  minutes o f adding the stop solution.
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3.2.7 17 BETA-OESTRADIOL
A commercial kit -  the IBL 17 beta-Estradiol ELISA (IBL Immuno-Biological 
Laboratories Hamburg, Germany) was used for quantification o f  17p-Oestradiol in all 
serum samples used in this study.
ASSAY PRINCIPLE
Oestradiol (E2) is a C 18 steroid hormone with a phenolic A ring.
OH
CH
HO
FIGURE 3.2 .7  Structure o f  17(3-Oestradiol.
M olecular formula: C 18H24 0 2
This was a solid phase ELISA, based on the principle o f com petitive binding. The 
microtiter wells were coated with an antibody, which was directed tow ards a unique 
antigenic site on the E2 molecule. Each sample contained endogenous E2, which 
competed with an E2 horseradish peroxidase conjugate for binding to the coated 
antibody on  the plate. Therefore the amount o f bound peroxidase conjugate was 
inversely proportionate to the concentration o f E2 in the sample. After addition o f the 
substrate, the intensity o f the colour developed was also inversely proportional to the 
concentration o f E2 in the sample. The sensitivity o f this assay was 9.7 pg/m l, and the 
inter- and intra- assay variations less than 10%. Duplicates samples, which varied > 
1 0 %, were repeated.
REAGENTS:
All reagents were stored at 2-8 °C until opened for use (after checking the expiry date) 
when it was allowed to come to room temperature, and included:
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1. Microtiter plate (96 well) coated with anti-E2 polyclonal rabbit antibody
2. Standards (0-6); 7 vials (ready to use)
Concentrations (pg/ml):
0 25 100 250 500 1000 2000
3. Enzyme conjugate: E2 conjugated to horseradish peroxidase (ready to use)
4. Substrate: TMB (ready to use)
5. Stop solution: 0.5M H2SO4 (ready to use)
6 . Wash solution: 40X concentrated 
ASSAY PROCEDURE
A plate plan was prepared prior to starting the assay.
All reagents were ready to use except for the wash buffer. This was prepared by making 
up the wash buffer (30ml) to a final volume o f 1200ml using deionised water.
Once the test had started, all steps had to be completed w ithout interruption, as the 
absorbance is a generally a linear function o f the incubation time and temperature.
To appropriate wells, 25 pL o f each standard, sample and control were added using a
micropipette dispenser. Following this, 200 pL o f enzyme conjugate was added to all
wells. The plate was then incubated on an orbital plate shaker at room temperature for 
1 2 0  minutes (without covering the plate), following which the wells were washed 
thoroughly (400pL/well) three times using the diluted wash solution. The plate was then 
dried by inversion onto paper towelling.
In the final step, lOOpL o f substrate was added to each well. The plate was again 
incubated at room temperature and colour was allowed to develop. A fter 15 minutes, the 
enzymatic reaction was stopped by adding 50 pL o f stop solution to each well. Within 
10 minutes, the absorbance was read at 450nm.
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3.3 BIOPHYSICAL OVARIAN RESERVE TESTS
3.3.1 INTRODUCTION
Ultrasound examination was performed on the same day that blood samples were taken 
(before ovarian stimulation). Inter-observer variability was m inim ised by having all 
ultrasound scans performed by a single investigator with expert ability in assessing 
these parameters (Conway et al. 1996). An Acuson 128 XP4 (Acuson USA) with a 2.5- 
4 MHz-vector probe (transabdominal) and a 5-7.5mHz EC-7 (transvaginal) probe were 
used to perform the scans.
3.3.2 ANTRAL FOLLICLE COUNT
Round or oval shaped echo-free structures from 2mm to 1 Omm within the ovaries were 
considered to be follicles. Total AFC was the sum of antral follicles m easured from both 
ovaries.
3.3.3 OVARIAN VOLUME
Ovarian volume was calculated for each ovary using the prolate ellipsoid formula: 
Ovarian volume = D1 x D2 x D3 x n/6, where D l, D2 and D3 were the maximal 
perpendicular diameters o f the ovary.
3.3.4 OVARIAN STROMAL BLOOD FLOW (OSBF)
Ovarian stromal blood flow velocity waveforms were obtained by placing the Doppler 
gate over the ovarian stroma which had the highest achievable signals, ensuring that no 
arteries near the surface o f the ovary were measured. Peak systolic velocity and 
pulsatility indices from both ovaries were than combined to provide the M ean Pulsatility 
Index (MPI) and M ean Peak Systolic velocity (MPS) respectively.
3.3.5 UTERINE DIMENSIONS
Uterine cross-sectional area (cm ) and endometrial thickness (mm) were calculated by 
examining the uterus in the sagittal plane.
3.4 IN VITRO STUDY
3.4.1 INTRODUCTION
The study design for the invitro study was discussed in chapter 3. Culture o f the breast 
cell line was carried out at the Ludwig Institute o f Cancer Research under the 
supervision o f Professor Mike O ’Hare. Culture o f granulosa cells was performed at the 
Centre for Reproductive Science Laboratory o f University College London under the 
supervision o f Dr Shanthi Muttukrishna.
3.4.2 BREAST CELL CULTURE
3.4.2.1 ESSENTIAL SKILLS
Before the actual experiment was started, essential cell culture techniques had to be 
learnt. This was initiated at the time the MCF-7 cell line was thawed and continued for 
up to one month before the actual experiments were carried out. These skills are listed 
below and are described in more detail as procedures are explained:
• Switching on the Laminar flow cabinet (LFC), sterilisation w ith 70% ethanol 
and ensuring adequate layout.
• Aseptic technique under the LFC, including handling and accurate transfer o f 
fluids with the pipettes and sterilising the LFC after use.
• Preparing medium for use including equilibrating the m edium in the flasks with 
CO2 using Pasteur pipettes.
• Use o f the incubator.
• Feeding cultures and monitoring for contamination with the inverted microscope.
• Counting cells using a haemocytometer and assessing viability using trypan blue.
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• Preparation o f stock medium, EDTA/PBS and antibiotics. All reagents were 
usually stored in the refrigerator (4-8 °C) with the exception o f EDTA/PBS, 
which could be stored at room temperature.
• Subculture o f established cell lines including accurate determ ination o f  seeding 
density.
• Writing all information in a lab note book and updating it everyday.
3.4.2.2 THAW ING THE CELL LINE
MCF-7 human mammary carcinoma cells (Soule et al. 1973b) frozen in ampoules 
containing 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen was used for 
the experiments.
REQUIREMENTS:
• 24-well culture flasks (Nunc, Denmark) -  these are polystyrene flasks with a 
negatively charged ionised base, encouraging cell attachment.
• Culture medium: The preferred medium for breast epithelial cells was a 
combination o f  D ulbecco’s modified Eagle’s medium (DM EM ) and H am ’s F12 
(Sigma), with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin.
• Sterile glass Pasteur pipettes
• 5, 10 and 25 ml plugged sterile pipettes with automatic pipette gun
• 15 and 30 ml sterile conical centrifuge tubes
• Waste beaker
• Labcoat and protective gloves with facemask
• Marker pen and adhesive tape
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PROCEDURE:
The cell line was located and the index carefully checked prior to rem oving the ampoule 
from the liquid nitrogen store. The ampoule was defrosted in 3-5 minutes (by keeping it 
within a clasped hand) and opened under the LFC. The cells were dispersed (by gentle 
tapping) and the contents o f the ampoule transferred to a 30 ml centrifuge tube using a 
lm l pipette. Cryoprotectant (DMSO) was removed by centrifuging at 1200 rpm for 
3minutes. The cells were resuspended in lm l of culture medium and transferred to a 
culture flask containing 15 ml medium (DMEM/F12 with 10% FCS) equilibrated with 
5% CO2 gas and incubated at 37° C in 100% humidity.
3.4.2.3 SUBCULTURE METHOD
INTRODUCTION:
A primary culture, once subcultured (or passaged) is then know n as a cell line. The 
MCF-7 cell line used in this study had already undergone 296 passages.
M onolayer cell cultures proliferate usually according to a set pattern. After 
seeding, a lag period is entered followed by an exponential or log growth phase. W hen 
the surface area o f the culture flask or the available substrate is occupied, the cell 
concentration reaches confluence. Subculture should take place ju st before, or at the 
time it happens, as cells will begin withdrawing from the cell cycle and take longer to 
recover when reseeded. MCF-7 cells have a tendency to clump, so passaging prior to 
confluence was essential.
FEED
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PLATEAU PHASE
CONFLUENCE
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EXPONENTIAL “LOG” PHASE
DAYS FROM SUBCULTURE
FIGURE 3.4.1 Standard logarithmic cell growth curve.
Standard cell growth curve (sem i log plot) showing the different phases o f  grow th and the tim ings for 
feeding and subculturing respectively.
PROCEDURE:
ADDITIONAL REQUIREM ENTS:
• 0.02 % EDTA (ethylenediaminetetraacetic acid) com bined with PBS (Phosphate 
buffered saline) (Sigma). This is prepared by mixing 5ml o f  2% EDTA (Sigma) 
in 500ml PBS giving 0.02% EDTA/PBS.
• Trypsin at a concentration o f 0.5mg/ml (0.02%).
The culture flasks were removed from the incubator and exam ined under the 
microscope to ascertain cell density, contamination and the general health o f the cells. 
Every time these cells were passaged, 2 flasks were prepared for transfer o f  the cells so 
that with every experiment, there was a back-up supply o f  M C F-7’s available to harvest. 
It was the policy o f  this lab to subculture once at least 80% confluence was obtained 
(assessed visually). Provided the cells were considered ready for subculture, the 
medium was discarded completely inside the LFC. The cells were w ashed three times 
using 10ml o f 0.02% EDTA/PBS. The purpose o f washing was to remove traces o f 
serum that would otherwise inhibit the action of trypsin and deplete the divalent cations, 
which were necessary for cell adhesion. Cell detachment from the culture flask was 
achieved by adding lm l o f trypsin (0 .0 2 %) and incubating in a humidified environment 
for 3-5 minutes. Once detachment had occurred, the cells were dispersed and washed in 
5ml medium (DMEM/F12 with 10% FCS) by centrifuging at 1500 rpm for 3 minutes. 
The cells were then resuspended in 8 ml o f medium. Seeding densities o f  1:4 and 1:8 
were prepared in two-subculture flasks by adding 2 ml and lm l respectively o f  this cell 
suspension to each. The flasks were then placed in a humidified incubator at 37° C and 
checked in an hour to ensure that no major pH change had occurred.
COUNTING THE CELLS:
Cell counts were performed after every subculture or adm inistration o f  trypsin for the 
undertaking o f experiments. This was achieved using a hem ocytom eter (Improved 
Neubauer). This device allows the cells to disperse w ithin an optically flat chamber o f 
know n depth (or volume). When counted within a defined area under the microscope, 
cell concentration can be derived.
145
ADDITIONAL MATERIALS:
• Yellow pipettor tips
• Automatic pipette (up to 200 pL)
• Hemocytometer with coverslip
It was not the policy o f this lab to routinely stain the cells w ith trypan blue as the MCF- 
7’s, which were viable, were easily distinguishable from those w hich were not (these 
looked like “shadows”). The surface o f the slide and coverslip were both cleaned with 
70% alcohol prior to use. The edges of the coverslip were wetted slightly and then 
placed down over the grooves o f the silver-lined counting area. Proper placement 
should have resulted in the appearance o f “Newton’s rings” (rainbow-like colours 
between the coverslip and the slide). The cells, after being trypsinised, were dispersed 
with the yellow-tipped pipette and a small amount withdrawn. This was then taken to 
the edge o f the coverslip and a drop drawn from the edge o f the coverslip by capillarity. 
The same was repeated on the other side. Any surplus fluid outside the coverslip was 
blotted away. The slide was then placed under the microscope and the central area o f the 
grid, bounded by parallel lines was focused on. The number o f  viable cells (n) within 
this 1mm was counted. The num ber o f  cells/ml (c) in this area was calculated by the 
formula c= n X 104. The volum e o f  the original sample then determines the total 
number o f cells. For example, i f  the original suspension volum e was 8 ml, the total 
number of cells in the suspension would be 8 X c, or 8 X n X 104. Determining the 
seeding density required for plating the cells will be discussed later.
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FEEDING THE CELL CULTURE:
Incubated culture flasks were inspected at least once daily for contamination. Cells 
required feeding approximately every 2 - 3  days. The need for feeding was based on the 
appearance o f the culture medium (changes in pH) and the morphology o f  the growing 
cells. To feed the culture, the medium was decanted under the LFC using the usual start­
up procedure. Fresh medium (25ml) was replaced and equilibrated with 5% CO2 using a 
Pasteur pipette. The culture flask was then replaced into the incubator and checked 
again in an hour to ensure that no major pH change had occurred.
FREEZING THE CELLS:
A fter the first passage was created from the thawed M CF-7’s, the rem aining cells from 
the thaw ed passage (p) 296 was frozen to create a back-up supply o f  cells for the 
experiment. The cryoprotectant used is DMSO (Lovelock & Bishop 1959), at a 
concentration o f 1 0 %.
PROCEDURE:
A DDITIONAL REAGENTS:
• L-15 medium (Leibovitz, Sigma) with 10%FCS and 1% penicillin/streptomycin.
This medium was normally used whenever cells need to be transferred, as it is
not CO2 dependent, and therefore maintains its pH in air.
• DMSO (10%) -  this was made by adding lm l o f  DM SO to 9ml o f  L-15 medium.
• 0.02 % EDTA/PBS
• 0 . 0 2  % trypsin
•  Cryoflasks (2ml) (Sarstedt, Germany) were used to place cells for storage. Each 
flask was individually labelled with the details o f the passage used e.g. MCF-7, 
p296 dated 12/4/05.
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The procedure was initially the same as for subculture as previously described. 
Following trypsinisation and centrifugation, the cells were resuspended in 6ml o f 
medium containing 10% DMSO. To each labelled flask (6 in total), lm l o f cells in 
medium were added. The cooling rate at which the cells were frozen needed to be slow 
at first to allow water to leave the cell but not so slowly as to allow  ice crystal formation. 
This was achieved by placing the vials into the head o f a freezing cham ber (Taylor 
Wharton neck plug cooler) for 20 minutes before lowering the height o f the ampoules 
quickly, which resulted in a super freeze at -70  to -9 0  °C. The cryoflasks were then 
transferred to the liquid nitrogen containers into carefully arranged rods, where the 
temperature dropped rapidly to between -180  and -190  °C. A careful record was made 
of all cells that were frozen or thawed.
PLATING THE CELLS:
The initial procedure was similar to that described for subculture (section 4.4.2.3 pg 
145-147). Before centrifuging the cells, the cells were filtered using a 40pm  nylon cell 
strainer. The purpose o f  this step was to remove clumps o f cells. The filtered medium 
and substrate was then centrifuged at 1500rpm for 3 minutes. The medium was 
discarded and the cells resuspended in 5ml medium. After dispersal, the cell 
concentration was estimated using the hemocytometer as previously described at a 
plating density o f 20000 cells/well.
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3.4.3 ESTABLISHING THE DOSE RESPONSE
INTRODUCTION
Initial experiments were carried out to optimise culture conditions prior to 
experimentation with cytotoxic agents. The optimised culture conditions were to 
maintain the MCF-7 cells in DMEM/F12 supplemented with 10% fetal ca lf serum and 
1% penicillin/streptomycin. The cells were grown in 100% hum idity after equilibrating 
in 5% CO2 at 37 °C at a plating density o f 20000cells/well.
The initial dose ranges chosen for this experiment were based on our 
collaborators’ (Professor John Hartley, Department o f Oncology) previous experience in 
establishing dose response in various cell lines including MCF-7 (Friedm ann et al. 2004; 
Friedmann et al. 2006; Kupchinsky et al. 2004). Several experiments were then 
performed to optimise the dose range for each drug.
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FIGURE 3.4.2 A typical sigm oidal dose response curve.
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PROCEDURE:
ADDITIONAL REAGENTS/MATERIALS:
• Electronic scale (A&D instruments, Abingdon, Oxford, UK)
• Hanks’ balanced salt solution (HBSS) (with 1% bovine serum albumin (BSA), 
gentamycin (1:1000) and amphoterecin (1:100))
• 0.2pm sterile filters
• 5 and 10 ml sterile syringes
• 100% ethanol
• 1M Hydrochloric acid (HCL)
• DMSO
• W ater
• Whirly mixer
• 2ml and 5ml flat bottom containers with lids
• lOOOpl, 200pL and 20pL graduated pipettes and pipette tips
DRUG A PPEA R A N C E M OLECULAR
W EIGHT(MW )
SOLUBILITY
RECO M M ENDED
STOCK
SOLUTION
STO RAG E
REQUIREM ENTS
DOXORUBICIN RED POW DER 580.0 W ATER ImM 2-8° C
M ELPHALAN WHITE
POW DER
305.2 100 % ETHANOL  
A N D  1M HCL
lOmM
ROOM  TEM P IN 
DARK
ENVIRO NM ENT
PACLITAXEL WHITE
POW DER
853.9 DM SO ImM 2-8° C
CISPLATIN COLOURLESS
FLUID
3.3 mmol W ATER 3.3m M
ROOM  TEMP IN 
D ARK
E NVIRO NM ENT
TABLE 3.4.1 Drug characteristics.
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To ensure consistency, the top concentration for each drug was concentrated X 20.
Drugs were freshly diluted in culture medium and filter sterilised prior to administration. 
Control cells received vehicle alone. All dose ranges (except paclitaxel) consisted o f 10- 
fold dilutions from a top concentration initially. Drug dilutions were performed under 
the LFC using carefully labelled 5ml cylindrical flasks and graduated micropipettes. 
The drugs were always added in the order o f doxorubicin first, followed by melphalan, 
paclitaxel and cisplatin respectively. The time taken from drug dilution to application in 
all 4 plates was no longer than 30 minutes. After application o f drug, the plates were 
carefully labelled and sealed with adhesive tape, then placed in a hum idified incubator 
at 37° C. The effect o f the drug was assessed under the microscope daily for up to 1 
week. After several experiments, the dose ranges were optimised as shown below after a 
72 hour exposure.
DRUG TOP CONC 1st d i l 2nd DIL 3rd DIL 4 th DIL
D O X O R UBIC IN
(nM)
100 50 25 12.5 6.25
M ELPHALAN
(pM)
25 12.5 6.25 3.13 1.56
PACLITAXEL
(nM)
50 25 12.5 6.25 3.13
CISPLATIN
(pM )
25 12.5 6.25 3.13 1.56
TABLE 3.4.2 Drug dilutions.
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PLATE 1 = DO XO RU BICIN
0 nM 6.25nM 12.5nM 25nM 50nM  lOOnM
CONTROL LOWEST HIGHEST
CONCENTRATION CONCENTRATION
FIGURE 3.4.3 Standard plate arrangement.
Final appearance o f  plate arrangement after the dose response was validated (doxorubicin  show n).
FIXING THE PLATES:
The purpose o f this procedure was to create a permanent visual representation o f  how 
the dose response range for each drug was achieved.
REAGENTS:
• 4% Formalin
• Hematoxylin
• PBS (Phosphate buffered saline)
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PROCEDURE:
The entire process was non-sterile and was therefore performed outside the LFC.
4% formalin was prepared by mixing 50ml o f -40%  formalin solution (Sigma, UK) in 
500ml PBS (Sigma, UK).
The plates to be fixed were removed and the medium from each well removed using a 
non-sterile pipette. The cells were then washed with PBS (1ml) after which formalin 
(lm l) was added to each well using a graduated pipette. The plates were covered, sealed 
and then placed in the refrigerator overnight.
The following day, the plates were removed and the form alin decanted into a 
running sink. The cells were then washed with PBS (lm l). Hem atoxylin (lm l) was 
added to each well and the plates allowed to stand for at least one hour.
Following this, the hematoxylin was removed from each well (and stored for 
later use). The plates were then washed in running water twice. This resulted in a blue 
colour. A fter the third wash, the wells were filled with approxim ately lm l o f  water each, 
and the plates sealed and stored in the refrigerator at 4-8°.
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3.4.4 GRANULOSA CELL CULTURE
3.4.4.1 GRANULOSA CELL SOURCE
Granulosa cells were isolated from human follicular fluid (hFF), collected from patients 
having oocyte recovery after stimulation for IVF. Patients underwent pituitary down- 
regulation for three weeks using a gonadotrophin releasing horm one (GnRH)-analogue 
followed by 7-10 days o f ovarian stimulation with high-purity follicle-stimulating 
hormone (FSH). Once there was a sufficient ovulatory response, patients were 
administered human chorionic gonadotrophin (HCG) for 36 hours after which any 
follicle > 10mm in diam eter was aspirated under ultrasound guidance.
3.4.4.2 M ATERIALS/REAGENTS
In addition to the standard apparatus used to culture the breast cell line MCF-7 as 
previously mentioned, several additional reagents were required for this culture.
• Laminar flow cabinet (LFC)
• Centrifuge
• Humidified incubator providing 5% CO2 and 20% O2.
• Inverted microscope
• Autoclave
• Hemocytometer (Improved Neubauer)
• Trypan blue
• 50ml sterile conical flasks (plastic)
• 5ml sterile flat bottom tubes
• Virkon ® and 70% ethanol
• Waste beaker with suction
• Sterile graduated pipettes lm l, 5ml, 10ml, 25ml
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• Sterile 20pL, 200pL  and lOOOpL pipettes
• Sterile plastic Pasteur pipettes
• Sterile glass beakers
• 60% percoll solution (Sigma): This is a non-toxic, sterile, isosm otic fluid, which
provides a density gradient for the separation o f  cells. Initially 100% percoll is 
prepared by adding 9ml to lm l o f  1.5M sterile sodium chloride solution (NaCl). 
60% percoll is then obtained by mixing 15ml o f  100% percoll w ith 10ml o f 
HBSS.
• HBSS supplem ented w ith penicillin/streptom ycin (1%); am photerecin 1:100 and 
gentam ycin 1:1000
• H yaluronidase (Sigma): This was prepared as a stock solution (lOmg/ml) by 
reconstituting the vial with 3ml distilled water. The stock was divided into 
500pL aliquots and frozen at -20°C for future use. A w orking concentration o f 
300pg/m l was achieved by diluting 450pL o f stock solution w ith 15ml HBSS 
(33-fold dilution).
• DM EM /F12 m edium  (GIBCO) supplem ented with antibiotics
• 20% FCS (GIBCO).
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3.4.4.3 G R A N U L O SA  CELL CULTURE PROCEDURE
A m eticulous aseptic technique was essential. All experim ents were carried out strictly 
under sterile conditions in a lam inar flow cabinet. Hum an follicular fluid (HFF) was 
pooled from each patient and centrifuged at 1100 rpm for 10 m inutes. The supernatant 
was discarded and the cells were w ashed with Hanks balanced salt solution (HBSS; 
Gibco Ltd.) containing am photerecin (1:100) and gentam ycin (1:1000). The granulosa 
cells were separated from red blood cells by centrifugation at 1 lOOrpm on a 60% Percoll 
layer for 30 minutes. A fter Percoll separation the granulosa cells w ere washed with 
HBSS and the cell aggregates incubated with 2ml o f HBSS containing 300pg/m l bovine 
testicular hyaluronidase (Sigm a) for 15 minutes (to reduce clum ping). A fter washing 
w ith HBSS the cell suspension was m echanically dispersed using sterile Pasteur pipettes 
to obtain m axim al dispersion A final wash with HBSS was perform ed and the resulting 
pellet resuspended w ith 2ml o f  culture medium consisting o f  D M EM /F12 (Gibco) 
containing 1% penicillin/streptom ycin, am photerecin (1:100), gentam ycin (1:1000) and 
20% fetal c a lf  serum  (FCS).
Cells were counted using the trypan blue exclusion m ethod on a hem ocytom eter. 
This was perform ed by placing 50pl o f  medium containing cells in a petridish and 
adding an equivalent volum e o f trypan blue (0.4%). The cells w ere layered on a 
hem ocytom eter using the m ethod described previously (section 4.4.2.3) Non-viable 
cells appeared deep blue in colour due to m em brane perm eability w hile viable cells 
excluded the dye.
Cells were plated at a density o f 20000 cells/well in 24-well non-treated culture 
plates (Nunc) and incubated in a water-saturated incubator w ith 5% CO 2 at 37°C 
throughout the experim ental period. Non-treated plates were chosen as the viability o f 
the granulosa cells was im proved following separation from the m edium  com pared to 
the coated plates em ployed for the M C F-7’s.
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<------------  GRANULOSA CELL LAYER
PERCOLL
RED BLOOD CELLS
FIG U R E 3.4.1 Percoll separation o f  granulosa cells.
D iagram  sh ow in g  percoll separation o f  G C ’s fo llow in g  centrifugation.
D RUG A D M IN ISTRA TIO N :
Drugs were added in an analogous fashion to that used for the breast cells and at the 
same concentrations. A fter initial experim ents, optimal exposure for the granulosa cells 
was 48 hours.
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3.4.5 FLOW CYTOM ETRY
3.4.5.1 IN TRODU CTION
These experim ents took place in the Departm ent o f  H aem atology, w hich was in close 
proxim ity to the cell culture laboratory. M r Arnold Pizzey perform ed the flow 
cytometry after the sam ples were adequately prepared. A com m ercial apoptosis 
detection kit, A nnexin-V -Fluos (Roche) was used for all experim ents.
3.4.5.2 G EN ERA L REQU IREM EN TS
• M ini-centrifuge
• G ilson pipettes -  20, 200 and lOOOpL
• Plastic Pasteur pipettes (non-sterile)
• 2ml Eppendorf tubes
• 2ml flat bottom  tubes with covers
• Cytom eter tubes
• M arker pen
• Phosphate buffered saline (PBS)
• 0.02%  EDTA
• 0.02%  trypsin
• L-15 m edium
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FOR STAINING:
• A nnexin-V -Fluos labelling reagent (250pL, stored at -20°C, Roche Diagnostics 
Germany)
• A nnexin V buffer (m ade in-house): To make 500ml o f  this solution, 1.19 g 
Hepes was dissolved in 500ml-distilled water. 100ml o f  6M  N aO H  was prepared 
by adding 24g o f  N aO H  to lOOml-distilled water. Using the pH meter, this 
solution was slowly added to the Hepes solution until a pH o f  7.4 was achieved. 
To this solution was added 140mM NaCl (4.09g) and 5mM  C aC ^  and placed on 
the m agnetic stirrer. Once m ade this buffer can be stored at 2-8°C for up to 3 
m onths.
• Propidium  Iodide (PI, Invitrogen): This was usually stocked at 2mg/ml. A 
functional concentration o f  50pg/m l was obtained by perform ing a 40-fold 
dilution w ith PBS.
• A nnexin-V -Fluos labelling solution: This was m ade by prediluting 20pL 
A nnexin-V -Fluos labelling reagent in lm l A nnexin-V  buffer and adding 20pL 
PI.
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3.4.5.3 FLOW CYTO M ETRY PROCEDURE
At the end o f  the experim ental period, cells were lifted from each plate in the same 
order that drug was adm inistered. Culture medium was pooled from each well in 
quadruplicate, placed in eppendorf tubes and centrifuged at 13g for 1 minute. The 
supernatant was stored at -20°C for horm one assays. The resulting pellet contained dead 
cells, which were included in the flow cytom etry analysis. Cells were then lifted from 
the plate using EDTA and 0.02%  trypsin. Cells from the quadruplicate treatm ents were 
then pooled for flow cytom etry. The cells were prepared for cytom etry by first washing 
the cells with PBS and centrifuging at 13g for 1 minute. The cell pellet was then 
resuspended in 100 pi o f  A nnexin-V -Fluos labelling solution. The cells were incubated 
for 10-15 m inutes at room  tem perature in cytometer tubes before analysing in the flow 
cytom eter. If  a longer period was necessary, the cells were kept on ice in the dark for up 
to 1 hour until ready for analysis.
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4. RESULTS IN VIVO STUDY
4.1 INTRODUCTION
The background, rationale and clinical study design have been discussed in chapters 2 
and 3 respectively.
Briefly, pre-m enopausal recipients o f  chem otherapy for breast cancer were 
analysed in two groups -  a longitudinal arm (group 1) and a cross-sectional arm (group
2). In group 1, patients were offered ovarian reserve testing prior to receiving 
chem otherapy, and w ere then followed up longitudinally by perform ing further testing 
im m ediately follow ing chem otherapy, and at several time-points afterw ards (see chapter
3). In the cross-sectional study, patients were tested for ovarian reserve prior to 
chem otherapy  (some patients were also part o f  the longitudinal study) and after 
chem otherapy  w hen they had resum ed regular m enstrual cycles. Patients with 
oestrogen-sensitive cancer were recruited provided they had not taken tam oxifen or 
G nRH  analogues (goserelin or leuprolin) for at least the preceding 12 weeks.
Controls were age-m atched, had no medical illness, had previously proven 
fertility (defined by virtue o f  having childbirth) and had a norm al m enstrual history. 
Those on oral contraception were asked to discontinue it and use alternative 
contraception for at least 8 weeks prior to testing.
U nfortunately, the longitudinal arm o f this study was severely affected due to 
the fact that m ost o f  the serum samples stored for analysis were lost in a freezer disaster 
over a Christm as holiday period. Samples which belonged to the controls and post­
chem otherapy group were retrieved by repeating the tests w here possible. This would 
explain m ost o f  the discrepancy in the num ber o f  samples (n) for the different hormones 
assayed. O ther reasons for any discrepancy were as follows:
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1. Some patients would not consent to the G test being perform ed, but allowed 
basal sam ples to be taken. As such stim ulated and delta horm one levels for 
these patients could not be obtained.
2. After an analysis o f  prelim inary data, it was decided not to continue testing o f 
inhibin A, activin A, follistatin and Pro aC  as these m arkers did no t appear to be 
discrim inatory.
3. W ith regard to biophysical param eters, it was not alw ays possible to record 
certain variables such as ovarian volume or antral follicle count due to factors 
w hich im peded optim al view ing (such as distended loops o f  bow el in the pelvis).
4.2 TOLERABILITY
All tests perform ed were well tolerated, with no adverse effects reported.
4.3 STATISTICAL ANALYSES
A norm ality test was done to assess the distribution o f  data. M ost variables in the cross- 
sectional data analysis had a gaussian distribution. As such, unpaired S tuden t’s t-tests 
were carried out to com pare biochem ical and biophysical param eters betw een patients 
and controls. O ne-way analysis o f  variance was used to com pare baseline param eters 
only. A p value < 0.05 was considered statistically significant. W hen a  significant 
difference was found, a post-hoc test (B onferroni’s m ultiple com parison) was used to 
compare differences betw een individual groups. V ariables w hich displayed a non- 
gaussian distribution were com pared using the K ruskal-W allis test, w ith  differences 
between individual variables analysed post-hoc using D unn’s m ultiple com parison tests.
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Data in the longitudinal group, w hich had a normal distribution were analysed using the 
paired t-test. N on-param etric variables were analysed using the W ilcoxon signed rank 
test.
Unless specifically indicated, all param eters displayed a gaussian distribution and 
results displayed represent the mean value ± the standard error o f  the m ean (SEM). All 
Statistical analyses were perform ed using GraphPad Prism version 3.00 for W indows 
(GraphPad Software, San D iego California USA) and Statistical Package for Social 
Sciences (SPSS Inc., Chicago, IL, USA).
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4.4 CROSS-SECTIONAL DATA
4.4.1 CLINICAL PARAMETERS
4.4.1.1 CH RO N O LO GICAL AGE
There was no statistically significant difference (P > 0.05) in age betw een all three
groups. The mean age for patients in the pre-chem otherapy group was 35.2 ± 1.5, for 
patients in the post-chem otherapy group 36.7 ± 0.6 and in the controls 34.5 ± 0.9.
AGE
NS
I I
4 0 -
34.46 ± 0.87 
(n = 24)
35.20 ±  1.47 
(n = 15)
36.68 ± 0.57 
(n = 22)
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4.1.1 Mean age o f study subjects.
Mean age (years) between all 3 groups. Not statistically significant (p > 0.05)
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4.4.1.2 BODY MASS INDEX
There was no statistically significant difference in BMI (kg/m2) between the 3 groups. 
The m ean BMI for patients in the pre-chem otherapy group was 24.27 ±  0.84, for 
patients in the post-chem otherapy group 24.59 ± 0.53 and in the controls 26.04 ± 1.02.
35n
30-
BODY MASS INDEX
NS
25-
E 20-
a>
CQ
15-
10 -
5-
0J
26.04 ±1.02
(n = 24)
24.27 ± 0.84
(n = 15)
24.59 ± 0.53
(n = 22)
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4 .4  1.2 M ean B M I o f  study subjects.
BM I in all three groups -  no statistically  sign ificant d ifferences in the m ean
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4.4.2 BIOCHEMICAL PARAMETERS
All biochem ical tests included basal estim ates as well as stim ulated and delta 
(stim ulated -  baseline, A) results following adm inistration o f  the G-test.
4.4.2.1 FOLLICLE STIM ULATING H ORM ONE
BASAL FSH:
O ne-way ANOVA revealed statistically significant differences overall am ong the 3 
groups (p = 0.0006). The m ain differences w ere betw een the controls and the post­
chem otherapy group (95%  Cl = -7.92 to -1.47), as well as betw een both patient groups 
(pre vs. post, 95%  Cl = -8.99 to -1.54). There was no statistically significant difference 
in basal FSH levels betw een patients in the pre-chem otherapy group and the controls 
(95% Cl -3.01 to 4.20).
E
3
E
x
CO
15.0n
12.5-
10 . 0 -
7.5-
5.0-
2.5-
0.0
BASAL FSH ***
p < 0.01
p < 0.05
I   1
NS
6.09 ± 0.49 
(n = 14)
6.62 ± 0.42 
(n = 24)
11.32 ±1.48 
(n = 21)
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4.2.1 Basal FSH levels in all 3 groups.
Basal FSH levels between all 3 groups showed a statistically significant difference. *** p < 0.001
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STIM ULATED FSH:
One-way ANOVA revealed statistically significant differences am ong the 3 groups (p = 
0.005). The main differences were between the controls and the post-chem otherapy 
group (95% Cl = -10.89 to -0.91), as well as between both patient groups (pre vs. post, 
95% Cl = -14.36 t o -1.13).
STIMULATED FSH **
 p < 0.05_______________
30-
25<
20 -
E
3
E
x
CO
151
10 -
0-
p < 0.05
NS
17.50 ± 1.37 
(n = 24)
23.40 ±1.70 
(n = 20)
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4 .4 .2 .2  M ean stim ulated lev e ls  o f  FSH  in all three groups.
N um bers in bold  print represent m ean values o f  each  group + the standard error o f  the m ean (SE M ).
** p < 0.01
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DELTA FSH:
O ne-w ay ANOVA did not reveal any statistically significant differences am ong the 
three groups (p = 0.42).
15.0-1
12.5-
10.0-
1  
3
E
x  7.5-]
CO
5.0H
2.5-
0.0J
A FSH
NS
NS
NS
10.88 ±1.33 
(n = 24)
8.79 ±1.16
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4.2.3 Delta (stimulated -  baseline) FSH levels between all groups. 
Not statistically significant (p = 0.42).
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4.4.2.2 LUTEINISING HORM ONE
There w ere no statistically significant differences in the mean values o f  basal LH, 
stim ulated LH and delta LH betw een the controls, pre-chem otherapy and post­
chem otherapy patients respectively. Further testing o f  LH was stopped after initial 
review o f  the data revealed no significant differences, which is w hy the num ber o f  
samples (n) tested is sm aller than for FSH for example.
BASAL LH
N S
2.9 ± 0.32 
(n = 16)
3.99 ± 0.61 
(n = 14)
8.42 ± 3.77 
(n = 14)
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4.2.4 Basal LH in all 3 groups.
Mean basal LH values not significantly different between all three groups.
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S T I M U L A T E D  LH
NS
25- 
2 0 -
E 
2
E 15- 
x
_ i
1 0 -  
5- 
0-
CONTROL PRE-CHEMO POST-CHEMO
2 5 . 4 9  ±  3 . 9 2  
( n  =  1 6 )
2 4 . 4 0  ±  2 . 2 4  
( n  =  8 )
2 1 . 0 2  ±  2 . 4 5  
(n = 12)
FIGURE 4.4.2.5 Stimulated LH levels. NS = not statistically significant.
30-
25-
20 -
15-
10 -
5-
0-
A LH
NS
1 6 . 0 8  ±  2 . 3 6  
( n  =  1 2 )
2 0 . 0 7  ±  1 . 7 3  
(n = 8)
2 2 . 5 9  ±  3 . 9 2  
( n  =  1 6 )
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4.2.6 A LH levels. 
NS = not statistically significant.
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4.4.2.3 OESTRADIOL
BA SA L E2:
O ne-w ay ANOVA revealed significant differences in the m ean basal oestradiol levels 
am ong the three groups. The m ain differences existed between the control group and the 
pre-chem otherapy patients (95%  Cl -214.0 to -0.5893; p<0.05) and betw een the pre- 
and post-chem otherapy groups (95% Cl 37.39 to 256.4; p<0.01). There was no 
significant difference in the m ean values between the controls and the post­
chem otherapy group. The overall ANOVA p value was 0.006.
BASAL E2 **
NS
p < 0.05
p < 0.05
300-
25 0 -
E 200-
o>
c l
CMLU
150-
252.0 ± 49.09 
(n = 14) r
100 -
50-
144.7 ±26.13 
(n = 24)
105.2 ± 16.21
(n = 21)
0J
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4.2.7 Basal oestradiol levels in all three groups.
** p < 0.01
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STIM ULATED E2:
ANOVA revealed significant differences between the m ean stim ulated oestradiol levels 
o f  the controls and the pre- and post-chem otherapy groups (overall p = 0.005) 
respectively. The overall difference was m ainly accounted for by significant differences 
between the controls and the post-chem otherapy group (95% Cl 45.05 to 391.0; p < 
0.01), and between both patient groups (95%  Cl 10.67 to 469.3; p <0.05). This was in 
contrast to the basal oestradiol ANOVA, w here one o f  the m ain differences existed 
between the controls and the pre-  chem otherapy group.
STIM E2 **
p <  0.01
600n NS
p < 0.05
500-
400-
E
LU
200 -
427.9 ± 55.87 
(n = 24)
449.9 ± 74.74 
(n = 9)
100 -
209.9 ± 37.5 
(n = 20)
0J
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4. 2.8 STIMULATED E2 in all three groups.
The discrepancy between n for basal vs. stimulated oestradiol was either due to the fact that some patients
defaulted from having the g-test performed, or from lost samples.
** p < 0.01
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DELTA E2:
The m eans for the controls and patients were significantly different (p = 0.002). The 
m ain differences arose from comparisons between the controls w ith the post­
chem otherapy group (95%  Cl 51.60 to 299.2; p < 0.01) and between the pre- and post­
chemotherapy groups (95%  Cl 25.20 to 353.4; p < 0.05). This was unlike the case seen 
with basal E2, w here there was no significant difference between patients in the post­
chem otherapy group and the controls. This implies that delta E2 has discrim inatory 
capacity as a m arker o f  ovarian reserve (see discussion section 5.10).
40(H
A E2 **
p < 0.01
NS
1 p < 0.05
350-
300-
250-
o>
a  20(h
150-
100 -
50-
0J
283.2 ± 40.34
(n = 24)
297.1 ± 58.43 
(n = 9)
107.8 ±23.9
(n = 20)
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4. 2.9 Delta oestradiol in all 3 groups.
Delta oestradiol significantly lower in the post-chemotherapy group. ** p< 0.01
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4.4.2.4 ANTI M ULLERIAN HORMONE
B A SA L AMH:
O ne-way ANOVA revealed highly significant differences (p = 0.0006) in mean basal 
AMH levels among the three groups. The greatest difference was seen betw een the 
controls and patients in the post-chem otherapy group (95% Cl 2.68 to 11.21; p < 0.001); 
however a significant difference was also detectable between the pre-chem otherapy and 
post-chem otherapy patients (95% Cl 0.62 to 11.02; p < 0.05). There was no significant 
difference betw een patients in the pre-chem otherapy group and the controls.
10 -
9-
8
7-
1  6 "o> 
c
§ 5" 
4
3
2
1 -
0
BASAL AMH ***
p < 0.001
NS
p < 0.05
0.95 ± 0.34 
(n = 17)
6.77 ± 1 .7  
(n = 9)
7.89 ± 1 .6 2  
(n = 18)
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4.2.10 Mean basal AMH levels in patients and controls.
** * p <  0.001
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STIM ULATED AMH:
The m ean values for stim ulated AMH levels between patients and the controls were 
found to be significantly different (p < 0.0006). M ost o f  the difference was found in the 
com parison between the controls and the post-chem otherapy group (95%  Cl 2.86 to
11.12; p < 0.001), although this was a gaussian approxim ation (M ann-W hitney test; this 
was likely due to the small sam ple size for the pre-chem otherapy group as a result o f  
lost samples). As expected, stim ulated AMH levels were not significantly different from 
basal AM H levels.
10 -
9-
8-
7-
I  6‘o>c
I  5- 
4- 
3-
2 -
1 -  
0-
STIMULATED AMH ***
p < 0.001
NS
NS
0.97 ±1.4 
(n = 17)
3.64 ±1.02 
(n = 4)
7.95 ± 1.62 
(n = 18)
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4.2.11 Stimulated AMH levels.
The distribution is non-gaussian for the post-chemotherapy group. *** p < 0.001.
1 7 S
DELTA AMH:
The mean A AM H levels between patients and the controls were not significantly 
different. This was likely due to the small num ber o f  sam ples obtained in the pre­
chem otherapy group (due to lost/spoiled samples as described earlier).
0 .6-1
0.5-
0.4-
I
~D)
C
|  0.3 
<
0.2
0 . 1-
0 . 0-
NS
0.06 ±0.15 
(n = 18)
A AMH
NS
0.28 ± 0.22
NS
0.01 ± 0.08 
(n = 17)
CONTROL PRE-CHEMO POST-CHEMO
FIG U R E  4 .4 .2 .1 2 A A M H  in patients and controls.
AMH levels are remarkably stable following gonadotrophin stimulation.
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4.4.2.5 INHfBlN B 
b a s a l  IMHIBIN B:
O ne-w ay ANOVA revealed highly significant differences in the m ean basal inhibin B 
levels among tb e tfiree groups (p = 0.0003). Further analysis revealed the main 
differences in th^ Ricans existed between the controls and the post-chem otherapy group 
(95% Cl 2b-26 to )02.5; p < 0.001) and between the pre-chem otherapy and post- 
chem otherapy groups (95%  Cl 9.285 to 102.2; p < 0.05). There was no significant 
difference between patients in the pre-chem otherapy group and the controls.
BASAL INHIBIN B ***
p < 0.001
NS
100 p < 0.05
83.61 ± 13.45 
(n = 18)
74.97 ±17.7 
(n = 9)
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4.2.13 Mean b*isal inhibin B.
The distribution for tfle ppst-chemotherapy group was non-gaussian. 
*** p c  0.001
1 7 7
STIM ULATED INHIBIN B:
O ne-w ay ANOVA revealed highly significant differences betw een the m ean levels o f  
stim ulated inhibin B am ong the three groups (p < 0.0001). The m ain difference existed 
between the controls and the post-chem otherapy group (95%  C l 98.87 to 217.5; p < 
0.001). The distribution for this group how ever was non-gaussian (M ann-W hitney test), 
and there was no significant difference in m ean stim ulated inhibin B betw een the 
controls and the pre-chem otherapy group (but the sample num ber is small (N = 4), as 
discussed previously for AM H).
STIMULATED INHIBIN B ***
p < 0.001
225-1 NS
200 -
175-
150-
E
NS
00
X 100- 
z 180.4 ±22.8 (n = 18)
75-
50- 87.21 ±21.21 
(n = 4)
25-
0J
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4.2.14Stimulated inhibin B levels in all three groups.
*** p < 0.001
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DELTA INHIBIN B:
There were highly significant differences in the mean A Inhibin B levels across the 
groups (p < 0.0001). This was again exem plified m ostly by the difference in the mean 
between the controls and the post-chem otherapy group (95%  Cl 52.76 to 134.8; p < 
0 .001).
A INHIBIN B ***
p < 0.001
120-
110 -
100-
90-
1  80- 
o>
a- 70- m
|  60- 
X
Z 50-
<
40-
30-
20-
10-
0-
96.82 ±16.38
(n = 18)
45.17 ±5.98
3.02 ± 2.3 
(n = 17)
CONTROL PRE-CHEMO POST-CHEMO
FIGURE 4.4.2.15 A Inhibin B in all three groups. 
The distribution in patients is non-gaussian.
*** p < 0.001
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INHIBIN A
There were no statistically significant differences in basal, stim ulated or delta inhibin A 
levels among the three groups. Analysis o f variance was calculated for basal samples 
only (p = 0.53), as the num ber o f  stimulated inhibin A samples in the patient groups 
were too small.
G R O U P M E A N M EAN M E A N
B A S A L STIM D E L T A
IN H IBIN  A INHIBIN A IN H IB IN  A
(pg/m l) (pg/m l) (pg/m l)
C O N TR O L S 12.48 ± 4 .8 7 9 .44  ±  2 .49 -3 .3 6  ± 7 .1 5
(n -  9) (n = 9) (n = 8)
PRE-CH EM O 3.9 22 .58 18.68
(n = 3) ( n = l ) ( n = l )
PO ST-C H EM O 11.81 ± 2 .9 2 23 .38  ±  8 .67 15.19 ±  8 .24
(n =  6) (n = 6) (n = 5)
T A B L E  4.4.1 Inhibin A  mean values in all three groups.
S u ffic ien t data for analysis w as obtained for the controls and the post-chem otherapy group only.
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4.4.2.7 ACTIVIN A
One-way ANOVA revealed that the mean basal levels o f  activin A were not 
significantly different between patients and the controls (p = 0.44). Stim ulated samples 
were low (N = 2) in the pre-chem otherapy group, m aking a one-w ay ANOVA 
unsuitable. However unpaired t-tests between the controls and the post-chem otherapy 
group revealed no differences in the means o f  stim ulated and delta levels o f  activin 
respectively.
G R O U P M E A N M EAN M E A N
B A S A L STIM D E L T A
A C T IV IN  A A C T IV IN  A A C T IV IN  A
(pg/m l) (pg/m l) (pg/m l)
C O N TR O LS 3 6 7 .2  ± 6 4 .5 8 338 .6  ±  58.29 -12 .2  ± 6 7 .1
(n = 16) (n = 15) 0 = 1 5 )
PRE-CHEM O 4 6 6 .7  ±  85.51 344 .6 -85.61
(n = 8) ( n = 2) 0  = 2 )
PO ST-C H EM O 2 9 9 .2  ± 9 5 .1 0 211 .8  ± 4 4 .6 9 -34 .5  ±  85 .4
(n = 7) 0  = 7) 0  = 7)
T A B L E  4 .4 .2  M ean activin A leve ls  in patients and the controls.
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4.4.2.8 FOLLISTATIN
One-way A NOVA was applied to basal follistatin results only as the sample size for 
stim ulated levels in the pre-chem otherapy group was very small (N = 1). There were no 
significant differences in the means among the three groups (p = 0.40).
G RO UP M E A N M EAN M E A N
B A S A L STIM D E L T A
FO L L IST A T IN FOLLISTATIN FO L L IST A T IN
(pg/m l) (pg/m l) (pg/m l)
C O N TR O L S 5 1 0 .4  ±  121.7 511.3 ± 7 9 .3 8 0 .9 2 2 2  ±  94 .08
(n = 9) ( n = 9) (n =  9)
PR E-C H EM O 4 9 0 .8  ±  128.0 1135.0 228.1
(n = 8) (n = 1) (n = 1)
PO ST-C H EM O 3 0 2 .6  ± 4 4 .8 2 3 93 .4  ± 115.8 9 0 .8 2  ±  119.7
(n = 6) (n = 6) (n = 6)
TA B L E  4 .4 .3  M ean follistatin  levels in all groups. 
The distribution w as G aussian for basal sam ples.
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4.4.2.9 ACTIVIN A/ FOLLISTATIN RATIO
The difference between the mean basal A/F ratios were not statistically significant (p = 
0.07). There were no significant differences in the means for stim ulated and delta a /f 
ratios in the post-chem otherapy group. Meaningful analysis in the pre-chem otherapy 
group was impossible due to the small number o f stim ulated activin and follistatin 
results.
G ROUP M EAN MEAN M E A N
B A S A L STIM D E L T A
A /F A/F A/F
R A T IO RATIO R ATIO
C O N TR O L S 0.78  ± 0 .3 2 0.69 ± 0 .1 7 0 .6 0  ± 0 .3 0
(n = 9) (n = 9) (n = 8)
PRE-CHEM O 1.84 ± 0 .5 9 0.11 0.52
(n -  8) (n = 1) (n = 1)
PO ST-C H EM O 0.77  ± 0 .1 8 0.64 ± 0 .1 9 0 .78  ± 0 .1 9
(n = 6) (n = 6) (n = 6)
TA BLE 4 .4 .4  M ean A /F ratios am ong all three groups.
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4.4.2.10 PRO aC
One-way ANOVA was only possible for basal pro aC  levels in all three groups due to 
insufficient samples from stim ulated patients in the pre-chem otherapy group. However, 
the differences in the m ean basal levels among the three groups w ere not significant (p 
= 0.95).
G RO UP M EAN M EAN M E A N
B A S A L STIM D E L T A
PRO a C PRO aC PRO a C
(pg/m l) (pg/m l) (pg/m l)
C O N TR O L S 193.7 ±47.40 268.6 ±38.96 70.29 ±31.15
(n = 15) (n = 14) (n=14)
PRE-C H EM O 212.9 ± 49.19 331.8 186.4
(n = 8) (n = 1) (n = 1)
PO ST-C H EM O 214.2 ±64.74 307.3 ±71.86 93.06 ± 14.16
(n = 6) (n = 6) (n = 6)
T A BLE 4 .4 .5  M ean Pro a C  values in all three groups.
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4.4.3 BIOPHYSICAL PARAMETERS
4.4.3.1 INTRODU CTION
A single operator with expert -  level experience and technical ability perform ed all 
ultrasound exam inations (M iss Anita Patel). On certain occasions, w hen M s Patel was 
unavailable, it was necessary to obtain the assistance o f another expert sonographer (Dr 
Bindhu Parikh). Inter-observer variability was verified to be low by random ly scanning 
three study subjects tw ice (with permission) independently on the same day by both 
sonographers and com paring the results.
All scans were perform ed prior to administration o f  the G-test. In 3 cases, scans 
were repeated 24 hours following the G-test (with permission). There were no 
noticeable differences in the biophysical param eters obtained prior to stim ulation in the 
same study subjects (data not shown). Where paired readings (both ovaries) were not 
obtainable, the results were omitted from the analysis. All biophysical param eters, with 
the exception o f  D oppler indices passed normality testing (distribution was gaussian).
4.4.3.2 O VARIAN V OLU M E
There were no statistically significant differences in total (TOV) and m ean (M OV) 
ovarian volum e am ong the three groups as assessed by one-way A NO V A (TOV: p = 0.1; 
MOV: p = 0.1).
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FIGURE 4.4.3.1 TOV between patients and the controls.
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4.4.3.3 ANTRAL FOLLICLE COUNT
Analysis o f  variance (ANOVA) showed highly significant differences in the mean total 
antral follicle count (TAFC) am ong the three groups (p < 0.0001). W hile no significant 
difference was detected between the controls and the pre-chem otherapy group (95% Cl 
-4.129 to 4.691; p > 0.05), there were significant differences betw een the controls and 
the post-chem otherapy group (95%  Cl 5.336 to 13.16; p < 0.001), as well as between 
the pre-and post-chem otherapy groups (95% Cl 4.559 to 13.38; p < 0.001). A similar 
picture was seen with the m ean antral follicle count (M AFC) am ong the three groups (p 
< 0.0001). No significant difference was detected between the controls and the pre­
chem otherapy group (95%  Cl -2.134 to 2.414; p > 0.05). Significant differences were 
detected how ever betw een the controls and the post-chem otherapy group (95% Cl 2.082 
to 6.118; p < 0.001) and between the pre-and post-chem otherapy groups (95% Cl 1.686 
to 6.234; p <  0.001).
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FIG U R E  4 .4 .3 .3  T A F C  in all three groups.
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FIGURE 4.4.3.4 MAFC in all three groups.
*** p < 0.001
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4.4.3.4 DOPPLER INDICES
These were assessed as mean pulsatility index (MPI) and m ean peak systolic velocity 
(M PS) respectively. The distribution was non-param etric and as such gaussian 
approximation o f  significance (Kruskal-W allis test) was employed. Comparisons 
between groups were perform ed using Dunn's M ultiple Comparison Test.
There was a significant difference in MPI between the pre- and post­
chem otherapy groups (difference in rank sum = 14.99, p < 0.05). No significant 
differences existed between the controls and the pre- and post-chem otherapy groups 
respectively. However the overall difference in the medians was significant (p = 0.02). 
There were no significant differences in the median MPS between the controls and 
patients from both groups (p = 0.02), nor were there significant differences w ithin the 
groups.
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(n = 11)
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FIGURE 4.4.3.5 MPI in all three groups.
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G aussian approxim ation. N S  =  no sign ificant d ifference.
4.4.3.5 UTERINE DIM ENSIONS
UTERINE CROSS-SECTIONAL AREA:
A nalysis o f variance did not reveal any statistically significant differences am ong the 
three groups (p = 0.77).
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FIGURE 4.4.3.7 Uterine CSA in all three groups. 
NS = no significant difference.
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ENDOM ETRIAL THICKNESS:
Analysis o f  variance did not reveal any statistically significant differences among the 
three groups (p = 0.09).
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FIGURE 4.4.3.8 Uterine ET in all three groups. 
NS = no significant difference.
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4.5 PROSPECTIVE DATA (1)
4.5.1 INTRODUCTION
The longitudinal data presented was limited due to an unexpected freezer shutdown over 
the Christmas period. However, some useful inform ation was still obtainable. In this 
dataset, patients were tested prior to chem otherapy, im m ediately following 
chem otherapy and at 3 to 6 month intervals afterwards. The num ber o f  patients tested 
prior to chem otherapy (n) was 14. O f these, it was possible to obtain longitudinal data 
on 8 patients. It is im portant to note that patients tested im m ediately post-chem otherapy 
were universally am enorrhoeic, and as such were not offered the G-test. The data 
displayed below  represents the results from patients who were tested before 
chem otherapy was adm inistered (during the early follicular phase) and immediately 
following com pletion o f  chemotherapy.
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PT. A GE / 
Y E A R S
PARITY C Y C L E /
days
BM l
(kg/m 2)
HISTO LO G ICAL
D IA G N O SIS
C H E M O T H E R A P Y
REGIM E
C U M U L A T IV E
D O SE
1 39 0+0 5/32 25 23 mm G3 ductal 
ca; ER/PR  
m oderately pos, 
H E R 2 3+
0/7  nodes pos
F E C X 6 F = 5760m g  
E = 576m g  
C -  5760m g
2 35 0+0 7 /30 23 50m m  G2/3  
ductal ca; ER 
w eakly pos, 2 /18  
nodes pos
F E C X 6 F = 6600m g  
E = 660m g  
C = 6600m g
3 32 0+0 4 /2 6 24 18mm G3 ductal 
ca, w eakly ER  
pos 1/14 nodes 
pos
EC X 4  
P aclitaxel X 4 
G em citabine X 4
E = 688m g  
C = 4400m g  
P =  1392m g  
G - 19152m g
4 35 0+0 5/30 30 25 mm G2 ductal 
ca; ER/PR neg; 
her2 3+; 0/8 
nodes pos
F E C X 6 F - 6480m g  
E -  648m g  
C = 6480m g
5 33 0+0 5 /30 21 G3 ductal ca, 
ER/PR neg, 
HER2 1 +
F E C X 6 F = 5810m g  
E =  596m g  
C =  5810m g
6 41 1+1 5 /28 26 42m m  high grade 
DCIS with 2 
invasive foci G2; 
ER/PR neg; 2 /12  
nodes pos
ECx4
paclitaxelx4
E = 702m g  
C = 4700m g  
P =  1368m g  
herceptin
7 31 0+1 3/34 20 G3 Invasive 
ductal ca; ER/PR  
neg; HER2 3+
ECx4
paclitaxelx4
E = 5 6 4 mg 
C = 3740m g  
P = 1074m g  
herceptin
8 38 0+0 6 /28 25 Grade 2 ductal 
carcinom a, 
ER +ve, H E R 2-ve
Ex4
C M Fx4
E = 8284m g  
C = 9920m g  
M = 640m g  
F = 9600m g
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T A B L E  4.5.1 C LIN IC A L  D A T A  OF PA TIEN TS IN L O N G IT U D IN A L  G R O U P
The patients in this group com prised the longitudinal arm o f  the study, with all patients having ovarian  
reserve tests performed prior to receiv ing  chem otherapy. C ycle length is depicted first by menstruation  
length fo llow ed  by cycle  length in days. A s per the study protocol, all patients in this group had ovarian 
reserve tests performed betw een cyc le  days 2 - 5 .  Relevant details o f  d iagn osis and chem otherapy  
regim en (including cum ulative d osages) are show n.
BMI = body m ass index, G = grade, ER = oestrogen  receptor status, PR = progesterone receptor status, 
HER2 = HER2 receptor status, Pos = positive, neg = negative, E = epirubicin, C = cyclophosph am id e, M 
= m ethotrexate, F = fluorouracil, P = paclitaxel, G = gem citabine
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4.5.2 BIOCHEMICAL RESULTS
4.5.2.1 BASAL FSH
Basal FSH levels were significantly different between groups (number o f  pairs = 8). The 
m ean o f  the differences was = - 38.85 (95% Cl -63.62 to -14.08), with an overall p = 
0.008.
BASAL FSH **
p < 0 .01
60-i
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1  40- 
2  
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£  30-|
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CD
20-1
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0J
4 6 .7 3 1 1 0 .8  
(n = 8)
7 .8 8 1 1 .4 0  
(n = 8)
PRE-CHEMO POST-CHEMO
F IG U R E  4 .5 .2 .1  B asal FSH  leve ls  pre vs. post chem otherapy in 8 patients.
* * p < 0 . 0 1
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4.5.2.2 BA SAL LH
Basal LH levels were not significantly different between groups (number o f  pairs = 6). 
T he mean o f  the differences was = -19.44 (95% Cl -46.41 to 7.526), with an overall p = 
0 . 12 .
BASAL LH
NS
35-
30-
25-
1
2
E 20 
I
ca 15 <
CO
10-
5-
0^
5.09 ± 0.97
24.53 ± 9.87
PRE-CHEMO POST-CHEMO
FIGURE 4.5.2.2 Basal LH levels pre vs. post chemotherapy in 6 patients. 
NS = no significant difference.
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4.5.2.3 BA SAL E2
A lthough the mean basal oestradiol levels were lower in patients following 
chemotherapy, the difference between pre- and post-chem otherapy levels was not 
statistically significant. The m ean o f  differences in the 8 pairs analyzed was 38.74 (95% 
Cl -103.6 to 181.1), overall p = 0.54.
BASAL E2
NS
200-i
1 7 5 -
1 5 0 i
E  1 2 5 -  
o>Q.
CM
W 1 0 0 -
_J <
CO <
m  7 5 -
5 0 J
2 5 -
0-
160.4 ±21.61
(n  = 8)
121.6 ±48.93
(n = 8)
PRECHEMO POSTCHEMO
FIGURE 4 .5 .2 .3  B asal oestradiol levels in 8 patients pre and post-chem otherapy. 
N S =  no significant difference.
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4.5.2.4 BA SA L  AM H
For reasons described previously, there were a limited num ber o f  sam ples available for 
analysis in  this group (num ber o f  pairs = 3). As such, the distribution was assum ed to be 
non-gaussian  and the W ilcoxon signed rank test used for analysis. There was a large 
d ifference in  bAM H levels pre vs. post chemotherapy, but this was not statistically 
significant.
BASAL AMH
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|  4H
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CO
24
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0J
4.40 ± 1.17 
(n = 3)
0.07 ± 0.02 
(n = 3)
PRE-CHEMO POST-CHEMO
FIGURE 4 .5 .2 .4  Basal AMH levels in 3 patients pre and post-chemotherapy. 
NS = no statistically  significant difference.
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4.5.2.5 B A SA L  INHIBIN B
As was the case with AM H, a statistically significant difference betw een pre- and post­
chem otherapy levels o f  inhibin B could not be determ ined due to the small num ber o f 
samples available (num ber o f  pairs = 3).
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62.5 ± 29.84 
(n = 3)
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(n = 3)
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FIGURE 4.5.2.5 Basal Inhibin B levels in 3 patients pre and post-chemotherapy. 
N S  = no statistically significant difference.
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4.5.3 BIOPHYSICAL PARAMETERS
4.5.3.1 OVARIAN V O LUM E
Total (TOV) and m ean (M OV) ovarian volumes were not significantly different 
between groups (num ber o f  pairs = 7). For TOV the m ean o f  the differences was 2.71 
(95% Cl -0.67 to 6.1), w ith an overall p = 0.1. For MOV, the m ean o f  the differences 
was = 1.25 (95%  Cl -0.34 to 2.85), w ith an overall p = 0.1.
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FIGURE 4.5.3.1 TOV in 7 patients pre and post-chemotherapy. 
NS = not significant
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FIGURE 4.5.3.2 MOV in 7 patients pre and post-chemotherapy. 
NS = not significant.
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4.5.3.2 AN TR AL FOLLICLE COUNT
Both total and m ean A FC levels were significantly different between groups (number o f 
pairs =  8). For TAFC, the m ean o f  the differences was = 9.88 (95% Cl 4.47 to 15.28), 
with an overall p = 0.004. For M AFC, the mean o f the differences was = 4.81 (95% Cl 
2.04 to 7.59), with an overall p = 0.005. Antral follicle count was the only parameter 
(biochem ical or biophysical) w here the correlation coefficient (r) showed that the 
pairings w ere effective (TAFC: r = 0.65, p = 0.04, M AFC r = 0.65, p = 0.04 
respectively).
TOTAL ANTRAL FOLLICLE COUNT **
p< 0.01
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FIGURE 4.5.3.3 TAFC in 8 patients’ pre and post-chemotherapy.
* *  p  <  0 . 0 1 .
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MEAN ANTRAL FOLLICLE COUNT **
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FIGURE 4.5.3.4 MAFC in 8 patients pre and post-chemotherapy.
** p < 0.01
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4.5.3.3 DOPPLER INDICES
In contrast to the cross-sectional analysis (section 5.4.3.4), these param eters followed a 
gaussian distribution on norm ality testing (5 paired results). Furtherm ore, m ean peak 
systolic velocity (M PS) was significantly lower in patients post-chem otherapy, whereas 
mean pulsatility index (M PI) was not. For MPS, the mean o f  the differences was = 0.08 
(95% Cl 0.01 to 1.45), p = 0.03. For MPI, the mean o f  the differences was =  0.45 (95% 
C l -1.6 to 2.5), p = 0.57.
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FIGURE 4.5.3.5 MPI in patients pre- and post-chemotherapy. 
N S  = not significant.
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4.5.3.4 UTERINE DIM ENSIONS
There were no significant differences in the m eans between both groups for CSA (n = 7) 
and ET (n = 8) respectively. For CSA, the mean o f  differences (m) = 3.41 (95% Cl - 
1.65 to 8.48), p = 0.2. For ET, the mean o f  the differences was = 1.32 (95% CI -1.60 to 
4.25), p = 0.31.
35i
30-
25
£ 20 
°  15
10
5-
UTERINE CROSS-SECTIONAL AREA
NS
26.11 + 1.82 
(n = 7)
PRE-CHEMO POST-CHEMO
FIG U R E 4 .5 .3 .7  C SA  in patients pre and post-chem otherapy.
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ENDOMETRIAL THICKNESS
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1
0
NS
6.58 ± 1.06 5.25 ± 0.82 
(n = 8)
PRE-CHEMO POST-CHEMO
FIGURE 4.5.3.8 ET in patients’ pre and post-chemotherapy. 
N S = not significant.
4.6 PROSPECTIVE DATA (2)
4.6.1 INTRODUCTION
A limited analysis was possible on 3 patients who were tested prospectively at least 3 
times: prior to chem otherapy (1), immediately post-chem otherapy (2), and at three 
monthly intervals (3) and (4) respectively. At time point (2) all three patients were 
am enorrhoeic. H ow ever w hen they were tested at time points (3) or (4), regular 
m enstruation had resum ed.
The num ber o f  patients analysed (n = 3) was too small to allow  statistical 
analysis using A NOVA (for reasons explained earlier); however it was still informative 
to docum ent the changes in various parameters o f  ovarian reserve where a sufficient 
num ber o f  paired  observations were possible.
The tim e points used to test patients are described in the table below. It is 
im portant to m ention that at tim e-point (2), patients were am enorrhoeic, and as such the 
G-test was not perform ed. A t all other time-points however, testing was performed in 
the early follicular phase o f  the m enstrual cycle.
C O DE T IM E -P O IN T  D EFIN IT IO N
1 P R E -C H E M O T H E R A P Y
2 IM M E D IA T E L Y  PO ST -C H E M O T H E R A P Y
3 3-M O N T H S  PO ST -C H E M O T H E R A P Y
4 6-M O N T H S  PO ST -C H E M O T H E R A P Y
T A B L E  4.6.1 D efin ition  o f  tim e points used in prospective study.
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4.6.2 BIOCHEMICAL PARAMETERS
4.6.2.1 BA SA L FSH
B A S A L  F S H  IN 3 L O N G I T U D I N A L  P A T I E N T S
70
60-
50-
|  4°- 
E
x
CO
30-
2 0 -
1 0 -
3 421
PATIENT A
PATIENT B
PATIENT C
A FSH IN 3 L O N G I T U D I N A L  P A T I E N T S
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60-
50-
E
3
E
x
COu.
40-
< 30-
2 0 -
PATIENT A 
PATIENT B 
PATIENT C
FIGURE 4.6.2.1 Basal and delta FSH in 3 patients followed prospectively.
Patients were tested at 3 time points (PATIENTS B+C) and 4 time points (PATIENT A) respectively.
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4.6.2.2 BA SA L E2
BASAL E2 IN 3 LONGITUDINAL PATIENTS
400
350-
300-
250
150-
100 -
50-
1 2 3 4
A E2 IN 3 LONGITUDINAL PATIENTS
700
600
500-
400-
300-
200 -
1 0 0 -
1 2 3 4
FIGURE 4.6.2.2 Oestradiol levels (basal and delta) in three patients followed prospectively.
PATIENT A 
PATIENT B 
PATIENT C
PATIENT A 
PATIENT B 
PATIENT C
2 1 1
4.6.3 BIOPHYSICAL PARAMETERS
4.6.3.1 TO TA L OVARIAN  V OLUM E
T O V  IN 3 L O N G I T U D I N A L  P A T I E N T S
1
1
1
6 -
4 -
3 421
FIGURE 4.6.3.1 TOV in 3 longitudinal patients.
It was not possible to determine TOV in patient C pre-chemotherapy.
PATIENT A 
—V— PATIENT B 
—A — PATIENT C
2 1 2
4.6.3.2 TOTAL A N T R A L  FOLLICLE COUNT
T A F C  IN 3 L O N G I T U D I N A L  P A T I E N T S
30
2 5 -
2 0 -
u.
2 3 41
FIG U R E 4 .6 .3 .2  T otal antral fo llic le  count in the sam e 3 patients fo llow ed  up prospectively. 
T he m ean values g iv e  a lm ost id en tica l p lots.
PATIENT A 
PATIENT B 
PATIENT C
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4.7 PROSPECTIVE DATA (3)
4.7.1 INTRODUCTION
Patients that were recruited for the first time following chem otherapy were also 
followed up at 3-m onthly intervals (n = 5). The results for all param eters followed a 
gaussian distribution. In som e cases, 3 time points were possible (time points 1, 2 and 3 
respectively), in w hich case a repeated measures ANOVA was used for statistical 
analysis. In the rest o f  cases where only 2 time points were included, paired t-tests were 
used to identify any differences between the means at different time points.
AGE  
/ years
PARITY BMI kg/m 2 HISTOLOGICAL
DIAGNOSIS
C H EM O TH ERAPY
REGIME
TIME ELAPSED  
/m onths
33 0 + 0 24 20m m  G3 IDCA. 
ER/PR neg
E-CM F X  8 37
38 0+1 28 19mm G3 IDCA  
ER/PR neg
D  X  4 
F E C X 4
8
37 0+1 21 25m m  G3 IDCA  
ER/PR neg
FEC X 6 58
37 1+0 24 60m m  G3 IDCA  
ER/PR neg
D X 4 
E-CM F X 6
54
36 0+ 0 23 85m m  G3 IDCA  
ER/PR neg
FEC X 6  
D X 2
15
T A B L E  4.7.1 D etails o f  patients recruited post-chem otherapy and tested prospectively .
G = grade ID C A  = in vasive ductal carcinom a, E = epirubicin, C = cyclophosph am id e, M = methotrexate,
F = 5-Fluorouracil, D = d ocetaxel
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4.7.2 BIOCHEMICAL PARAMETERS
4.7.2.1 FOLLICLE STIM ULATING HORM ONE
There w ere no significant differences between the three times tested for basal, 
stim ulated or delta FSH as determined by Bonferroni’s multiple com parison tests.
B A S A L  F S H
I B 3
I B 2
I B 1
S T I M F S H
I S T I M 1 
I S  T I M 2 
I S  T I M 3
I 0  2
I 0  3
FIGURE 4.7.2.1 Serial FSH levels in 5 patients tested post-chemotherapy. 
Tests were performed at three consecutive 3-monthly time intervals.
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4.7.2.2 OESTRADIOL
Basal and stim ulated E2 levels w ere not significantly different between groups, however 
delta oestradiol was significantly different, overall p = 0.02.
B A S A L  E 2
4 0 0
3 0 0
2 0 0
1 0  0
0
B1 B2 B3
I B 1 
I B 2 
I B 3
S  T I M E 2
g 4 0 0 
*  a
3 0 0 -
I S  T I M  
I S  T  I M 
I S  T I M
A E 2 *
p = 0 .0 2
2 5 0 
2 2 5 
2 0 0 
1 7 5 
1 5 0 
1 2  5 -  
10 0 
7 5 -  
5 0 -  
2 5
I D 1 
I D 2 
I D 3
FIG U R E 4 .7 .2 .2  O estradiol lev e ls  at 3 different tim e points. 
A E2 p =  0 .02
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4.7.2.3 AM H  A N D  INHIBIN B
For these param eters, only two time points were available for analysis as there were 
insufficient num bers (n) for the third time point. No statistically significant difference 
was found.
PARAM ETER TIM E POIN T 1 
(n = 5)
TIME POINT 2 
(n = 5)
T-TEST
B AM H 1.9 ± 0 .8 7 0.41 ± 0 .1 4 NS
STIM AM H 2.01 ± 0 .8 6 0.36 ± 0 .11 NS
A AM H 0.1 ± 0 .2 9 -.05 ± 0.09 NS
B IN H B 23.94 ± 8 .5 5 14.6 ± 4 .6 NS
STIM INH B 22.5 ± 7.6 19.02 ± 7 .8 8 NS
A I N H B -1.44 ± 1.09 4.42 ± 3 .3 6 NS
T A B L E  4 .7 .2  A M H  (n g /m l) and inhibin B (p g /m l) in 5 patients tested seria lly  post-chem otherapy. 
N S = not sign ifican t
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4.7.3 BIOPHYSICAL PARAMETERS
4.7.3.1 OVARIAN VOLUM E
M ean ovarian volum es (M OV) were not significantly different betw een the three time 
points (p = 0.87, n = 4).
MEAN OVARIAN VOLUME
Ea>
I 40 >
c(0
1 3 
o
FIGURE 4.7.3.1 Mean ovarian volume at three different time points.
Although the overall p = 0.05, there was no significant difference between individual time points using 
Bonferroni’s multiple comparison tests.
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4.7.3.2 AN TR A L FOLLICLE COUNT
Overall there w ere no significant differences in the m ean values for M AFC, although 
the p value was approaching significance (p =  0.06, n = 4).
MEAN ANTRAL FOLLICLE COUNT
o£L
<
7
6
5
4
3
2
1
0
MAFC 3MAFC 2MAFC 1
MAFC 1 
MAFC 2  
IMAFC 3
FIGURE 4.7.3.2 MAFC at three different time intervals in the same patients. 
Overall p > 0.05.
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4.8 CORRELATIONS
Correlation statistics w ere perform ed using SPSS comparing each o f  the ovarian reserve 
markers w ithin each o f  the three groups studied: controls, pre-chem otherapy and post­
chem otherapy patients respectively. Bivariate analysis was perform ed using Pearson’s 
correlation coefficients. S ignificant correlations were flagged at the 0.01 level (two- 
tailed) or the 0.05 level (tw o-tailed).
AM H as a basal m arker correlated with AE2 in both patients and the controls 
respectively, (r = 0.759, p < 0.001; r = 0.518, p < 0.05) as well as basal inhibin B (r = 
0.842, p < 0.001) It w as the only param eter in addition to bFSH to correlate with 
chronological age in patients only (r = 0.78, p < 0.05). Delta (A) inhibin B correlated 
best with biophysical m arkers o f  ovarian reserve. In controls, inhibin B correlated 
positively with TA FC and M A FC (r = 0.494, p < 0.05; r = 0.509, p < 0.05), whereas 
delta oestradiol correlated  positively w ith TAFC in the pre-chem otherapy group, but not 
the controls (r = 0.670, p < 0.05).
Overall, basal m arkers w hich appeared to correlate the m ost w ith other markers 
were AM H  and inhibin B. Post-stim ulation however, oestradiol and inhibin B levels 
correlated w ith both biochem ical m arkers, including basal AM H, and were the only 
markers to correlate w ith AFC. No correlations w ith ovarian volum e were identified.
220
4.9 LOST SAMPLES
An attem pt was m ade to determine w hether or not the samples affected by the freezer 
mishap could be utilized. This was possible because some o f  these samples had been 
assayed prior to the accident, thus allowing a comparison to be m ade between the 
results o f  assays perform ed on the same sample before and after the freezer mishap. 
Assays were repeated for oestradiol, inhibin B and AMH. Although the steroid assay 
(oestradiol) results appeared alm ost comparable, the results for inhibin B and AMH 
were too disparate. The decision was therefore made not to use any o f  the samples 
previously stored in the freezer.
OESTRADIOL:
Basal E2 comparison of assays
1500-,
1250-
E 1000-
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FIGURE 4.9.1 Oestradiol assay repeated on the same samples.
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Basal AMH comparison of assays
25 - |
2 0 -
15-
10 -
AA5-
0 5 10 15 20 25
A  Original A M H  
A R epeat A M H
AMH original assay (ng/ml)
AMH assay repeated on the same samples.
2 2 2
INHIBIN B:
B a s a l  I n h i b i n  B  c o m p a r i s o n  o f  a s s a y s
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FIGURE 4.9.3 Basal inhibin B repeated in the same samples.
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FIGURE 4.9.4 Delta inhibin B repeated in the same samples.
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4.10 DISCUSSION
4.10.1 INTRODUCTION
The results o f  this study show  that biochemical and biophysical tests may be used to
accurately estim ate ovarian  reserve in premenopausal recipients o f  chem otherapy for 
breast cancer. O varian reserve testing (ORT) on the whole is a relatively new concept. 
In the reproductive m edicine setting, ORT has become established as a predictor o f 
response to controlled ovarian hyperstim ulation (COH). Further applications o f  ORT 
have been investigated, including its application in predicting reproductive (or ovarian) 
age. The following discussion  w ill incorporate the data obtained from this study as it 
pertains to the pathophysiology and estim ation o f ovarian reserve in young patients with 
breast cancer.
4.10.2 CROSS-SECTIONAL DATA
This study confirm s the observation o f a recent paper where the new  ovarian 
reserve tests such as inhib in  B, AM H and AFC were investigated in breast cancer 
patients before and after treatm ent (A nderson et al. 2006). However, our study is the 
first in w hich dynam ic ovarian reserve testing (g-test) has been evaluated in breast 
cancer patients. In an IVF setting, basal ovarian markers can be norm al yet these 
patients do not respond to stim ulation. Hence, dynamic tests are used in assisted 
reproductive technology setting as they give a better indication o f  the ovarian response 
to stimulation. W e believe the g-test can add to the discrim inatory capacity provided by 
basal markers alone, as the underlying pathophysiology o f  chem otherapy-m ediated 
gonadotoxicity is in fact dynam ic.
In the recently published study, AMH concentration in particular was found to 
be useful as an early indicator o f ovarian ageing, including the assessment o f 
chem otherapy-induced ovarian follicle loss (A nderson et al. 2006). Contrary to this
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study w here the patients were 28-52 years o f  age, our study cohort comprised a 
significantly younger patient cohort (mean age o f patients was 41.3 in the chemotherapy 
arm o f  the A nderson study, com pared with 35.2 and 36.7 in the pre- and post­
chem otherapy arm s o f  our study -  see figure 4.4.1.1), and included an age-matched 
control group w ith proven fertility. This was in keeping with our objective, which was 
to evaluate O RT in young w om en with breast cancer. It is this group where validation o f 
ORT could potentially lead to adequate counselling and treatm ent with regards fertility 
preservation, at a tim e w hen therapeutic intervention is still feasible.
Previous studies in breast cancer focused mainly on the incidence o f 
am enorrhoea and prem ature m enopause respectively (Bines, Oleske, & Cobleigh 1996; 
G oodwin et al. 1999). O ther investigators assessed the endocrine consequences o f 
chem otherapy in patients w ith breast cancer, but the analysis was limited to 
gonadotrophin and steroid  alterations respectively (Dowsett & Richner 1991; Mehta, 
Beattie, & Das G upta 1992; Padm anabhan et al. 1987). These studies were performed 
long before the concept o f  ovarian reserve was realised. The im portance o f these 
alterations were accurately surm ised as being detrim ental to fertility, but the limitations 
o f these studies prevented m eaningful application in clinical practice (Hensley & 
Reichman 1998).
There are several reasons for the difficulty in assessing these patients 
appropriately. One o f  the factors involved includes the possibility o f  ovarian reserve 
being dim inished even prior to chem otherapy being adm inistered. A prospective study 
o f ovarian function in patients undergoing bone m arrow  transplantation (BMT) for 
haem atological m alignancies identified evidence o f  gonadal insufficiency before BMT, 
which m ay have been exacerbated by conditioning regim ens (chem otherapy and total 
body irradiation) prior to BM T being perform ed (Chatterjee et al. 1994). This was
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evidenced by the significantly lower levels o f  oestradiol levels seen in patients 
following the H M G  stim ulation test compared with the controls.
Our data suggest that ovarian reserve was intact prior to chem otherapy in a 
breast cancer cohort, im plying that m ulti-agent chem otherapy was the m ain factor that 
led to dim inished ovarian reserve. A lkylating agents such as cyclophosphamide, which 
are non cell-cycle specific are m ore toxic to the ovaries than cell-cycle specific agents 
such as m ethotrexate and fluorouracil. It is unclear however, what effect multi-agent 
chem otherapy has on ovarian reserve, especially given the fact that newer agents are 
continually being developed (A w ada et al. 2003). All the biochemical and biophysical 
markers with the exception o f  basal oestradiol (bE2) levels provided evidence that 
ovarian reserve was in tact prior to chem otherapy (see section 4.4: cross-sectional data).
The G-test w as chosen in this study as it provided an ovarian response, which 
was less potent than the H M G  test, an im portant factor to consider in patients with 
breast cancer. W hile bE2 levels w ere significantly higher in patients (pre-chemotherapy) 
compared to the controls, there was no significant difference between stimulated and 
delta E2 levels. This m ay be explained by the fact that bE2 levels correlate more with 
the underlying disease, as it has been shown that high plasm a oestradiol concentrations 
have been linked to breast cancer developm ent regardless o f  m enopausal status (Clamp, 
Danson, & C lem ons 2002). O estradiol increase in response to the G-test however, 
probably correlates better w ith ovarian reserve, w hich w ould explain the lack o f a 
significant difference in patients com pared with the controls in addition to the other 
markers o f  ovarian reserve (see figure 4.4.2.9).
At the m id-point o f  recruitm ent, our data also suggested at the time that basal 
activin A levels were higher in patients com pared to the controls. This seemed plausible 
at the tim e, as elevated serum  activin A levels had been detected in post-menopausal 
women with breast cancer (Reis et al. 2002). W hen the com plete dataset was analysed
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however, the m ean activin A levels in patients pre-chem otherapy were not significantly 
different from the controls (see section 4.4.2.7). It would be necessary to analyse a 
greater cohort o f  patients and controls to elucidate the possibility that activin A levels 
are increased in prem enopausal w om en with breast cancer.
Perhaps the m ain factor involved in assessing these patients 
appropriately is the fact that the pathophysiological process is dynamic, w ith both acute 
and cum ulative effects. As such, efforts to grade the extent o f  ovarian damage, and 
indeed ovarian recovery by clinical, biochem ical and biophysical param eters are limited 
by the dynam ic processes involved (Chatterjee & Kottaridis 2002). Furthermore, 
extrapolation o f  data from  one cancer cohort to another is inappropriate due to 
differences in disease, type o f  chem otherapy and the dem ographics o f the population 
studied. A consideration for future study would be to perform ovarian reserve testing at 
different time points during the chem otherapy course. This might allow  the acute nature 
o f ovarian injury to be exam ined as part o f  the overall dynam ic process.
In the fertility setting, the m ost im portant aspect o f  dim inished ovarian reserve 
and the associated decline in reproductive potential is that its onset is highly variable 
(Scott, Jr. & H ofm ann 1995). These points, in addition to the fact that there is a paucity 
o f prospective, controlled data outside a reproductive m edicine setting, makes current 
evaluation o f  m arkers o f  ovarian reserve very difficult indeed. To the best o f our 
knowledge, it appears that no single m arker can be clinically useful in assessing ovarian 
reserve, leading to the evaluation o f  multiple markers (Lutchm an Singh, Davies, & 
Chatterjee 2005).
These recognised lim itations o f  studying ovarian reserve in patients with cancer 
greatly influenced the study design em ployed. For exam ple, a single cancer cohort was 
studied as opposed to variable cancer types. Patients and controls were recruited only if  
they had regular m enstrual cycles (26 to 34 days). Furtherm ore, it was anticipated that
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young patients with breast cancer were likely to have high grade, oestrogen receptor 
(ER) negative disease, and were likely to receive adjuvant chem otherapy. Controls 
were chosen who were healthy, age-m atched and had proven fertility by virtue o f 
having at least one childbirth  in the past. A lthough this made recruitm ent o f  controls 
more difficult, it helped to ensure that the results obtained were more likely to represent 
a gold standard o f  reference ranges for ovarian reserve in healthy controls than other 
examples quoted in the literature. N evertheless the m ean and m edian values for 
biochemical and biophysical param eters o f  ovarian reserve for the controls in this study 
compare favourably w ith control data reported elsewhere (Fitzgerald et al. 1994; 
M acnaughton et al. 1992; M uttukrishna et al. 2000; Ng et al. 2003; Pavlik et al. 2000; 
Scheffer et al. 1999; W elt et al. 1999). There is a distinct paucity in the literature 
however regarding reference ranges for new er markers o f ovarian reserve such as AMH.
Clinical characteristics alone are not useful in predicting ovarian reserve (hence 
the original m otivation behind the identification o f  other m arkers). However, significant 
alterations in clinical characteristics can alter the interpretation o f  results. Hence it is 
im portant to point out that in this study; there were no significant differences in age, 
body mass index (BM I) or cycle length (25 to 34 days) betw een patients and the 
controls.
B iochem ical param eters, which appeared to discrim inate between patients and 
the controls in the cross-sectional dataset, were serum FSH, oestradiol, inhibin B and 
AMH. The data relating to the use o f  FSH in estim ating ovarian reserve in breast cancer 
is limited. Though w idely used in a reproductive m edicine setting, its m ain limitations 
arise from a lack o f  reproducibility  (Sharara, Scott, Jr., & Seifer 1998). The pulsatile 
nature o f  FSH secretion is believed to be one o f  the factors responsible for this variation. 
To minimise this possibility, we took four (4) tim ed sam ples, 15 minutes apart and used 
a mean value as a “true” representative figure. Basal FSH levels were significantly
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different across the three groups (controls, pre-chem otherapy and post-chem otherapy 
patients, p = 0.0006 -  see figure 5.4.1). Following the G-test, stim ulated FSH levels 
were also significantly different (p = 0.01 -  figure 4.4.2.2). However, delta FSH levels 
did not confer any discrim inatory capacity (figure 4.4.2.3). FSH is an indirect marker o f 
ovarian reserve and depends on the presence o f an intact hypothalam ic-pituitary-ovarian 
(HPO) axis. A dm inistration o f  the G-test causes a supraphysiologic increase in FSH 
causing a tem porary increase in pituitary secretion o f FSH and LH, to which the ovaries 
respond by releasing oestradiol. It is the amount o f oestradiol released (delta) which 
correlates with ovarian reserve, not delta FSH, which is in keeping w ith the results. This 
overall increase in oestradiol production by the developing follicles would eventually 
suppress FSH levels, thus form ing the basis o f the CCCT, which was not used in this 
study.
Basal oestradiol (E2) levels were significantly higher in the pre-chemotherapy 
group com pared to the controls. This may have a role in the pathophysiological process 
o f  breast cancer as described earlier. No significant difference existed between the 
control and the post-chem otherapy group. In fact, higher levels o f  basal E2 were seen in 
the pre-chem otherapy group as opposed to the post-, which one w ould not expect, as 
higher levels o f  E2 are associated w ith dim inished ovarian reserve. Both stimulated and 
delta E2 levels w ere significantly different however, being m uch lower in the post­
chem otherapy group com pared with the pre-chem otherapy group and the controls 
respectively. This supports the notion that the G-test confers discrim inatory capacity.
If  delta E2 were significantly different because o f  the G-test, then one would 
expect inhibin B levels to be significantly different as well, due to the regulatory role 
inhibin B has on FSH secretion (specifically m onotropic FSH rise). N ot surprisingly 
therefore, basal, stim ulated and delta inhibin B levels were all significantly different 
between patients and the controls (figures 5.4.2.13, 5.4.2.14 and 5.4.2.15). W hilst
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inhibin B is m ainly secreted by pre-antral follicles (Klein et al. 1996), inhibin A is 
produced prim arily during the late follicular phase by mature follicles and the corpus 
luteum (Roberts et al. 1993). This would explain why the form er is a more reliable 
marker o f  ovarian reserve, as our results confirm. The added discrim inatory capacity as 
provided by the G -test for inhibin B and oestradiol is consistent w ith the theory that the 
pathophysiological processes taking place within the ovary are in fact dynamic -  thus 
necessitating a dynam ic form  o f  assessment.
AMH is considered a direct m arker o f ovarian reserve as it is produced by FSH- 
sensitive early antral follicles. In this way, it may be a more sensitive predictor o f 
ovarian reserve than o ther m arkers such as AFC and inhibin B, w hich detect more 
mature prim ordial follicles. A M H  expression by granulosa cells is relatively stable 
(Gruijters et al. 2003), and is independent o f  GnRH or gonadotrophin regulation, with a 
relatively stable expression  over the menstrual cycle(Cook et al. 2000; La M arca et al. 
2006). This w ould explain  w hy serum AM H levels were mostly unchanged in our study 
following the G -test (figures 4.4.2.11 and 4.4.2.12), a phenom enon detected in other 
studies (Pastor et al. 2005; van Rooij et al. 2002). Our results confirm that basal AMH 
levels were dram atically reduced in the post-chem otherapy group com pared to both the 
control and the pre-chem otherapy group (figure 4.4.2.10). This is in keeping with 
another study w hich assessed ovarian reserve in survivors o f  childhood cancer (Bath et 
al. 2003). In that study, inhibin B failed to discriminate between patients and the 
controls while FSH levels did. This is a surprising result, and is in contrast w ith our own 
data. G iven the fact that inhibin B has a crucial role in regulating FSH response, it is 
difficult to explain the pathophysiology o f that finding adequately. W hat is much more 
likely, as has been the problem  with ovarian reserve studies in general, is that a 
m ethodological flaw  was exposed.
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All other param eters tested, including activin A, follistatin and pro aC were 
found not to be discrim inatory. This mirrors the situation in assisted reproduction, 
where none o f  these m arkers have been found to be useful predictors o f  ovarian reserve.
W ith regard to biophysical parameters, our data suggests that AFC is 
most useful, w ith AFC being significantly reduced in patients post-chemotherapy 
compared to the controls (figure 4.4.3.3). AFC has been extensively studied recently in 
the reproductive m edicine setting and there is no doubt that its popularity as a marker o f 
ovarian reserve has gained considerable momentum. In a study which used a control 
group very sim ilar to our ow n, AFC correlated best with chronological age, as well as 
stimulated E2 and inhibin  B levels (Scheffer et al. 2003). One could argue that 
stim ulated inhibin B levels reflect the response from a larger group o f small, FSH 
sensitive follicles not yet detectable on USS, whereas E2 stim ulation reflects larger, 
visible antral follicles capable o f  E2 production. If  this is the case, it is debatable 
whether a stim ulation test such as the G-test adds any discrim inatory capacity to AFC 
alone. Several studies have been published in a fertility setting w here AFC correlates 
well with the response to exogenous gonadotrophins (Bancsi et al. 2002; Hendriks et al. 
2005). It w ould be useful therefore to exam ine AFC im m ediately after ovarian 
stim ulation occurred. W e attem pted to do this in three patients and three controls (data 
not shown). O verall, there was no difference in AFC or any other biophysical parameter 
at the beginning or the end o f  the G -test respectively. This is in keeping with the 
observations o f  other investigators, where AFC had been assessed as part o f  the CCCT 
in patients undergoing IVF. In that study, no significant differences were detected 
between basal, stim ulated and dow n-regulated AFC (Ng et al. 2005).
W hile studies in cancer are limited, AFC and ovarian volum e have been found to 
be useful in assessing ovarian reserve in childhood survivors o f  cancer (Larsen et al. 
2003a; Larsen et al. 2003b) and patients undergoing BM T (Chatterjee et al. 1994). Our
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results did not show a significant difference in OV between patients and the controls 
(figure 4.4.3.1). There is still some debate as to the usefulness o f  OV in predicting 
ovarian reserve. W hile it is clear that ovarian volume m easurements are known to be 
discrim inatory in patients who are postmenopausal (Flaws et al. 2000; Flaws et al. 
2001), its value in predicting reproductive age is unreliable. This may be because the 
sensitivity and specificity o f  the test in identifying non-pregnancy is reduced in patients 
who are still having regular m enses, thus allowing more subtle alterations in ovarian 
reserve to be missed. I f  this was true, then OV would have limited application in 
assessing ovarian reserve in patients w ith cancer, as subtle alterations in ovarian reserve 
are param ount in identifying those at risk o f  a premature menopause. There remains the 
possibility that the im aging m odality itself may be the limiting factor regarding the 
usefulness o f  OV in assessing ovarian reserve. The recent introduction o f  3D USS into 
clinical practice m ight prove the solution for this. The results o f further research into 
this area are anticipated.
The other biophysical param eters tested included uterine dimensions (uterine 
cross-sectional area and endom etrial thickness) and ovarian stromal blood flow (PI and 
MPS). None o f  these param eters were significantly different between patients and the 
controls. In the case o f  uterine dim ensions, one w ould probably not expect any 
significant changes unless pelvic or total body irradiation (TBI) were administered, as is 
often the case in haem atological m alignancy (M eirow  & N ugent 2001). Ovarian stromal 
blood flow theoretically w ould be expected to be more useful. Studies however are still 
very limited. The m ost recent, from a reproductive m edicine setting imply no use for 
OSBF to predict response to IVF using 2D pow er doppler (used in this study) (Ng et al. 
2005) or even 3D doppler (Ng et al. 2006).
Correlations were perform ed to examine relationships between individual 
markers o f  ovarian reserve. It is interesting to note that only bFSH in the post-
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chem otherapy group, and bAM H + bE2 in the pre-chem otherapy group correlated with 
chronological age. This is probably because the age range o f  the study subjects was 
quite narrow, preventing a meaningful correlation statistic. The m edian age o f  patients 
was 35.5 and 37 (pre- and post-chem o) years respectively thus necessitating a similar 
age ranges for the controls. As such, most o f the study group were already in their mid­
thirties, a time w hen reproductive ageing is known to accelerate (Baird et al. 2005). It 
was entirely appropriate to exam ine this age group however, as it the one most relevant 
to patients with breast cancer. The responses o f oestradiol and inhibin B to the G-test 
correlated highly w ith bA M H  and AFC respectively, but not with FSH. This adds to the 
hypothesis that these m arkers o f  ovarian reserve are inter-related, each possibly 
providing a different aspect o f  inform ation on ovarian reserve. The right combination o f 
these factors therefore m ay produce the m ost accurate assessm ent o f  ovarian reserve in 
these patients.
4.10.3 PROSPECTIVE DATA
W hile the cross-sectional data discussed earlier provided very useful insight into the 
evaluation o f  ovarian reserve markers in breast cancer, it is unfortunate that sufficient 
data was not accrued prospectively as it m ight have conferred some predictive capacity. 
The reasons for this w ill be explained when the m ethodology is discussed in more detail. 
Nevertheless, it was intuitive to observe the variation in markers o f  ovarian reserve over 
time in selected patients.
For m ost param eters in the longitudinal group, it was possible to obtain eight 
paired sam ples, representing pre-and post-chem otherapy sam ples respectively. As 
already m entioned, there were no significant differences betw een patients and the 
controls, w ith the exception o f  basal oestradiol. All longitudinal patients became
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am enorrhoeic during the course o f their chemotherapy. As such, only basal parameters 
were com pared pre-and post-chem otherapy, since the G-test could not be performed.
The param eters, w hich were discriminatory between these two groups, were 
FSH, E2 and AFC. It can be deduced that the multi-agent chem otherapy received by 
these patients suppressed ovarian function resulting in a hypoestrogenic state, with a 
corresponding high FSH  and am enorrhoea (figure 4.5.2.1). Reduced AFC probably 
reflects a reduction in the num ber o f  mature antral follicles capable o f  producing E2 
(figure 5.5.2.3). O varian volum e, as was the case in the cross-sectional data, was not 
significantly different betw een both groups (figure 4.5.3.1). This may be a reflection o f 
the fact that the induced hypoestrogenic state was temporary. It can be argued that in 
terms o f  reproductive ageing, a reduction in ovarian volum e is a relatively late event 
that comes about after a protracted period o f  dim inished ovarian reserve. It is plausible 
that despite these patients being am enorrhoeic, the unchanged ovarian volumes implied 
that resum ption o f  ovarian  function, albeit at a level lower than the pre-chemotherapy 
state, was likely to occur. In fact, all patients in the post-chem otherapy arm o f  the cross- 
sectional analysis had resum ed normal menses, indicating that the effects o f  the multi­
agent chem otherapy received were at least partially reversible.
Basal A M H  and inhibin B levels (figures 4.5.2.4 and 4.5.2.5) were not 
significantly different, as was the case with the cross-sectional data. This was likely 
because insufficient pairs o f  sam ples were analysed -  three pairs com pared to eight for 
the other param eters.
In three patients, it was possible to assess ovarian reserve param eters after the 
resumption o f  m enses had occurred (section 4.6). It was possible to perform  the G-test 
in these patients, w here it was shown that the ovarian response to gonadotrophins was 
well below  that com pared to the pre-chem otherapy state. W hile m eaningful statistical 
comparisons were not possible, the data clearly showed resum ption o f  ovarian activity
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(biochem ical and biophysical) at a variable level from the pre-chem otherapy state. For 
exam ple basal FSH showed a distinct rise immediately following chem otherapy but 
appeared  to fall over the following 6 months, a trend which was also apparent following 
the G -test (figure 4.6.2.1). Basal oestradiol levels were reduced following chemotherapy, 
bu t it was interesting to note that delta oestradiol levels rem ained low even up to six 
m on ths after resum ption  o f  menses (figure 4.6.2.2). This is in keeping with the 
hypothesis that the pathophysiological processes involved are in fact dynamic and 
variab le, with delta oestradiol potentially providing additional discrim inatory capacity 
in term s o f ovarian reserve. In term s o f biophysical parameters, AFC appeared to show 
a trend  o f m arked reduction immediately following chemotherapy, with delayed 
recovery  up to six m onths after resum ption o f menses (figure 4.6.3.2).
These conclusions are based on a small sample size. To properly elucidate the 
course  o f ovarian recovery, further longitudinal follow up with a larger number o f 
patien ts w ould be necessary  to allow stratification according to chem otherapy type and 
dose.
Prospective data was also accumulated on five patients who were recruited after 
com ple tion  o f  chem otherapy (section 4.7). In these patients, it was possible to perform 
dynam ic testing on at least 3 occasions. There was a significant difference overall in 
d e lta  E2 between the three tim e points tested. There was not a gradual increase or 
decline  however, but a fluctuating pattern, despite the fact that the m ean time from 
com pletion  o f  chem otherapy to the time o f testing was 34 months. This suggests that 
a lthough  ovarian function is present, reduced ovarian reserve results in variation o f 
ovarian  function. O f course this possibility can only be adequately tested with a larger 
num ber o f  patients follow ed up to a fixed outcome -  the ideal one being onset o f 
prem ature m enopause.
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4.10.4 METHODOLOGICAL DIFFICULTIES
The aim  o f  this study was to evaluate biochemical and biophysical markers o f ovarian 
reserve in young patients w ith breast cancer. Being the first study o f  its kind in a breast 
cancer cohort, the study m ethodology designed in a robust fashion in order to ensure 
that reliable data was obtained, which would eventually form the basis o f a larger study.
Recruitm ent o f  patients was difficult. Although the incidence o f  breast cancer is 
rising in the UK, it is still an uncom m on disease in women aged less than 40 years and 
even m ore so in w om en aged less than 35 years. Suitable candidates for the study were 
first identified at their first discussion at the breast MDT meeting. A t that point patients 
have either had prim ary surgery or been considered for primary chemotherapy. There is 
lim ited tim e from that point before the commencement o f chemotherapy. Patients are 
then seen by the m edical oncologist and treatment usually com m enced within two 
weeks after that visit. A t a tim e when patients are confronted with the enormous task o f 
digesting their diagnosis and treatm ent plan, there was very little time to discuss the 
study w ith  them  and obtain inform ed consent. Despite this, m ost patients who were 
approached shared a great interest in taking part in the study.
Furtherm ore, all tests were well tolerated with no short-term adverse effects reported.
The m ain obstacle perhaps was to perform the ovarian reserve testing during the 
early follicular phase. T reatm ent was initiated regardless o f  their m enstrual cycle status. 
If  patients were recruited after the early follicular phase had passed, it was considered 
unethical to ask them to w ait until their next menstrual cycle before starting 
chem otherapy. Interestingly, a recent study has shown the incidence o f  amenorrhoea 
follow ing chem otherapy in w om en with early breast cancer was actually increased if  
treatm ent was started in the follicular phase (Di Cosimo et al. 2004).
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Patients requesting fertility preservation were also recruited. Embryo or oocyte 
cryopreservation w ere the options com monly available for these patients. In both cases, 
a controlled ovarian hyperstim ulation is required to allow harvest o f oocytes. This 
involved either long stim ulation protocols (initial downregulation in the luteal phase 
followed by hyperstim ulation), or if  time was limited, short GnRH agonist protocols 
without conventional dow nregulation. This again made it very difficult to perform ORT 
at the specified time. It w ould be possible to assess ovarian reserve in these patients by 
virtue o f their response to CO H  how ever, a valid consideration for future study as this 
group has the advantage o f  defined end-points for study (oocytes retrieved) allowing 
short-term predictive value to be potentially established.
Biophysical tests w ere perform ed mostly by a single operator (Ms Anita Patel) 
using a com bination o f  transvaginal and abdom inal USS. On a few occasions, it was 
necessary to have the biophysical profile perform ed by another experienced 
ultrasonographer (D r B Parikh). Som e o f  the observations were repeated by Ms Patel to 
ensure that inter-observer variability  was minimized.
Biochem ical assays w ere done under the supervision o f  Dr M uttukrishna. Well- 
established in-house assays w ere perform ed w hen possible, otherwise commercial kits 
were used. A fter a six-m onth laboratory and ELISA training process, it was then 
possible for me to carry out all assays under indirect supervision. A rigid documentation 
process was utilized to allow  rapid review  o f  errors and to ensure reproducibility.
The m ost im portant difficulty faced during this study occurred during sample 
storage. All serum  sam ples w ere centrifuged w ithin two hours o f  venesection and the 
serum stored in quadruplicate at -20°C until ready for assaying. Some o f  these samples 
were assayed at the m idpoint o f  the study to obtain prelim inary data. As per usual 
laboratory protocol, sam ples were perform ed in batches to reduce inter and intra-assay 
variability. U nfortunately there was a com plete failure o f  the freezer mechanism
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(including the failsafe), w hich resulted in the samples being left at room temperature for 
an unknow n tim e during a Christm as vacation period. There was no precedent in the 
literature to guide w hat use was possible with these samples. We decided to re-assay the 
samples that were done previously to compare the results (section 4.9). This revealed 
that although the gonadotrophin and steroid results appeared similar, the protein-based 
hormones such as AM H  and inhibin showed large discrepancies. There was no option 
but to destroy these “spoiled” sam ples w ithout using the data. This incident caused the 
loss o f  many longitudinal sam ples thus severely affecting the prospective arm o f the 
study. W here possible, volunteers w ere asked to have their tests repeated. Further 
samples were then stored in quadruplicate, how ever 2 samples each were placed into a - 
80°C and -20°C freezers respectively.
4.10.5 SU M M ARY
This study confirm s the use o f  biochem ical and biophysical param eters o f ovarian 
reserve in a breast cancer cohort, and is the first to introduce the concept o f dynamic 
ovarian reserve testing in this group. The m ethodology was robust and included 
elaborate methods o f  testing -  all o f  which appeared to be well tolerated. The cohort 
was disease standardised and received sim ilar types o f  treatm ent which were 
cyclophospham ide based. B iochem ical markers, w hich appeared to be discriminatory, 
included FSH, A M H, inhibin  B and oestradiol in response to the G-test. The only 
clearly discrim inatory biophysical m arker was the antral follicle count. There was good 
correlation betw een A FC and other markers o f  ovarian reserve. These results taken 
together support the hypothesis that ovarian reserve is reduced in young, regularly 
cycling w om en follow ing treatm ent w ith chem otherapeutic agents for breast cancer. 
The data also add to the understanding o f the pathophysiological processes involved.
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These findings have major implications for breast cancer survivors, for whom 
reproductive issues are a major concern (Partridge et al. 2004). Furtherm ore, the 
potential exists for ovarian reserve testing to be applied in patients w ith different types 
o f cancer.
To achieve this, a large sample size should be followed up longitudinally to 
determine the potential therapeutic role o f ovarian reserve testing in this cohort.
239
5. RESULTS IN VITRO STUDY
5.1 INTRODUCTION
The background, aim and study design for the in vitro study have already been 
discussed in detail in chapters 3 and 4.
BREAST CELL CULTURE:
Briefly, M CF-7 cells were m aintained in D ulbecco’s M odified Eagle M edium plus 
H am ’s F12 (D M EM /F12) supplem ented with 10% fetal ca lf serum and 1% 
penicillin/streptomycin. The cells were plated in 24-well plates at 20,000 cells per well 
and incubated overnight. A dose response for each drug was then obtained by applying 
standard dilutions o f  each drug to the plate in quadruplicate and m onitoring its effect 
using an inverted phase contrast m icroscope. Once the dose range for each drug was 
established, experim ents w ere carried out a m inim um  o f  six tim es, w ith each plate 
having a 72-hour exposure o f  each drug. Follow ing this exposure, the cells were lifted 
with 0.02% Trypsin and ED TA , washed with w ashed w ith phosphate buffered saline 
(PBS) and resuspended in A nnexin-V -Fluos/ Propidium Iodide solution prior to analysis 
in a Flow Cytom eter. The m edium  from each well was also centrifuged and the 
resulting pellet o f  “dead” cells w ashed and resuspended as above to add to the flow 
cytometric analysis.
GRANULOSA CELL CULTURE:
Briefly, cells obtained from  different follicles in the same patient were pooled and 
centrifuged at 1100 rpm  for 10 minutes. The supernatant was discarded and the cells 
washed and resuspended w ith Hanks balanced salt solution (HBSS) containing 1% 
penicillin/streptom ycin. The granulosa cells were separated from red blood cells on a
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60% Percoll layer, w ashed with HBSS and the resulting cell aggregate incubated for 15 
minutes w ith 0.1% bovine testicular hyaluronidase in 2ml HBSS. After washing with 
HBSS the cells were m echanically dispersed, washed in HBSS and resuspended in 
DM EM /F12 supplem ented w ith 1% penicillin/streptomycin, 1% amphoterecin, 0.1% 
gentamycin and 20%  FCS. Cell viability was determined by the trypan blue exclusion 
method and cells counted using a hemocytometer. Cells were plated at a density o f 
20000 cells per well and incubated overnight in a water saturated incubator with 5% 
CO2 at 37° C for drug exposure the following day. Administration o f drug was identical 
to that described for the breast cells w ith an exposure o f 48 hours. A shorter exposure 
time was used for the granulosa cells as it was difficult to m aintain the viability o f the 
cells for longer periods. As described earlier, cells were lifted with EDTA/Trypsin and 
cells from quadruplicate w ells w ere pooled for flow cytometry. The medium from each 
well was stored separately, and later pooled for assays o f  inhibin A and oestradiol.
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5.1.1 DATA ANALYSIS
Using annexin/PI staining as described previously, each cell culture experim ent was 
quantified into 4 dom ains (D):
ANALYSIS
PARAM ETER
DEFINITION
D1 NECROTIC CELLS
D2 LATE APOPTOSIS
D3 LIVING CELLS
D4 EARLY APOPTOSIS
TA B L E  5. 1 Interpretation o f  cy tom etric  data.
V iable cells are quantified in D 3. Early and late apoptosis characterizes dying and dead ce lls  respectively  
(D 2 + D 4).
All param eters passed norm ality  testing (Gaussian distribution). The data were then 
normalized to achieve m axim um  significance. Dose-response curves were obtained for a 
minimum o f 6 experim ents. From  these experiments, one-way analysis o f  variance was 
used to obtain the m ean viability or cell death for each drug concentration used. Log- 
transform ing the drug concentrations and non-linear regression curves were then 
em ployed to obtain the LD 5 0 . All Statistical analyses were perform ed using GraphPad 
Prism version 3.00 for W indow s (GraphPad Software, San D iego California USA) and 
Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA).
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5.2 CYTOMETRY RESULTS
5.2.1 BREAST CELLS
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FIGURE 5.2.1.1 Effect o f doxorubicin on cell viability and apoptosis in MCF-7 cells.
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DOXO RUBICIN A N D  BREAST CELLS -  M EANS PLOTS:
The means plots were derived from using one-way ANOVA. The overall significance 
for the difference between groups was p = 0.06 for normalised apoptosis and p = 0.05 
for normalised viability respectively (n = 6).
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FIGURE 5.2.1.2 Doxorubicin concentration vs. viability and apoptosis in breast cells.
Data points represent the mean and the error bars represent the standard error of the mean (SEM).
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MELPHALAN
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FIGURE 5.2.1.3 Effect o f melphalan on cell viability and apoptosis in MCF-7 cells.
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M ELPHALAN A N D  BR EA ST CELLS - M EANS PLOTS:
Using one-way ANOVA, the overall significance for the difference between groups was 
p = 0.0001 for normalised apoptosis and p = 0.0001 for normalised viability 
respectively (n = 6).
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FIGURE 5.2.1.4 Melphalan concentration vs. viability and apoptosis in breast cells.
Data points represent the mean and the error bars represent the standard error of the mean (SEM).
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FIGURE 5.2.1.5 Effect ofpaclitaxel on cell viability and apoptosis in MCF-7 cells.
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PACLITAXEL A N D  BR EA ST CELLS - M EA N S PLOTS:
Using one-way ANOVA, the overall significance for the difference between groups was 
p = 0.007 for normalised apoptosis and p = 0.0001 for normalised viability respectively 
(n = 6).
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FIGURE 5.2.1.6 Paclitaxel concentration vs. viability and apoptosis in breast cells.
Data points represent the mean and the error bars represent the standard error o f the mean (SEM).
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CISPLATIN
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FIGURE 5.2.1.7 Effect o f cisplatin on cell viability and apoptosis in MCF-7 cells.
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CISPLATIN A N D  BR EA ST CELLS - M EANS PLOTS:
Using one-way ANOVA, the overall significance for the difference between groups was 
p = 0.002 for apoptosis and p = 0.0001 for normalised viability respectively.
CISPLATIN AND BREAST CELLS 
VIABILITY VS APOPTOSIS
1-110110-t
-100100
90-
-80^  80-0s*
h 70- 
§
>  60-Q
UJ
®  50-
-70
-50
5Q£ 40-O W 
Z
30-
40
-30
-2020-
-10IQ-
15 2510 20 300 5
O73
Vimo
>
13
oV)
V)
VIABILITY
A PO PTO SIS
CISPLATIN CONCENTRATION fiM/ml
FIGURE 5.2.1.8 Cisplatin concentration vs. viability and apoptosis in breast cells.
Data points represent the mean and the error bars represent the standard error of the mean (SEM).
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5.2.2 GRANULOSA CELLS
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FIGURE 5.2.2.1 Effect o f doxorubicin on cell viability and apoptosis in granulosa cells.
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DO X O R U BIC IN  A N D  G R A N U L O SA  CELLS - M EA NS PLOTS:
Using one-way ANOVA, there was a significant difference between different 
concentrations o f drug for normalised apoptosis (p < 0.001) and normalised viability 
respectively (p < 0.001, n = 6).
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FIGURE 5.2.2.2 Doxorubicin concentration vs. viability and apoptosis in granulosa cells.
Data points represent the mean and the error bars represent the standard error of the mean (SEM).
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FIGURE 5.2.2.3 Effect o f melphalan on cell viability and apoptosis in granulosa cells.
M ELPH A LA N A N D  G R A N U L O SA  CELLS - M EA N S PLOTS:
Using one-way ANOVA, there were significant differences between different 
concentrations o f drug for normalised apoptosis (p < 0.05) and normalised viability 
respectively (p < 0.05, n = 6).
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FIGURE 5.2.2.4 Melphalan concentration vs. viability and apoptosis in granulosa cells.
Data points represent the mean and the error bars represent the standard error of the mean (SEM).
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FIGURE 5.2.2.5 Effect o f paclitaxel on cell viability and apoptosis in granulosa cells.
PA C LIT A X EL A N D  G R A N U L O S A  CELLS - M E A N S PLOTS:
Using one-way ANOVA, there were no statistically significant differences between 
various concentrations o f  drug and normalised apoptosis or normalised viability 
respectively (n = 6).
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FIGURE 5.2.2.6 Paclitaxel concentration vs. viability and apoptosis in granulosa cells.
Data points represent the mean and the error bars represent the standard error o f the mean (SEM).
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FIGURE 5.2.2.7 Effect o f cisplatin on cell viability and apoptosis in granulosa cells.
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CISPLA T IN  A N D  G R A N U L O SA  CELLS - M EA N S PLOTS:
Using one-way ANOVA, there were significant differences between various 
concentrations o f  drug for normalised apoptosis (p < 0.01) and normalised viability 
respectively (p < 0.001, n = 6).
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FIGURE 5.2.2.8 Cisplatin concentration vs. viability and apoptosis in granulosa cells.
Data points represent the mean and the error bars represent the standard error o f the mean (SEM).
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5.3 DOSE RESPONSE
5.3.1 INTRO DUCTIO N
Based on the m eans plots obtained from drug concentration vs. normalised viability and 
apoptosis respectively, non-linear regression was used to establish sigmoid dose- 
response curves for breast and granulosa cells respectively. From these curves, it was 
possible to extrapolate log EC50, and calculate EC50 by using the antilog. As apoptosis 
was being used as a m arker o f  cell death, EC50 in this setting was equivalent to LD50.
5.3.2 D O X O R U BIC IN
DOXORUBICIN DOSE RESPONSE 
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FIGURE 5.3.1 Combined dose response curves -  doxorubicin.
Sigmoidal dose-response curves for both breast cells and granulosa cells (GC) plotted against a 
logarithmic scale for doxorubicin concentration.
The results for log EC50 and EC50 respectively are displayed on the graph.
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5.3.3 M ELPH ALAN
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FIGURE 5.3.2 Combined dose response curves -  melphalan.
Sigmoidal dose-response curves for both breast cells and granulosa cells (GC) plotted against a 
logarithmic scale for melphalan concentration. The results for log EC50 and EC50 respectively are 
displayed on the graph.
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5.3.4 PACLITAXEL
PACLITAXEL DOSE RESPONSE
BREAST VS GRANULOSA CELLS
100
90 -
80-
C/5
V)O(-
CL
o
CL<
o111<0
_l<
or
o
z
20-
10-
-12 -11 -10 ■9 8 ■7 6
BR EA ST CELLS
LOGEC50 -8.327
EC50 4.7050e-009
▲ GRANULOSA CELLS
LOGEC50 -7.722
EC50 1.8960e-008
LOG[PACL!TAXEL] LOG[M]
FIGURE 5.3.3 Combined dose response curves -  paclitaxel.
Sigmoidal dose-response curves for both breast cells and granulosa cells (GC) plotted against a 
logarithmic scale for Paclitaxel concentration. The results for log EC50 and EC50 respectively are 
displayed on the graph.
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5.3.5 CISPLATIN
CISPLATIN DOSE RESPONSE
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FIGURE 5.3.4 Combined dose response curves -  cisplatin.
Sigmoidal dose-response curves for both breast cells and granulosa cells (GC) plotted against a 
logarithmic scale for Cisplatin concentration. The results for log EC50 and EC50 respectively are 
displayed on the graph.
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5.4 HORMONE RESULTS
5.4.1 G RANULO SA CELLS
5.4.1.1 INTRODUCTION
As described earlier in the chapter, the granulosa cell conditioned medium was assayed 
separately for inhibin A and oestradiol respectively. In this section, the results of these 
experiments are displayed. In a similar fashion to that described for the cytometry 
analysis, the data were normalised against the controls to reduce the variability between 
individual patients.
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5.4 .1 .2  D O X O R U B IC IN
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FIGURE 5.4.1 Granulosa cell hormone release -  doxorubicin.
Normalised oestradiol and inhibin A quantified from the media used to culture the granulosa cells at
different concentrations o f  doxorubicin.
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D O XO RUBICIN A N D  H O R M O N E R ELEASE -  M EA N S PLOTS:
Using one-way ANOVA, there were significant differences between various 
concentrations o f drug with p < 0.05 for normalised oestradiol and p < 0.01 for 
normalised inhibin A respectively (n = 6).
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FIGURE 5.4.2 Doxorubicin concentration vs. normalised oestradiol and inhibin A release.
Data points represent the mean and the error bars represent the standard error of the mean (SEM).
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5 . 4 . 1 . 3 M E L PH A LA N
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FIGURE 5.4.3 Granulosa cell hormone release -  melphalan.
Normalised oestradiol and inhibin A quantified from the media used to culture the granulosa cells at
different concentrations o f melphalan.
2 6 6
M ELPH A LA N A N D  H O R M O N E RELEASE -  M EANS PLOTS:
Using one-way ANOVA, there were significant differences between various 
concentrations o f  drug for normalised oestradiol (p < 0.05) but not for normalised 
inhibin A (n = 6).
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FIGURE 5.4.4 Melphalan concentration vs. normalised oestradiol and inhibin A release.
Data points represent the mean and the error bars represent the standard error of the mean (SEM).
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FIGURE 5.4.5 Granulosa cell hormone release -  paclitaxel.
Normalised oestradiol and inhibin A quantified from the media used to culture the granulosa cells at
different concentrations o f paclitaxel.
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PA CLITAX EL A N D  H O R M O NE RELEASE -  M EA N S PLOTS:
Using one-way ANOVA, there were no statistically significant differences between 
various concentrations o f  drug with p > 0.05 for normalised oestradiol and normalised 
inhibin A respectively (n = 6).
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FIGURE 5.4.6 Paclitaxel concentration vs. normalised oestradiol and inhibin A release.
Data points represent the mean and the error bars represent the standard error o f the mean (SEM).
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5.4.1.5 CISPLATIN
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FIGURE 5.4.7 Granulosa cell hormone release -  cisplatin.
Normalised oestradiol and inhibin A quantified from the media used to culture the granulosa cells at
different concentrations o f cisplatin.
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CISPLATIN A N D  H O R M O NE RELEASE -  M EA N S PLOTS:
Using one-way ANOVA, there were significant differences between various 
concentrations o f  drug with p < 0.001 for normalised oestradiol and p < 0.05 for 
normalised inhibin A respectively (n = 6).
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FIGURE 5.4.8 Cisplatin concentration vs. normalised oestradiol and inhibin A release.
Data points represent the mean and the error bars represent the standard error of the mean (SEM).
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5.5 COMBINED DATA: CYTOMETRY AND HORMONES
5.5.1 INTRODUCTION
The combined cytometry and hormone release data after drug administration for the 
granulosa cells will be displayed. Hormone release from the granulosa cells appeared to 
be biphasic. In the case o f inhibin A release, there appeared to be an initial surge into 
the medium at low drug concentrations followed by a gradual decline. Oestradiol 
release into the medium decreased at low concentrations before rising slowly. This 
pattern of release made it difficult to compare directly with the cytometry parameters at 
the same drug concentration, in that sigmoidal dose response curves could not be 
constructed in a fashion analogous to that used for the cytometry data. Nevertheless the 
cytometry and hormone release data were overlaid in the graphs below for illustrative 
purposes.
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5.5.2 DOXO RUBICIN
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FIGURE 5.5.1 Combined cytometry and hormone data for granulosa cells -  doxorubicin. 
Cytometry and hormone data overlaid using a doubly Y-axis against doxorubicin concentration.
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5.5.3 MELPHALAN
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FIGURE 5.5.2 Combined cytometry and hormone data for granulosa cells -  melphalan. 
Cytometry and hormone data overlaid using a doubly Y-axis against melphalan concentration.
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5.5.4 PACLITAXEL
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FIGURE 5.5.3 Combined cytometry and hormone data for granulosa cells -  paclitaxel. 
Cytometry and hormone data overlaid using a doubly Y-axis against paclitaxel concentration.
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FIGURE 5.5.4 Combined cytometry and hormone data for granulosa cells -  cisplatin. 
Cytometry and hormone data overlaid using a doubly Y-axis against cisplatin concentration.
2 7 6
5.6 DISCUSSION
5.6.1 INTRODUCTION
This is the first study to examine the cytotoxic effect of chemotherapeutic agents used to 
treat breast cancer, by using a granulosa cell model compared to a breast cell control.
The results indicate that at equivalent dosages, these drugs (with the exception 
of doxorubicin in this model) are more toxic to breast cells than granulosa cells. 
Furthermore, assessment o f inhibin A and oestradiol concentrations in the culture media 
of granulosa cells suggest an important role for these hormones in the apoptotic 
pathways involved in chemotherapy-mediated gonadal damage.
5.6.2 CELL CULTURE
The MCF-7 cell line was derived from a pleural effusion taken from a patient with 
metastatic breast cancer in 1970 (Soule et al. 1973). Since then it has become a 
prominent model for oestrogen receptor-positive breast cancer worldwide, having found 
many applications in experimental therapeutics (Levenson & Jordan 1997). This cell 
line has been studied longer than any other in breast cancer, and as a result is very well 
characterized in the literature. Many variants exist, all o f which are considered to be 
excellent as in vitro models for studying the mechanisms o f chemoresistance as it 
relates to susceptibility to apoptosis (Simstein et al. 2003). Apoptotic pathways for 
several of the drugs used in this study have been identified to act via the Bcl-2 family of 
proteins using this system. For example, (4-hydroxy)cyclophosphamide increases pro- 
apoptotic Bax levels, while doxorubicin causes a decrease in Bcl-2 expression and an 
increase in Bax levels (Leung & Wang 1999). Paclitaxel has been shown to upregulate 
several pro-apoptotic Bcl-2 proteins and downregulate anti-apoptotic Bcl-2 proteins 
(Vakkala et al. 1999).
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The use o f a cell line in this experiment also provided several other advantages. 
For instance the cells are relatively robust compared to those obtained from primary 
culture, and stocks could be easily replenished. There are however several important 
disadvantages. With successive subcultures, or “passages”, cell lines are prone to 
genotypic and phenotypic drift (Burdall et al. 2003). In fact, many biological differences, 
including karyotypic variation, have been shown among MCF-7 cell lines from different 
laboratories (Bahia et al. 2002; Osborne, Hobbs, & Trent 1987). Overall however breast 
cell lines, especially those best characterized such as MCF-7, are considered to reflect to 
a large extent, the features o f breast cancer cells in vivo (Lacroix & Leclercq 2004).
Primary granulosa cell culture was chosen as the target cell type for this 
experiment. In order to study the effects o f cytotoxic agents on these cells, it was 
important to have a well-defined and validated in-vitro culture system available 
(Muttukrishna, Groome, & Ledger 1997). Granulosa cell death by apoptosis is a critical 
event in follicular atresia during growth and development o f the ovarian follicle 
(Hughes, Jr. & Gorospe 1991; Tilly et al. 1991). Furthermore, there is evidence that 
apoptosis-associated signaling pathways are required for chemotherapy-mediated germ 
cell destruction (Perez et al. 1997). It was logical therefore to study apoptosis as a 
marker o f cytotoxicity shared by both cell types in question.
278
5.6.3 FLOW CYTOM ETRY DATA
The flow cytometric data analysis revealed that the LD50 for all drugs, with the 
exception o f doxorubicin (figure 6.3.1), was lower for breast cells than granulosa cells. 
For Paclitaxel, the LD50 for granulosa cells was almost forty times that o f breast cells 
(figure 6.3.3), for melphalan almost three times (figure 6.3.2) and for cisplatin more 
than four times (figure 6.3.4). This implies that these three drugs are far more potent at 
equivalent doses in breast cells than for granulosa cells. There are some limitations to 
the interpretation o f this data however. In this study, the potency of these drugs is 
measured in terms o f their ability to induce apoptosis in these cells. It is possible that 
toxicity is exerted by non-apoptotic mechanisms as well. Furthermore, it is not clear 
what effect these drugs would have when administered as multi-drug combinations, as 
is the case in vivo. Kugawa and co-workers reported that cell death caused by a 
combination of cyclophosphamide, doxorubicin and 5-fluorouracil in an MCF-7 cell 
line was completely non-apoptotic (Kugawa et al. 2004). This stresses the point that 
while flow cytometric analysis by annexin labeling is very efficient at identifying the 
frequency o f early and late apoptosis in cell populations, it provides limited information 
on the mechanism o f cell death. To achieve this, complementary methods should be 
used, such as DNA fragmentation analysis (“DNA laddering”), gel electrophoresis of 
DNA (“COMET”) or end labeling cells to detect DNA strand breaks (TUNEL) 
(Darzynkiewicz & Traganos 1998). In terms o f the aims o f this study however, flow 
cytometry was entirely appropriate.
The implications o f the above findings are that it introduces the possibility of 
tailoring drug treatments that are potent enough to destroy malignant breast cells while 
sparing granulosa cells, and by extension, preserving ovarian reserve. The need for such
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treatments in young women with breast cancer have been mentioned for some time 
(Goldhirsch et al. 2001).
There are several explanations as to why doxorubicin gave an unexpected result. 
The most likely is that the MCF-7 line used in our lab had acquired a form of resistance 
to doxorubicin. At the time the study had started, this particular line had already 
undergone almost 300 “passages”, raising the possibility that some degree of biological 
variation might have occurred over time. There are several examples of doxorubicin 
resistant MCF-7 strains in the literature -  engineered or otherwise (Ahn et al. 1996; 
Brown & Fenselau 2004; Guo-Chang & Chu-Tse 2000). The other possibilities would 
include inherent problems with establishing the dose response, especially with the 
granulosa cells, which will be discussed later.
5.6.4 HORMONE A N A LY SIS
Luteinised granulosa cells (LGC’s) can be functionally assessed by measuring hormone 
concentrations in the culture medium. These cell culture models have been extensively 
investigated where secretion o f the inhibins, activin and oestradiol have been shown to 
be regulated by gonadotrophins (Foldesi, Breckwoldt, & Neulen 1998; Lau et al. 1999; 
Muttukrishna, Groome, & Ledger 1997; Welt & Schneyer 2001). Because inhibin A is 
considered a product o f the mature dominant follicle (and corpus luteum - Groome et al. 
1994; Muttukrishna et al. 1994), culture medium from LGC’s would be expected to 
have significant amounts o f this hormone.
Our data suggests that at initial concentrations o f drug, inhibin A levels are 
increased significantly with a corresponding decrease in oestradiol levels. There was a 
consistent pattern o f hormone release for all drugs with the exception of Paclitaxel 
(figures 6.4.1 to 6.4.8). In the case of doxorubicin, melphalan and cisplatin, inhibin A
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levels rose two to three fold at the lowest concentration o f drug compared to the 
controls. These levels then gradually recovered to concentrations similar to the control 
sample. The opposite effect appeared to happen with oestradiol. While not as dramatic 
compared to inhibin A, there was a clear decline in oestradiol levels following 
administration o f the lowest concentration of drug. These levels rose gradually as drug 
concentrations increased. These results may be reflective o f the apoptotic processes 
involved. The increased inhibin A levels may reflect a physiologic protective 
mechanism of the granulosa cell to reduce apoptosis. Granulosa cells (isolated from 
follicles o f women participating in an IVF program) cultured in an enriched inhibin A 
environment have been shown to correlate with reduced levels o f apoptosis (increased 
anti-apoptotic and reduced pro-apoptotic proteins). This reduction in apoptosis also 
correlated with increased levels o f oestradiol, but the anti-apoptotic effect o f inhibin A 
was still apparent even at low oestrogen levels (Denkova et al. 2004). Other 
investigators have identified increased oestrogen as being an important factor in 
reducing apoptosis, possibly mediated by increased inhibin levels (Billig, Furuta, & 
Hsueh 1993; Campbell & Baird 2001; Song & Santen 2003). This has not been a 
universal finding however, as some investigators have shown evidence of inhibin A 
having a negative autocrine or paracrine effect on estradiol production by granulosa 
cells using a rat culture model (Jimenez-Krassel et al. 2003).Others have shown that 
inhibin A increases apoptosis in early ovarian antral follicles o f rats (Vitale et al. 2002).
Another explanation for increased inhibin A levels is that inhibiting FSH release 
from the anterior pituitary is a physiological mechanism to reduce oestradiol secretion 
by granulosa cells (Ho et al. 2006). Oestradiol secretion by granulosa cells was not 
measured in that study, limiting adequate elucidation o f the proposed mechanism. It 
may be possible however that increased inhibin levels as a result o f cytotoxic injury 
contributes to the hypo-oestrogenic state seen in patients following chemotherapy.
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While our results indicate that basal oestradiol levels are reduced, we could not find any 
significant increase in inhibin A levels compared to the controls. This may be explained 
by the fact that this was an in vitro study, and as such, the physiologic effect of FSH 
suppression would not be a factor. The question remains whether inhibin A exerts its 
influence on oestradiol release via the HPO axis, or in an autocrine/paracrine fashion at 
the level of the ovary, or a combination of both. Cytotoxic agents used to treat breast 
cancer may induce these changes by interacting with membrane-signalling pathways on 
granulosa cells. Further study in this area would involve using a narrower dose range to 
pinpoint the events which occur at the time of inhibin release. Additionally, culture 
conditions might be manipulated further in an effort to mimic the physiologic conditions 
seen in humans.
The only other study which experimented on granulosa cells in vitro measured 
progesterone concentration in cultured rat and human granulosa cells exposed to 4- 
hydroperoxy (activated) cyclophosphamide in vitro (Ataya, Pydyn, & Ramahi-Ataya 
1990). This study limited its analysis to a single agent and no comparison with the effect 
on breast cells was attempted.
This study has provided useful insight into the dose-related response of 
granulosa cells to cytotoxic agents used to treat breast cancer. Based on these results, it 
seems plausible to investigate further the possibility of modifying dosages of cytotoxic 
agents so hat a lethal effect is incurred on malignant breast cells while sparing that of 
granulosa cells. Further research is needed regarding the mechanism of cell kill in 
granulosa cells however. One option is to perform COMET assays on both cell types to 
determine which cell type has more efficient DNA repair to determine which cell type 
has a more efficient DNA repair apparatus.
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6. GENERAL DISCUSSION
6.1 IN VIVO STUDY
The results o f this study show that biochemical and biophysical tests may be used to 
accurately estimate ovarian reserve in premenopausal recipients o f chemotherapy for 
breast cancer. This can have a major impact on the management o f fertility-related 
issues and premature ovarian failure in these patients.
Markers o f ovarian reserve have been assessed for some time in the fertility 
setting, where it became established that clinical characteristics alone were unreliable in 
predicting reproductive age. So far, biochemical and biophysical parameters appear to 
be more reliable than chronological age. Despite extensive investigation however, the 
ideal test remains to be identified. To the best of our knowledge, no definitive single 
marker for assessing ovarian reserve in patients with cancer has been identified, leading 
to the use o f multiple markers (Dutchman Singh, Davies, & Chatterjee 2005).
In general, patients in this study all received cyclophosphamide-based 
chemotherapy. All patients resumed regular menstrual cycles after a variable period of 
amenorrhoea indicating that the effects o f these agents are at least partially reversible. 
Despite this, clinical characteristics (patient age and BMI) were not found to be 
discriminatory once cyclical activity had resumed. This is in keeping with the generally 
accepted notion that clinical characteristics alone are not reliable estim ates of 
reproductive age. Biochemical markers, which appeared to be discriminatory, included 
FSH, AMH, inhibin B and oestradiol in response to the G-test. The only discriminatory 
biophysical marker was the antral follicle count. There was good correlation betw een 
AFC and other markers o f ovarian reserve. These results taken together support the 
hypothesis that ovarian reserve is reduced in young, regularly cycling women following 
treatment with chemotherapeutic agents for breast cancer. The data also add to  the
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understanding of the pathophysiological processes involved, in that ovarian reserve was 
potentially intact in these patients prior to chemotherapy. This implies that 
chemotherapy was the main factor that led to diminished ovarian reserve.
Young women treated for cancer have unmet needs for fertility and menopause- 
related information (Duffy, Allen, & Clark 2005). Counselling about the effect of 
chemotherapy on premature ovarian failure and fertility is also considered an 
overlooked aspect o f preparation for adjuvant chemotherapy in young women with 
breast cancer (Thewes et al. 2005). Many patients are left with significant anxieties and 
insufficient information about reproductive issues (Schover et al. 1999). A unique web- 
based survey o f fertility issues in young women with breast cancer revealed that only 
51% felt that their concerns were addressed adequately. Also, 29% percent of women 
reported that infertility concerns influenced treatment decisions (Partridge et al. 2004).
Estimation o f functional ovarian reserve in these patients can have a significant 
impact on how patients are counselled both before and after chemotherapy. These tests 
can be applied both pre and post-chemotherapy where patients can be classified into 3 
groups: normal, poor and intermediate ovarian reserve. In the pre-chemotherapy patient, 
this information can be used to predict the response to ovarian stimulation for 
embryo/egg cryopreservation, allowing appropriate counselling and modification of 
treatment. For example patients deemed to have normal ovarian reserve prior to 
potentially sterilising chemotherapy might opt to have embryos cryopreserved knowing 
that their response to COH is likely to be adequate. The same may be applied to patients 
post-chemotherapy for treatment of subfertility. Alternatively, patients with normal 
ovarian reserve may be counselled regarding adequate contraception. Furthermore, the 
potential exists to counsel patients appropriately regarding the onset o f a premature 
menopause. In some cases, treatment decisions for the patient’s cancer can be affected. 
For example in women with breast cancer where there is an option for either cytotoxic
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chemotherapy or reversible endocrine ablation, the latter m ay be preferred if ovarian 
reserve is already diminished prior to treatment.
This study was limited by small sample size and limited longitudinal analysis 
(for reasons described earlier). Despite this, it is important in several respects. It is the 
first of its kind to evaluate dynamic ovarian reserve in a young, cycling breast cancer 
cohort, all o f whom had received cyclophosphamide-based chemotherapy. The 
methodology employed is robust and included elaborate methods o f testing- all of 
which appeared to be well tolerated. To realise the full potential for ovarian reserve 
testing in these patients, longitudinal follow up with a larger number o f patients would 
be important to investigate the recovery o f ovarian function in these young women with 
breast cancer, and allow stratification according to chemotherapy type and dose. To 
achieve this, large, prospective, adequately controlled studies are required specific to 
different geographical areas (multi-centre) in a control population o f comparable 
reproductive age to determine the potential role o f ovarian reserve testing in clinical 
practice. This would allow specific data such as pregnancy outcome and age at 
menopause to be acquired, enabling correlation with markers o f  ovarian reserve. The 
aim would be to develop a clinical tool, which may allow classification o f ovarian 
reserve (e.g. into normal, intermediate, and poor). This tool would allow a more 
accurate assessment o f  ovarian reserve including the prediction o f response to future 
treatment.
Furthermore, should multi-agent chemotherapy prove to  be the main factor 
affecting ovarian reserve, the potential exists for ovarian reserve testing to be applied to 
different cancer cohorts.
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One must stress however that these examples represent only the potential of 
ovarian reserve testing in these patients, as these applications remain as yet unproven. 
Furthermore, while fertility and quality of life issues are important, they must not be 
pursued at the expense o f the patient’s overall treatment and welfare. While potentially 
informative, ovarian reserve testing can only help and clarify the decision-making 
process in a limited group o f patients, as malignancy and reproductive issues are 
complex and difficult.
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FIGURE 6. 1 Management of reproductive issues in young women with breast cancer.
The initial diagnosis and management plan is determined by the breast multi-disciplinary meeting (MDM). By this point, consideration should be made for urgent referral to the 
reproductive medicine team (Rep Med). Here, ovarian reserve tests might be performed, which can be used to counsel and treat patients effectively especially if the aim is to 
determine the patient’s response to IVF. If time permits, and the patient has a partner, IVF with embryo freezing is recommended. If there is no partner, oocyte freezing may be 
more appropriate. If no time permits, then ovarian tissue freezing should be considered. The role of GnRH agonists has not yet been elucidated. Following treatment, regular 
follow-up is recommended, as the patient’s needs may be different. This includes management of POF-related effects and restoration of fertility. The latter may include 
reimplantation of an ovarian allograft or embryos if these were procured prior to chemotherapy. For some patients, contraception may need to be discussed if there are no active 
reproductive ambitions.
QOL = quality of life, ORT = ovarian reserve tests, —  = demarcation pre vs postchemo.
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FIGURE 6. 2 The proposed role o f ovarian reserve tests in young women with breast cancer.
ORT can be applied pre- and post-chemotherapy to classify patients into 3 groups -  normal, poor and 
intermediate ovarian reserve as a guide to counseling and treatment respectively.
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6.2 IN VITRO STUDY
The cell culture experiment was the first study of its kind to compare the cytotoxic 
effect o f chemotherapeutic agents commonly used to treat breast cancer using a parallel 
invitro cell culture model comprising breast and granulosa cells respectively.
The results indicate that at equivalent dosages, these drugs (with the exception 
o f doxorubicin in this model) are more toxic to breast cells than granulosa cells. 
Furthermore, assessment o f inhibin A and oestradiol concentrations in the culture media 
of granulosa cells suggest an important role for these hormones in the apoptotic 
pathways involved in chemotherapy-mediated gonadal damage.
Flow cytometric data analysis revealed that the LD50 for all drugs, with the 
exception o f doxorubicin, was low er for breast cells than granulosa cells. For Paclitaxel, 
the LD50 for granulosa cells was alm ost forty times that of breast cells, for melphalan 
almost three tim es and for cisplatin  more than four times. This implies that these three 
drugs are far m ore potent at equivalent doses in breast cells than for granulosa cells. 
There are some limitations to the interpretation of this data however. In this study, the 
potency of these drugs is m easured in terms of their ability to induce apoptosis in these 
cells. It is possible that toxicity is exerted  by non-apoptotic mechanisms as well. For this 
reason, future experiments w ould  need to incorporate tests which elucidate the 
mechanism of cell death, such as D N A  fragmentation analysis (“DNA laddering”), gel 
electrophoresis o f  DNA (“COM ET” ) or end labeling cells to detect DNA strand breaks 
(TUNEL). A nother point for consideration in the future is to employ multi-drug 
administration (analogous to in vivo use), as it is not clear what effect this would have.
One explanation for the fact that doxorubicin’s results were not similar to the 
other drugs is tfeat this was a true effect -  that is doxorubicin is in fact more toxic to 
granulosa cells than breast cells. T h is would seem unlikely given the fact that alkylating
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agents appear to have a greater cytotoxic effect on ovarian reserve in vivo compared to 
anthracycline drugs. One would not expect therefore, that doxorubicin would be more 
toxic to granulosa cells than melphalan when compared to breast cells. What is more 
likely is the development of doxorubicin resistance to the MCF-7 cell line in vitro.
One o f the main limitations of this experiment was that the cell culture 
conditions were not fully optimised. This pertained especially with regards to the 
granulosa cell culture. In comparison, the breast cell culture was relatively easy to 
perform and sustain as would be expected with cell line (an advantage o f using this 
resource). The primary granulosa cell culture was particularly difficult to maintain 
beyond 48 hours. One of the main reasons for this could be contamination of the 
specimen at the time o f collection (ie. at the time of follicular aspiration). Ideally cell 
culture conditions would have been optimised to achieve sufficient cell viability to 72 
hours as was the case with the breast cell culture. It would be imperative that cell 
culture conditions are optimised prior to any future experiments o f this nature.
The release o f inhibin A and oestradiol into the culture medium by the granulosa 
cells may provide a further means of elucidating the mechanism o f cell death in 
granulosa cells exposed to cytotoxic agents. It is possible that cytotoxic agents used to 
treat breast cancer may induce these changes by interacting with membrane-signalling 
pathways on granulosa cells. Further study in this area would involve using a narrower 
dose range to pinpoint the events which occur at the time o f inhibin release. 
Progesterone levels could be included in the analysis as this is also expressed by 
luteinised granulosa cells in vitro. It would be instructive to assess the effect o f effect of 
cytotoxic agents on hormone release of breast cells in vitro. The possibilities here could 
include activin A and Inhibin A. If these hormones were released from breast cells in a 
functional manner analogous to granulosa cells, it might be possible to calculate dose
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response curves on both cell types after administration of cytotoxic agents and compare 
them with dose obtained from flow cytometry to determine if any correlation existed.
The implications of the above findings are that it introduces the possibility of 
tailoring drug treatments which are potent enough to destroy malignant breast cells 
while sparing granulosa cells, and by extension, preserving ovarian reserve. If the 
mechanism of granulosa cell cytotoxicity could be elucidated, it may be possible to 
choose cytotoxic agents based on this knowledge. This experiment could also be 
modified to examine the effect o f agents that suppress ovarian apoptosis (sphingosine-1- 
phosphate) as has been shown previously in mice (Morita et al. 2000). Further research 
is needed regarding the mechanism of cell kill in granulosa cells however. One option is 
to perform COMET assays on both cell types to determine which cell type has more 
efficient DNA repair to determine which cell type has a more efficient DNA repair 
apparatus.
Finally, this experiment could be incorporated into the clinical study discussed 
in section 6.1. For example, patients undergoing fertility preservation prior to 
chemotherapy could have follicular fluid samples obtained at the time o f embryo/egg 
capture and the resulting granulosa cell culture used to perform the same experiments 
described, using the same chemotherapy combination administered in vivo. This would 
allow a more accurate assessment of the cytotoxic effect of these agents on granulosa 
cells, and correlate it with markers of ovarian reserve. The control sample would be 
obtained from patients undergoing controlled ovarian hyperstimulation for unexplained 
or male factor infertility.
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6.3 CONCLUSION
Addressing the quality of life concerns of young patients with breast cancer has 
assumed ever increasing importance due to the progressive rise in incidence rates 
coupled with improved survival. There is a lack of pertinent data relating to ovarian 
reserve testing in breast cancer, and information pertaining to ORT in a subfertile 
population cannot be extrapolated to include patients with breast cancer, as the 
pathophysiology is distinct.
This thesis has contributed to the establishment of potentially useful biochemical 
and biophysical parameters of ovarian reserve in young women with breast cancer. 
Further research could potentially allow ovarian reserve testing to be applied clinically 
in patients with cancer as a guide to counselling and treatment in terms of fertility 
preservation.
The in vitro study was performed to supplement the in vivo study. This provided 
evidence to support the notion that cytotoxic agents used to treat breast cancer might 
have varying degrees of toxicity on malignant breast cells compared to granulosa cells 
as measured by apoptosis. Further study in this area might eventually lead to correlation 
with clinical outcome in vivo. The aim would be to develop drugs which are selectively 
cytotoxic to malignant breast cells, whilst having minimal or no effect on granulosa 
cells.
Finally, the objective o f this information would always be for the benefit o f the 
psychological and physical well being of the patient.
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CONFIDENTIAL
INFORMATION LEAFLET 
(Volunteers)
Estimation of ovarian reserve in patients treated by cytotoxic drugs for 
cancer
W e would like to a sk  you to take part in the above-m ention ed  study.
What is this study about?
C hem otherapy u se d  for treatm ent is likely to c a u se  d a m a g e  to the o v a r ie s  o f s o m e o n e  treated  
for cancer. This m ay a ffect their ability to produce e g g s  properly, w hich can  lead  to problem s  
with having children (fertility), a ffect their periods and can  e v e n  lead  to an early  m en o p a u se . 
Not e v ery o n e  is a ffected  in the s a m e  w ay a s  patients m ay still h a v e  regular period s and have  
the ability to p rod u ce e g g s  (ovulation) and a lso  have children. H ow ever, having regular periods  
d o e s  not gu aran tee  that the ovaries  are producing e g g s  normally.
Currently no reliable m eth o d s are available to find out which p atien ts treated  by ch em oth erap y  
can  produce e g g s  normally. With early d iagn osis  and better c a n c e r  care , m any patients are  
now  surviving longer and w ould like to h ave  a family.
W e are a m ed ical team  b a se d  at University C o llege  H ospital w h o  is in terested  in performing a 
study, which looks at w h eth er  or not w e  can u se  certain te s ts  to tell if ch em o th era p y  received  
during treatm ent for c a n cer  c a u s e d  d a m a g e  to the ovaries. W e  plan to  d o  th is by working out 
som eth ing  called  “ovarian r e se r v e ”. This is basically  is the am ou n t o f “g o o d ” e g g s  that the  
ovary contains. This study is primarily a im ed to help ca n c e r  p atien ts . A lthough w e  h op e that 
the information w e  obtain from this study can  be u sed  to a d v ise  and help  them  regards having 
a family, w e  m ust tell you that any information w e  g e t from your taking part in this study would 
not b e  o f any direct benefit to yourself.
What wiii I be asked to do?
Basically  th ere  are two te s ts  w e  w ould like you to h ave, both o f w h ich  are e ssen tia lly  harm less  
and c a u s e  little or no pain. This includes blood te s ts  and u ltrasound s c a n  of the pelvis, which  
will be d o n e  at two s ta g e s , with and without an injection of a h orm on e ca lled  buserelin .
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Test without injection:
On the s e c o n d  d ay  of your period w e  w ould like you to c o m e  in to hospital clinic. W e would
then take your m ed ical history like w e  w ould in a normal clinic visit. After this, w e  would n eed
to take s o m e  blood t e s t s  over a 1-hour period. This would be d o n e  by p lacing a s in g le  n eed le  
in your arm with an attachm ent, s o  w e  d on ’t need  to inject you  m ore than o n c e . W hile the  
blood te s t  is being d o n e , w e  would like to perform an ultrasound looking at your ovaries in 
particular. U sually this is d o n e  by placing the sca n  on your tum m y, but so m e tim e s  if w e  c a n ’t 
s e e  your o v a r ies  properly, w e  do s o  by placing the sca n  in th e  vag in a . T his is called  a 
transvaginal sc a n , and fe e ls  sim ilar to having a tam pon inserted.
Test with injection:
T he last part o f the te s t  is ca lled  the G -test. To do this, w e  h ave  to g iv e  you an injection under  
the skin containing a drug ca lled  buserelin . This drug works by c a u sin g  your o v a r ies  to r e le a se  
oestro g en  horm one, in a lm o st the s a m e  w ay that your brain r e le a s e s  h orm on es to c a u s e  the  
ovary to work properly. After th is is g iven , w e  would n eed  you to c o m e  back  at th e  s a m e  tim e 
the next day  to h a v e  o n e  final blood test taken.
How often must these tests be done?
W e w ould like you to h a v e  th e  te s t  only o n ce
Are there side effects with these tests?
Blood te s ts  are routine te s ts  you m ay h ave had before for other r e a so n s . T his is exactly  the  
sa m e . S o m e tim e s  it can  c a u s e  b ru ises and so m e  discom fort. U S S  is u sually  p a in less  apart 
from the p ressu re  se n sa tio n  and the discom fort or m e s s in e s s  o f th e  jelly, w hich  is u sed  during 
scanning.
Are there side effects with taking buserelin?
S o m e tim e s  w om en  w h o take this drug for a long period e x p e r ie n c e  sy m p to m s like the  
m e n o p a u se  su ch  a s  hot flu sh es . W e do not b e lieve  this will h a p p en  in your c a s e  b e c a u s e  w e  
are only giving you o n e  d o se .
Are there any safety measures I should take before doing the test?
Y es. If you w ere  taking the oral contraceptive pill, w e  w ould n e e d  you  to stop  taking them  for 1 
m onth b efore the te s ts  are perform ed. R em em b er to u s e  barrier m eth o d s of family planning 
su ch  a s  co n d o m s or a diaphragm  in the m ean tim e.
U C X
What happens to the information you acquire?
Any information w e  obtain from your history or investigations during th e  stu dy will be kept 
strictly confidential and m a n a g ed  by UCLH. Your nam e and a d d r e ss  will b e  kept sep ara te ly  
from any information about you s o  that you cannot be identified from it. T h e m em b ers o f the  
research  team  will b e  resp on sib le  for all information related to the study.
What happens to the samples that are taken?
All the sa m p le s  are usually  stored  in a freezer until they are te s te d . W e  usually  store  th e se  
sa m p le s  for s o m e  tim e (5 y e a r s  or m ore). This allow s us to rep eat t e s t s  on  the s a m e  sa m p le s  
later on, su ch  a s  w h en  a n ew  te s t  is d iscovered . Eventually sa m p le s  are d estro y ed  by fire.
Do I have to take part?
It is up to you to d e c id e  w h eth er  or not to take part in this study. If you  d e c id e  to tak e part you  
are free to c h a n g e  your mind at any  tim e and without giving a rea so n .
What if I have questions?
You m ust fee l free to con tact any m em ber of the study group to a n sw e r  any  q u e stio n s  you  
might h ave . You can  con tact u s by post or phone or e-m ail Dr Lutchm an S in gh  at his e-m ail 
a d d ress . If you con tact us by p h on e w e  will be happy to p h on e you  back. W e  will be happy to 
a n sw er  your q u estio n s.
THANK YOU FOR CONSIDERING TAKING PART IN THIS STUDY
Research team:
Miss Melanie Davies (principal investigator)
Dr Ratna Chatterjee 
Dr Kerryn Lutchman Singh
Contact details:
Address: Reproductive Medicine Unit
Tel: 
e-mail: 
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Estimation of ovarian reserve in patients treated by cytotoxic drugs for 
cancer
W e would like to a sk  you to take part in the ab ove-m en tion ed  study.
What is this study about?
W e know that ch em o th era p y  you  rece ived  (or will receive) to treat your c a n c e r  is likely to 
c a u s e  d a m a g e  to your o v a r ies . T his m ay affect your ability to p rod u ce e g g s  properly, which  
can lead to prob lem s with having children (fertility), affect your period s and ca n  e v e n  lead  to an  
early m en o p a u se . Not e v e r y o n e  is affected  in the s a m e  w ay, a s  s o m e  o f you  m ay still h ave  
regular p eriod s and h a v e  the ability to produce e g g s  (ovulation) and a lso  h a v e  children. 
H ow ever, having regular p eriod s d o e s  not guarantee that your o v a r ie s  are producing e g g s  
normally.
Currently no reliable m eth o d s are available to find out which p atien ts treated  by ch em oth erap y  
can  produce e g g s  norm ally. With early d iagn osis  and better c a n c e r  care , m an y  patien ts are  
now  surviving longer and w ould like to h ave  a family.
W e are a m ed ical team  b a se d  at University C ollege  Hospital (UCLH) w h o  are in terested  in 
performing a stu dy w hich look s at w hether or not w e  can  u s e  certain  t e s t s  to tell us if 
chem otherapy you rece iv ed  during your treatm ent for ca n cer  h a v e  d a m a g e d  your ovaries. W e  
plan to do this by working out your ovarian reserve, which b a sica lly  is  th e  am ou n t o f “g o o d ” 
e g g s  you h ave in your ovary. W e  think it is important that you know  th is  inform ation s o  that you  
m ay b e better equ ipped  to plan your future regarding children. T h is inform ation would a lso  be  
usefu l to your doctors if you e v e r  n e e d e d  help to h ave  children. W e  h o p e  even tu a lly  to be able  
provide this information to all w o m en  w ho h ave b een  treated  for c a n c e r  with different typ es of 
chem otherapy .
What will I be asked to do?
B asically  there are two te s ts  w e  w ould like you to h ave , both o f w h ich  are e sse n tia lly  harm less  
and c a u s e  little or no pain. T his includ es blood te s ts  and ultrasound s c a n  of the pelvis, which 
will be d on e  at tw o s ta g e s , with and without an injection of a h orm on e ca lled  buserelin .
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Test without injection:
On the s e c o n d  day  of your period w e  would like you to c o m e  in to hospital clinic. W e would  
then take your m ed ical history like w e  would in a normal clinic visit. After this, w e  w ould n eed  
to take s o m e  blood t e s t s  over  a 1-hour period. This would be d o n e  by placing a s in g le  n eed le  
in your arm with an attachm ent, s o  w e  don ’t n eed  to inject you m ore than o n c e . W hile the  
blood test is being d o n e , w e  w ould like to perform an ultrasound looking at your ovaries in 
particular. U sually this is d o n e  by placing the sca n  on your tum m y, but so m e tim e s  if w e  c a n ’t 
s e e  your ova r ies  properly, w e  do s o  by placing the sc a n  in the vag ina . T his is called  a  
transvaginal sc a n , and  f e e ls  sim ilar to having a tam pon inserted.
Test with injection:
T he last part o f the te s t  is ca lled  th e  G -test. To do this, w e  h ave  to g ive  you an injection under  
the skin containing a drug ca lled  buserelin . This drug w orks by cau sin g  your ovar ies  to r e le a se  
oestro g en  horm one, in a lm o st th e  s a m e  w ay that your brain r e le a s e s  h orm on es to c a u s e  the  
ovary to work properly. After this is g iven , w e  would n eed  you to c o m e  back  at th e  s a m e  tim e  
the next day to h a v e  o n e  final b lood test taken.
How often must these tests be done?
W e w ould like you to h a v e  th e  te s t  5  tim es: before you h ave the ch em oth erap y , im m ediately  
after com pletion  of the ch em oth erap y , at 6 m onths, 12 m onths and at 2 4  m onth s after 
com p letion  of ch em oth erap y . If you h ave  already finished your ch em oth erap y , then the first 
te s t  will b e  om itted.
Are there side effects with these tests?
Blood te s ts  are routine te s ts  you m ust b e  having for your ca n cer  treatm ent. S o m e tim e s  it can  
c a u s e  bru ises and s o m e  discom fort. U S S  is usually p a in le ss  apart from the pressu re  
sen sa tio n  and the d iscom fort or m e s s in e s s  o f the jelly, which is u se d  during sca n n in g .
Are their side effects with taking busere/in?
S o m e tim e s  w om en w ho take this drug for a long period e x p e r ie n c e  sy m p to m s like the  
m e n o p a u se  su ch  a s  hot flu sh es . W e  do not b elieve  this will h ap p en  in your c a s e  b e c a u s e  w e  
are only giving you o n e  d o se .
Are there any safety measures I should take before doing the test?
Y es. If you w ere  taking the oral contraceptive pill (O C P), w e  w ou ld  n e e d  you to stop  taking 
them  for 1 m onth before the te s ts  are perform ed. R em em b er  to u s e  barrier m eth od s of family 
planning su ch  a s  co n d o m s or diaphragm  in the m ean tim e.
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What happens to the information you acquire?
Any information w e  obtain from your history or investigations during th e  study will be kept 
strictly confidential and m a n a g ed  by UCLH. Your nam e and a d d r e ss  will b e  kept sep ara te ly  
from any information about you s o  that you cannot be identified from it. T h e m em b ers of the  
research  team  will b e  resp o n sib le  for all information related to the study.
What happens to the samples that are taken?
All the sa m p le s  are usually  stored  in a freezer until they are te s te d . W e  usually  store  th e s e  
sa m p le s  for s o m e  tim e (5 y e a r s  or m ore). This allow s us to repeat t e s t s  on th e  s a m e  sa m p le s  
later on, su ch  a s  w h en  a n ew  te s t  is d iscovered . Eventually sa m p le s  are d estro y ed  by fire.
Do I have to take part?
It is up to you to d e c id e  w h eth er  or not to take part in this study. If you  d e c id e  to take part you  
are free to c h a n g e  your m ind at any tim e and without giving a rea so n . W h atever  your d ec ision , 
it will not affect the standard  ca re  that you receive in any w ay.
What if I have questions?
You m ust fee l free to con tact any m em ber of the study group to a n sw e r  any  q u e stio n s  you  
m ight have. You can  con tact u s  by post or phone or e-m ail Dr Lutchm an S in gh  at his e-m ail 
a d d r e ss . If you con tact u s by p h on e  w e  will be happy to ph on e you  back. W e  will b e  happy to 
a n sw er  your q u estio n s.
THANK YOU FOR CONSIDERING TAKING PART IN THIS STUDY
Research team:
Miss Melanie Davies (principal investigator)
Dr Ratna Chatterjee 
Dr Kerryn Lutchman Singh 
Contact details:
Address: Reproductive Medicine Unit
Tel: 
e-mail: 
Version 2 15/05/03
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CONSENT FORM 
(Volunteers)
THIS C O PY  OF THE C O N SEN T FORM IS FOR YOU TO  KEEP
P atient identification num ber for study:
Form version:
Name of principal researcher: Miss Melanie Davies 
P le a se  initial box
I confirm that I have read and understood the information sheet dated ....................
(version  ) for the above study and have had the opportunity to ask questions.
I confirm that I have had sufficient time to consider whether or not I want to be  
included in the study
I understand that my participation is voluntary and that I am free to withdraw 
at any timeand without giving any reason.
I agree to take part in the above study.
OCX
Title of project: Estimation of ovarian reserve in patients treated by cytotoxic drugs for cancer 
Nam e of Principal investigator: Miss Melanie Davies
Name of volunteer Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Nam e of the researcher to contact if there are any problems
Version 2, 15/4/03
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CONSENT FORM 
(Patients)
THIS C O PY  OF THE C O N SEN T FORM IS FOR YOU TO K EEP
P atient identification num ber for study:
Form version:
Name of principal researcher: Miss Melanie Davies
Please initial box
I confirm that I have read and understood the information sheet dated ....................
(version  ) for the above study and have had the opportunity to ask questions.
I confirm that I have had sufficient time to consider whether or not I want to be  
included in the study
I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected.
I understand that sections of any of my medical notes may be looked at by m em bers  
from the research team, or from regulatory authorities where it is relevant to my taking 
part in research.
I give permission for th ese  individuals to have a ccess  to my records.
I agree to take part in the above study.
I agree / do not agree (p lease delete as appropriate) for my sibling(s) to be approached  
to take part in this study.
I understand that I am under no obligation to allow my sibling(s) to be approached and 
I am free to change my mind at any time without my medical care or participation in this 
study being affected
"OCX
Title of project: Estimation of ovarian reserve in patients treated by cytotoxic drugs for cancer  
Nam e of Principal investigator: Miss Melanie Davies
Name of patient Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Name of the researcher to contact if there are any problems
Version 3, 15/7/03
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CONSENT TO DISCLOSURE OF CLINICALLY RELEVANT INFORMATION
It has been fully explained to me that the results o f the tests that I have had performed as 
part o f this study may be relevant to my clinical care. I understand fully the usefulness 
and limitations o f this information.
I would like to consent to the disclosure o f clinically relevant data in the following 
manner:
(delete as appropriate)
My oncologist or consultant dealing with my treatment: Yes/No/Undecided
My GP: Yes/No/Undecided
I consent to the inclusion o f clinically relevant data into my medical case notes where 
any member o f the medical team responsible for my care may have access to it as part o f 
my clinical care:
Y es/No/Undecided
PATIENT NAME:
SIGNATURE:
DATE:
Version 1 Date: 15/5/03
8.5 LABORATORY EQUIPMENT AND CONSUMABLES
8.5.1 GENERAL EQUIPMENT IN VIVO STUDY
ITEM M A N U FA C T U R E R /SU PP L IE R
Autom ated Plate W asher W ellw ash 4 Mk II plate w asher (Therm o  
Electron Corp, B io sc ien ce  T ech n olog ies, 
Basingstoke, UK )
M RX 2 M icroplate Reader D ynex T echnologies, C hantilly, V A , U SA .
Nunc-Im m uno™  M axi Sorp  
96 M icroW ell™  Plates
NuncBrand, Fisher S cien tific  U K  
Loughborough, Leicestershire LEI 1 5RG, 
UK.
Plate shaker Labsystem s W ellm ix, Finland
Shaking waterbath-CS 200  G refrigerated  
im m ersion cooler
Grant Instruments (C am bridge) Ltd., 
Cambridgeshire, UK.
W horly m ixer 
(V ortex- G enie 2)
Scientific Industries, Inc. 
Bohem ia, N Y  11716 U SA .
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8.5.2 GENERAL EQUIPMENT IN VITRO STUDY
N A M E  OF A PPA R A TU S SU PPLIER/M AK E
A U T O C L A V E  
M idas 40  priorclave
Priorclave Ltd 
129/131 Nathan W ay  
W oolw ich SE28 OAB, 
UK.
DISPENSERS
M A N U A L  M U L T IC H A N N E L
Scientific laboratory supplies (SL S) 
W ilford Industrial Estate 
Nottingham , N G 1 1 7EP, UK.
D ISPEN SE R S
ELECTRONIC M U LT IC H A N N E L  
(G enex Alpha)
Genex
Unit 1, Barton Hill W ay, 
Torquay TQ2 8JG UK.
D ISPEN SER S
SE M I-A U T O M A T E D  PIPETTE
Gilson, S.A .S, 
95400 vlliers le Bel, 
France
D ISPEN SER
ELECTRONIC PIPETTE G U N  
(G enex D elta)
G enex Delta
Unit 1, Barton Hill W ay,
Torquay TQ2 8JG UK.
ELECTRONIC SCALE A & D instruments, 
Abingdon, Oxford, UK
FLOW C YTO M ETER  + SOFTW ARE
Beckm an-Coulter EPICS ELITE
Software- B/C F low  station analysis version 4.5
Beckm an- Coulter, 
M iam i, FL,
U .S .A
FREEZER (- 20° C) Liebherr, Germ any
H EM O CYTO M ETER SIG M A C hem ical Co; 
St Louis, U S A
H U M ID IFIED  IN C U B A T O R LEEC Ltd 
N ottingham , U K
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L A M I N A R  FLOW  C A B IN ET Heto-H olten (U K ) Ltd, 
Cam berley, Surrey, UK  
Gelaire flow  laboratories, 
North Som erset, U K
L A R G E  C ENTRIFUG E  
(C e n ta u r  2 bench-top centrifuge)
Fisons scientific  (M SE ) instruments
Fisons Scientific  Apparatus Ltd., Loughborough,
L eics., U.K.
M A G N E T IC  STIRRER Jencons-PLS
Unit 15, Imberhorne Industrial Estate 
East Grinstead, W est Sussex, RH19 1XZ 
UK.
M IN I-C E N T R IF U G E Sanyo Gallenkam p PLC, 
Loughborough, Leics, UK
M U L T IF U N C T IO N  TO PLO A D IN G  
A N A L Y T I C A L  B A L A N C E S
A &  D  instruments, 
Abingdon, Oxford, UK.
O P T I C A L  M IC R O SC O PE  
( C K 3 0 /  C K 4 0  culture m icroscope)
O lym pus Optical Co., Ltd., 
Tokyo, Japan
pH M E T E R Jencons-PLS
Unit 15, Imberhorne Industrial Estate 
W est Sussex, RH19 1XZ, UK.
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8.5.3 CONSUMABLES (IN VIVO AND IN VITRO)
ITEM M A N U FA C TU R ER  OR SU PPLIER
2 ml FLAT BOTTOM  TU BES WITH CAPS Hughes and H ughes Ltd, 
UK.
5, 10,25,50 ML STERILE C O N TA IN ER S Bibby Sterilin Ltd, Staffordshire, UK.
STERILE A N D  N O N  -ST E R IL E  PLASTIC  
PASTEUR  PIPETTES
Alpha laboratories Ltd, 
Hampshire, UK.
5, 10, 25m l STERILE PIPETTES Sterilin, B ibby sterilin Ltd, Staffordshire, UK.
20 , 200 A N D  lOOOpL PIPETTE TIPS (N O N - 
STERILE)
(Manufacturer -  Gilson;
Calibration -  Caltech)
Gilson, S.A .S,
95400 vlliers le B el, France. 
Caltech
4 Tanners Drive,
M ilton Keynes M K14 5N A , UK.
C Y TO M ETER  T U B E S (FO R  PLACING  
SAM PLES IN C Y TO M ETER )
BD Falcon, BD B iosciences Europe, B elgium
EPPENDO RF T U B E S Sarstedt, A ktlengesellschaft & C o., Germany
96-W ELL M ICROTITER PLA TES NuncBrand, Fisher Scientific  
Loughborough,
Leicestershire LE11 5R G U K .
STERILE 24-W ELL C ULTUR E D ISH E S WITH  
LIDS
NuncBrand, Fisher Scien tific  
Loughborough,
Leicestershire LEI 1 5R G U K .
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STERILE 24 A N D  80C M 2 C ULTUR E FLASKS NuncBrand, Fisher S cientific UK
Loughborough, Leicestershire LE11 5RG
UK.
8.5.4 REAGENTS (IN VIVO STUDY)
ITEM M A N U FA C T U R E R /SU PPL IE R
AM H A SS A Y  KIT Immunotech  
SA  M arseille, France.
INHIBIN B A SSA Y  KIT
D SL -10 -84100  ACTIVE® Inhibin B Enzyme-
Linked Im munosorbent (E L ISA )
D iagnostic System s laboratories, Inc. T exas, 
U SA.
FSH A SSA Y  KIT IBL Im m uno-B iological Laboratories Hamburg, 
Germany.
LH A S SA Y  KIT IBL Im m uno-B iological Laboratories Hamburg, 
Germany.
17 beta-Estradiol KIT IBL Im m uno-Biological Laboratories Hamburg, 
Germany.
ELISA A M PLIFIC ATIO N  SY STE M Invitrogen Life T echnologies  
Paisley, UK.
BO V IN E SERU M  A L B U M IN  (B S A ) Sigma-Aldrich C om pany Ltd. 
Gillingham, Dorset SP8 4X T , UK.
CONCENTRATED H Y D RO CH LO RIC  A N D  
SULPHURIC ACID
Sigma-Aldrich C om pany Ltd. 
Gillingham, D orset SP8 4X T , UK.
M O U SE SERUM Sigm a-Aldrich C om pany Ltd. 
Gillingham , D orset SP8 4X T , UK.
Triton® X -100 Sigm a-A ldrich C om pany Ltd. 
Gillingham , D orset SP8 4X T , U K .
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8.5.5 REAGENTS (IN VITRO STUDY)
R EA G EN T M A N U FA C T U R E R /SU PP L IE R
A N N E X IN Roche D iagnostics Ltd.
Bell Lane, L ew es East Sussex , BN 7 1LG UK.
AM PHOTERECIN GIBCO cell culture; 
Invitrogen Ltd , P aisley, U K
DM SO Sigm a- Aldrich C om pany Ltd. 
St Louis., U SA
D M EM /F12 M ED IU M GIBCO cell culture; 
Invitrogen Ltd , Paisley, UK.
EDTA 0.02 % in PBS PromoCell GmbH Sickingenstra[3e H eidelberg, 
Germany.
FORM ALIN  
(37%  in solution)
Sigm a-Aldrich C om pany Ltd. 
G illingham , D orset SP8 4X T , UK.
G EN TA M Y CIN GIBCO cell culture; 
Invitrogen Ltd, Paisley, UK.
H B SS M E D IU M GIBCO cell culture; 
Invitrogen Ltd, Paisley, U K .
H EM A TO X Y L IN Sigm a-Aldrich C om pany Ltd. 
Gillingham , D orset SP8 4X T , U K .
H Y A L U R O N ID A SE Sigm a-Aldrich C om pany Ltd. 
Gillingham , D orset SP8 4X T , U K .
L-15 M EDIUM GIBCO cell culture; 
Invitrogen Ltd, P a isley , U K .
PERCOLL Am ersham  B io sc ien ces  Ltd. 
B uckingham shire H P7 9 N A , UK.
PRO PIDIUM  IODIDE  
(1 m g/m l)
Sigm a-A ldrich  C om pany Ltd. 
G illingham , D orset SP8 4X T , UK.
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STREPTO M YCIN/PENICILLIN GIBCO cell culture; 
Invitrogen Ltd, Paisley, UK.
T R Y P A N  BLU E Sigm a-Aldrich C om pany Ltd. 
Gillingham , D orset SP8 4X T, UK.
T R Y PSIN  (X 10) GIBCO cell culture; 
Invitrogen Ltd, Paisley, UK.
8.5.6 DRUGS
DRU G M A NU FA CTU RER
D O X O R U B IC IN Sigm a-Aldrich Company Ltd. 
G illingham , Dorset SP8 4 XT, UK.
M ELPH ALAN Sigm a-A ldrich Company Ltd. 
G illingham , Dorset SP8 4XT, UK.
PACLITAXEL Sigm a-A ldrich Company Ltd. 
G illingham , Dorset SP8 4XT, UK.
CISPLATIN Sigm a-Aldrich Company Ltd. 
Gillingham , Dorset SP8 4XT, UK.
BUSERELIN Sanofi-Aventis Ltd.
Guildford, Surrey GUI 4Y S, UK.
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